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CHAPTER I 
 
BIOCATALYTIC PATHWAY DESIGN AND ENZYME OPTIMIZATION 
 
Introduction 
The field of synthetic biology aims to harness and control biological function to 
accomplish specific tasks1 and utilizes techniques and concepts from molecular biology 
and engineering2. The ultimate goal of synthetic biologists is to predict and design 
biological components and systems which respond in a particular and defined fashion3. 
To do this synthetic biologists combine gene ‘parts’ into ‘devices’ which perform a 
defined function3. Devices are then combined to form ‘systems’. By providing the system 
with a ‘chassis’3 – or biological host – synthetic biologists have reported tasks such as 
synthesis of fine chemicals and commodities4, 5, reporting of and response to local 
environmental conditions by bacteria6, 7, and logic calculations which control function 
based on a particular input or combination of inputs8-10. 
One particularly fruitful area of synthetic biology is the synthesis of fine 
chemicals, commodities, fuels and drugs in microbial factories. Synthetic biologists and 
metabolic engineers generate microbial factories by expressing biosynthetic pathways in 
microbial hosts. Metabolic flux, the rate at which precursors are moved through the 
pathway to form product, is optimized to increase product yield and the concentration of 
bioproducts by controlling pathway expression through gene repressors and promoters, 
modulating relative protein concentrations by varying the strength of ribosomal binding 
sites (rbs) or adjusting mRNA stability, and co-localizing pathway components using 
protein scaffolds. 
A microbial factory provides a number of advantages over large scale extractions 
or de novo chemical synthesis. The aforementioned classical production methods are 
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often associated with low yields or high waste streams and therefore higher costs. Often, 
producing organisms are not available at the scale required for large-scale extraction, as 
is the case for the anticancer drug paclitaxel and the oseltamavir precursor shikimic 
acid11. These limitations have been circumscribed through generation of culturable plant 
growths and construction of a microbial factory, respectively. In de novo synthesis great 
effort is often required to establish a chemical synthetic pathway yielding enantiopure 
product. Even still, chemical routes may suffer from incomplete conversion or the 
generation of side-products making purification of the final compound a necessity. Many, 
if not most, chemically synthesized molecules are not natural products, though, meaning 
they cannot be directly generated in a microbial factory and a biosynthetic pathway must 
be created for bacterial synthesis. 
In contrast, microbial factories take advantage of enzymes to synthesize complex 
entities with excellent stereo- and regiocontrol in an environmentally friendly process. 
Processes utilize ambient temperatures and pressure, water as solvent and renewable 
catalysts in the form of enzymes which are generated through catabolism of useable and 
renewable feed-stocks. Even outside of cells enzyme biocatalysts are becoming readily 
available for many critical reactions. The synthesis of key chiral precursors of the 
cholesterol drug atorvastatin and anti-diabetic sitagliptin have been greatly improved 
through incorporation of enzymatic steps12, 13. 
In this work, the generation of biosynthetic pathways for construction of microbial 
factories is introduced and methods for the pathway optimization are examined. These 
principles are applied to the generation of a biocatalytic pathway for directed 
biosynthesis of the nucleoside analog 2´,3´-dideoxyinosine. 2´,3´-Dideoxyinosine (ddI, 
didanosine, Videx®) is critical to the treatment of individuals infected with Human 
Immunodeficiency Virus (HIV), which as of 2010 affected 33.3 million people worldwide. 
At this same time, the World Health Organization estimated that government subsidized 
 3 
 
treatment costs were approximately US $209/patient/year making the drug unaffordable 
for most of the 33.3 million people affected by HIV14. Furthermore, with unsubsidized 
costs in the United States currently at US $4 478.55/patient/year, a significant pressure 
is placed on the government to treat citizens15. 
It has been shown that ~66% of the manufacturing cost for ddI is derived from 
synthesis of the active pharmaceutical ingredient16. A large part of this cost can be 
attributed to stereocontrol of the 1´- and 4´-carbons during synthesis. Natural 
nucleosides are often utilized as starting materials to take advantage of the previously 
set stereocenters. However, bulk adenosine and inosine is quite expensive, costing 
several hundred dollars per kg, driving up the price of the final product. Methods 
incorporating de novo sugar synthesis into formation of ddI utilize glutamate as an 
inexpensive starting material available in bulk and therefore do not suffer from high 
starting material costs. Nevertheless, these syntheses suffer from low yields which are 
compounded by the generation of a mixture of products (e.g. α- and β-anomers or 
regioisomers). Furthermore, the use of exotic catalysts and column chromatography in 
chemical synthesis results in large waste streams containing hazardous materials. 
Methods have been developed that utilize enzymes to form the final product, thereby 
controlling the stereochemistry and simplifying purification in a process resembling 
kinetic resolution. Although a stereochemically pure product is formed, chemical 
synthesis of the precursor molecule is still problematic. Chemical routes for the synthesis 
of ddI are discussed in detail later in Chapter 1. 
The proposed pathway, outlined in Figure 1, utilizes chemical synthesis to 
generate 2,3-dideoxyribose from glutamic acid and enzymes to accomplish 
transformation into ddI. Early incorporation of enzymes allows for use of the inexpensive 
starting material glutamate but is likely to present an enhanced overall yield and a 
significantly reduced waste stream over previous syntheses.  
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While the advantages of directed biosynthesis are clear, transformations 
catalyzed by naturally-occurring enzymes are then utilized to form the final product. 
Because these enzymes are native to other substrates, namely ribose derivatives, 
function is typically sub-optimal for immediate process application. Enzyme engineering 
methods such as rational design and directed evolution are applied to improve turnover 
for the targeted substrate. Ultimately, lower net manufacturing costs will broaden the 
availability of effective anti-HIV drugs to peoples currently provided with less expensive, 
albeit less effective, regimens17. 
 
Figure 1-1. Proposed directed biosynthesis of 2´,3´-dideoxyinosine from glutamic acid 
proceeds through 2,3-dideoxyribose. 2´,3´-Dideoxyinosine is a nucleoside analog of 
inosine. 2,3-Dideoxyribose is an unnatural sugar, similar to ribose. The numbering 
scheme for ribose and inosine carbon atoms is shown. 
 
 
 
Formation of microbial factories and pathway construction 
Efficient, large-scale production of complex molecules such as β-lactams, 
lovastatin and vancomycin has long been accomplished through fermentation of 
metabolically engineered organisms. These early microbial factories represent cases of 
innate biosynthesis, as the compound is synthesized in the naturally producing 
organism5. While numerous compounds have been generated in this fashion18, for a 
number of reasons many valuable products are not available through innate 
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biosynthesis. For example, producers may not be amenable to culture, fermentation or 
genetic manipulation or cannot be persuaded to up-regulate the production of a desired 
metabolite. 
 
Figure 1-2. Heterologous pathway construction for biocatalytic synthesis of noninnate 
bioproducts. Enzymes (E1, E2, En) from biosynthetic pathways are transferred from the 
native producer (colored ovals) to form heterologous pathways (beige cells).  Substrates, 
intermediates and products are represented by letters (A, B, C, D, F). Non-natural 
substrates or products are represented by greek letters (α, β, γ, ∆, φ). Engineered 
enzymes are denoted by the greek letter ε. Enzymes can be recombined in any order 
and any combination, as shown for de novo pathway design (E). 
 
 
 
To overcome these difficulties, pathway genes can be transplanted into a 
heterologous host for expression and metabolic optimization19. This process is depicted 
in Figure 1-2A. Such a compound is known as a noninnate bioproduct5. This form of 
heterologous pathway transfer is the most straightforward. Recapitulation of the pathway 
in a secondary host allows process engineers to decouple production from regulatory 
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elements present in the native host, thereby increasing product titers19. An example of 
heterologous pathway transfer is the generation of 1-butanol from acetyl-CoA, originally 
biosynthesized in Clostridium acetobutylicum and transferred to Escherichia coli20. 
Engineering of the native host proved difficult as butanol formation is tied to pH, redox 
conditions and sporulation. Transfer to a secondary host enabled increased production 
levels of butanol outside the realm of host control. 
While transfer of the pathway to a heterologous host can be advantageous it also 
presents its own challenges. Functional expression of an enzyme outside its native 
environment is often poor due to inclusion body formation or other environmental 
differences.  Low enzyme levels thereby decrease product formation. Transfer of a 
related enzyme from a tertiary species, in a process called pathway parallelization, may 
enable more effective production of the target molecule (Figure 1-2B). By screening the 
activity of various homologs, Steen and coworkers were able to generate a noninnate 
pathway for n-butanol bioproduction in Sacchoromyces cerevisiae21. Similarly, 
concatenation of homologous enzymes from C. acetobutylicum, E. coli K-12, Clostridium 
beijerinckii, and Thermoanaerobacter brockii enabled the synthesis of isopropanol in 
concentrations as high as 45 mM in 10 hours22. 
A particular challenge in heterologous pathway transfer is the supply of precursor 
substrates into the pathway. In directed biosynthesis precursors are generated 
exogenously or obtained from commercial sources and product is formed through 
biocatalytic conversion upon addition of the precursor to the microbial culture. The 
directed biosynthesis process is also known as a ‘hosted’ biocatalytic pathway since the 
primary function of the microorganism is the expression and maintenance of pathway 
DNA and enzymes. Alternatively, ‘integrated’ biocatalytic pathways utilize precursors 
generated as part of the native metabolism of the host which enables fermentation and 
the transformation of inexpensive or complex feed-stocks into the desired product23. The 
 7 
 
generation of n-butanol and isopropanol in E. coli by C. acetobutylicum pathway genes 
is an integrated pathway as acetoacetyl-CoA is formed by the host and fed into the 
heterologous pathway20-22. 
Frequently, a host organism does not generate the necessary precursors for 
biosynthesis of a target compound so pathways from two unrelated organisms are 
combined into a single heterologous pathway for optimized biosynthesis of a non-native 
product19. Pathway combination is depicted in Figure 1-2C. The generation of artemisinic 
acid, a direct precursor of the anti-malarial drug artemisinin is a well-heralded case of 
pathway combination. Genes for the biosynthesis of isopentenylpyrophosphate through 
the mevalonate pathway were transferred from S. cerevisiae into E. coli, thereby 
bypassing native control of isopentenylpyrophosphate synthesis through the 
deoxyxylulose 5-phosphate pathway and allowing for orthogonal control of enzyme 
function24. Subsequent turnover by amorphadiene synthase and a cytochrome P450 
monooxygenase from the native producer Artemisia annua affords the noninnate 
bioproduct artemisinic acid24, 25. 
In addition to naturally occurring molecules, heterologous pathways can be re-
appropriated to synthesize other molecules or non-natural molecules through off-target, 
promiscuous activities of enzymes in the pathway (Figure 1-2D). In further work by 
Atsumi and Hanai, isobutanol and other higher-order alcohols were generated by 
hijacking the 2-keto acid precursors of valine, threonine, norvaline, phenylalanine, 
isoleucine, and leucine26. Combination with the final steps of the Ehrlich pathway 
provides the alcohol products through a broad substrate-range 2-keto acid 
decarboxylase from Lactococcus lactis and an alcohol dehydrogenase from S. 
cerevisiae. Control of the predominant product is provided through upregulation of 
specific amino acid precursors. For instance, isobutanol production reached 23 mM 
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when the ilvIHCD genes for valine biosynthesis were over-expressed to enhance 2-
ketoisovalerate synthesis. 
Promiscuous activities can also be introduced through mutagenesis of key 
enzymes in the pathway. A pathway similar to that of Atsumi and Hanai for branched 
chain alcohol biosynthesis26 was utilized to generate the C6 branched alcohol 3-methyl-
1-pentanol. In this pathway, enzymes in the leucine biosynthesis pathway were altered 
to accept 2-keto-3-methylvalerate in place of 2-ketoisovalerate. The 2-keto acid 
decarboxylase was then mutated to accept the larger substrate to increase product 
titers27. Runguphan and O’Connor were able to generate unnatural alkaloids in hairy-root 
cell cultures of Catharansus roseus upon introduction of a mutated strictosidine 
synthase28, 29. Entrance into the monoterpene indole alkaloid pathway is controlled by 
strictosidine synthase, which catalyzes the condensation of tryptamine and secologanin. 
Tryptamine analogs were fed to hairy-root cultures harboring the mutant gate keeper 
enzyme resulting in the biosynthesis of various unnatural alkaloids as the unnatural 
strictosidine product filtered through the downstream pathways. In another case, Tsuge 
et al30 altered the make-up of biological polyhydroxyalkanoates (PHA), potential 
biodegradable thermoplastics, to include C8–C12 subunits.  Through structure-guided 
mutations the substrate binding pocket of the R-specific enoyl-coenzyme A hydratase 
portion of a PHA synthase was widened and deepened to accept the larger substrates30. 
Many enzymes already possess a desired promiscuous activity but the high-level 
native activity consumes significant amounts of precursor compounds or other off-target 
function decreases the yield of desired product. Mutagenesis alters the enzyme 
specificity and funnels the pathway to a particular product. This reduces the flow of 
precursors to unwanted side products and is a key strategy to maximize pathway flux. 
To produce propionate from α-ketobutyrate, Chang and Cronan sought a mutant 
pyruvate oxidase with increased activity31. Rational mutagenesis and site-directed 
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saturation mutagenesis were used to identify a mutant deficient in normal pyruvate 
function. The final mutant possessed wild-type levels of α-ketobutyrate activity but 
significantly reduced pyruvate activity. Pyruvate would act as an intracellular competitive 
inhibitor and an enzyme with increased discrimination should be a better producer of 
propionate. Overall, by increasing the enzymes specificity the yield of product relative to 
initial substrate is improved and, furthermore, the unbalancing effect of high enzyme 
activities on innate metabolites in the host organism is removed. 
De novo pathway design is the generation of non-existing or non-natural 
pathways from unrelated enzymes (Figure 1-2E). It enables streamlined synthesis of 
compounds with natural pathways too complex for heterologous expression or the 
formation of unnatural compounds for which a natural pathway does not exist19. Few 
examples of de novo pathways, as they are defined here, have been demonstrated. 
Moon et al constructed a pathway for bacterial production of glucaric acid from glucose 
which utilizes 5 disparate enzymes from three independent sources32. This pathway 
provides a significant savings over mammalian pathways for glucaric acid production, 
which typically require 10 conversion steps. A second example of de novo pathway 
design for a natural compound exists in the synthesis of 1,3-propanediol from glucose, 
utilizing glycerol as an intermediate33. Flux through the pathway was optimized for both 
energy efficiency and overall product yield for each glucose molecule entering the 
pathway. Import and phosphorylation of glucose was improved by replacing the 
endogenous system with a designed system. Furthermore, an E. coli aldehyde 
dehydrogenase, previously uncharacterized but now known to be involved in oxidative 
stress reduction34, was incorporated in the pathway which utilizes NADPH instead of 
NADH. This, along with other metabolic engineering elements, increased product titers 
significantly over the previously used fermentative 1,3-propanediol production methods. 
Finally, to my knowledge, the sole example of a de novo pathway for the biosynthesis of 
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an unnatural molecule is the generation of D- and L-1,2,4-butanetriol in E. coli from D-
xylose and L-arabinose, respectively35. Enzymes from Pseudomonas fragi and 
Pseudomonas putida, along with endogenous enzymes, were brought together to form 
the final product, a critical precursor to nitro-containing explosives. 
One of the most important steps in de novo pathway design is the generation of 
the pathway itself. Development of a de novo biocatalytic pathway is aided by a broad 
knowledge of enzyme functions from primary metabolic pathways and, additionally, 
biochemical reactions in the formation of secondary metabolites. Using this information, 
one can imagine a design strategy which utilizes similar planning processes to classical 
pathway construction in organic synthesis, namely, a retrosynthetic analysis to identify 
simple precursors which are commercially available or present in innate metabolism. 
The design of de novo biosynthetic pathways in a retrosynthetic manner has been 
termed bioretrosynthesis36, 37. 
The bioretrosynthetic approach is empowered by re-appropriation of enzyme 
functionalities which catalyze a desired chemical transformation, albeit on a different but 
similar substrate. This is analogous to general practices in organic chemistry, where 
reaction conditions shown to affect a particular chemical change, such as the reduction 
of a ketone to an alcohol, are recreated in the presence of a novel precursor37. Enzyme 
re-appropriation significantly increases the number of possible biocatalytic 
transformations. However, nature has only generated enzymes for a limited number of 
chemical rearrangements on a limited number of substrates. Enzyme engineering 
methodologies such as rational design and directed evolution enable tuning of enzymes 
to possess particular characteristics, e.g. increased activity, enantioselectivity or 
thermostability. Furthermore, significant progress has been made in the design of 
enzymes with totally novel chemistries that do not exist at all in nature. Enzyme 
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engineering methodologies and examples of their application are discussed in more 
detail later in Chapter 1. 
Many enzyme databases have been generated to organize the immense amount 
of data that has been generated through genome sequencing and enzyme and pathway 
characterization; these include Swiss-Prot, BRENDA, KEGG, and MetaCyc. Most of 
these databases are organized by substrate, enzyme classification or species making 
them difficult to search for common functional group interchanges, a necessity for 
recycling enzyme functionality. Indeed, several groups have generated classification 
schemes based on chemical conversion, which have been reviewed19, but a consensus 
has not yet been reached. 
In the past decade several algorithms have been proposed which attempt to 
automate the pathway design process. In general, they categorize enzyme activity using 
carefully curated libraries of transformations based on enzyme classification number or 
by functional group interconversion. Suggested pathways, of which there are sometimes 
thousands, are prioritized by thermodynamic feasibility, maintenance of stoichiometric 
balance, effect upon native metabolism or heterologous expression of the pathway on 
host growth and/or predicted rate and flux. These algorithms have been applied to the 
prediction of pathways for amino acids38 and polyketides39 (BNICE), degradation of 
xenobiotics (University of Minnesota-Pathway Prediction System, UM-PPS) 40, 41, novel 
carbon fixation42, branched-chain alcohols43, and other value-added compounds 
(DESHARKY)44. A major criticism of some algorithms is a limitation of target compounds 
to previously observed biological molecules, as is the case for some applications of 
BNICE and also UM-PPS which is limited to generating pathways for degradation. 
It is possible that thousands of potential pathway solutions can be found for the 
generation of a compound from metabolic precursors as a single precursor can 
potentially undergo multiple reactions to form multiple products, which can again 
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undergo multiple reactions. Many algorithms enumerate all possible pathways for a 
particular target resulting in computationally intense calculations and rigorous 
prioritization of potential pathways. For instance, in the prediction of pathways for 
isopropanol and 3-hydroxyproprionate, experimentally demonstrated novel pathways 
were ranked 17th out of 42,344 and second out of 4,524, respectively26, 43. Rodrigo et al 
overcame combinatorial and enumerative issues by implementing a Monte Carlo-based 
algorithm (DESHARKY) which allows for reverse steps during the design calculations 
which removes enzymes from the proposed pathway. The decision to go backwards in 
the design process uses a probability based on the number of introduced steps and 
unnatural compounds proposed. This keeps pathways short and ensures precursors are 
metabolically available, thereby improving convergence of the algorithm on a single 
answer. The step-removal heuristic in DESHARKY is enabled by the bioretrosynthetic 
approach: pathways which would require long or circuitous routes on the way to 
predetermined metabolic precursors are easily recognized and avoided. Amazingly, a 
biocatalytic pathway for glucaric acid was proposed by DESHARKY with remarkable 
similarity to the one engineered by Moon et al32. 
Numerous products have been generated in microbial factories through 
heterologous pathway expression. Several excellent reviews have been written 
highlighting examples of noninnate biosynthesis and heterologous pathway 
construction5, 18, 19, 23, 45. 
 
Bioretrosynthetic Pathway Construction 
In addition to a pathway design method, the bioretrosynthetic approach has 
potential as an engineering paradigm37. To date, pathways have been assembled and 
optimized in the order of the reactions in the pathway (Figure 1-3). A bioretrosynthetic 
approach to pathway assembly would start with the product-forming enzyme, the 
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ultimate enzyme, and retro-consecutively incorporate enzymes to the front of the 
pathway in a reverse step-wise manner to the penultimate enzyme, and so on (Figure 1-
3). 
 
Figure 1-3. Paradigms for de novo heterologous pathway construction include pathway 
recruitment which optimizes enzymes in a front-to-back manner and bioretrosynthesis 
which optimizes the ultimate enzyme first and proceeds in a reverse stepwise manner 
thereby requiring a single screen. SM – starting material; P – product; I – intermediate; E 
– enzyme. 
 
 
 
Bioretrosynthesis as an engineering paradigm is inspired by the retro-evolution 
hypothesis for pathway evolution in nature37, first proposed by Norman Horowitz in 
194546. Here, early organisms have developed in a nutrient rich environment. As a 
critical nutrient, such as a nucleoside or amino acid, is consumed the organism develops 
a means to synthesize it from available precursors. As the precursor is consumed a 
second enzyme evolves to synthesize the precursor from other available molecules, and 
so on. The formation of pathways in this way uses product selection as the primary 
selective pressure on the organism. The retro-evolutionary model contrasts with the 
recruitment model, where genes are assembled into cassettes in a forward step-wise 
manner, starting with basic environmental components and progressively incorporating 
genes for enzymes which generate more complex molecules. This, however, implies that 
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intermediates generated during the early evolution of the pathway provide a selective 
advantage to the organism. Correspondingly, the retro-evolution hypothesis assumes 
that intermediates and precursors are available from the environment and limits the 
evolution of pathways to compounds available in the prebiotic earth, like those 
generated in Miller–Urey-type experiments47. 
The bioretrosynthetic engineering strategy provides a number of advantages 
over the traditional front-to-back protocol. First, it requires only a single assay for the 
product molecule or a method for measurement of consumption of the penultimate 
intermediate. Traditional forward pathway construction would require n assays for n 
enzymes in the pathway (Figure 1-2A). The bioretrosynthetic approach, in contrast, 
reduces the number of assays required for pathway optimization from n to one. Second, 
in a forward-constructed pathway it is generally necessary to re-optimize intermediate 
enzymes after completion of the pathway to maximize pathway flux by balancing the rate 
of formation and concentration of intermediates, expression levels of enzymes, reduce 
feedback inhibition or competition from structurally related molecules, decrease the 
metabolic burden of enzyme production, and so forth. In contrast, reverse step-wise 
construction optimizes pathway flux for high product yields throughout the building 
process. By beginning with optimization of the ultimate enzyme intermediate formation 
rates by early enzymes are improved relative to the final enzyme. Therefore, some 
intermediate enzymes must not be maximally improved but improved only to the point 
that they are no longer the rate-limiting step. Furthermore, a fully optimized pathway 
would utilize each enzyme in a stoichiometric ratio alleviating the need for engineering of 
expression and allowing the entire pathway to be placed behind a single promoter and 
each enzyme behind a similar rbs. 
Bioretrosynthetic pathway engineering has certain prerequisites to its laboratory 
implementation. First, suitable enzymes to catalyze desired transformations, and their 
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genetic material, must be identified and collected. In addition to the databases and 
software previously discussed for pathway design, metagenomic analyses have 
increased the collection of gene sequences potentially encoding enzymes for useful 
chemical transformations2, 19, 45. Second, intermediate and starting materials must be 
available to feed into the pathway. The acquisition of intermediates and/or starting 
materials sometimes requires chemical synthesis of numerous molecules as the 
pathway is formed. Finally, a robust assay for detecting product formation or 
consumption of a penultimate intermediate must be in place. The assay must be 
sensitive enough to measure small levels of enzyme turnover but also possess a large 
functional range so as to enable comparisons of enzyme turnover during the late stages 
of optimization. 
 
Engineering Strategies for Enzymes 
The utility of biochemical reactions in the synthesis of organic molecules, 
providing regio- and enantiospecifity along with environmentally friendly conditions, has 
long been recognized48 and synthetic biology efforts have enabled biocatalytic 
compound production in microbial factories from inexpensive starting materials, as 
illustrated above. However, broad application of enzymes in synthesis is severely limited 
by their inherent instability, inability to accommodate alternative substrates, limitation to 
a small range of reaction conditions, and frequent requirement for expensive cofactors. 
These limitations are characteristics of finely-tuned enzyme active site dynamics and 
global protein architecture and must be overcome for controlled application of 
biocatalytic transformations in organic processes, directed biosynthesis, and microbial 
factories. 
To overcome these limitations, enzymes with new or improved functions are 
increasingly generated from existing enzymes through a 2-fold strategy consisting of 
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rational active site remodeling through mutagenesis, to modify binding specificity for a 
desired reaction or substrate, followed by more stochastic methods such as directed 
evolution. First, a suitable progenitor enzyme or scaffold with a measurable starting 
activity must be identified along with acquisition of some knowledge of the active site 
geometry from structural data or homology models. If an enzyme meeting the 
aforementioned criteria is identified, first or second shell active site residues are selected 
for mutation and functional assessment49-51. Saturation mutagenesis is often applied to 
generate the full complement of amino acids at targeted active site residues, as even the 
most prudently selected active site mutations may result in unexpected catalytic 
consequences28. 
To streamline efforts to redesign substrate specificity, it would be desirable to 
identify a subset of potentially beneficial mutations, particularly in cases in which 
permutations of several active site residues may be required. Computational protein 
design strategies allow for large numbers of enzymes to be generated and analyzed in 
silico for alternative ligand specificity and improved activity on non-cognate substrates52. 
Many such algorithms for the design of novel small molecule binding sites have been 
developed and will be described briefly below. 
Stochastic methods identify mutations outside the binding site which have a 
pronounced affect on enzyme function and enable enzyme engineering even in the 
absence of structural data. Nature fine-tunes the function of enzymes and metabolic 
pathways through natural selection, which embodies a two-fold process: the occurrence 
of a mutation and the advantage that mutation confers on the organism. Directed 
evolution is the embodiment of natural selection in the laboratory. It has been utilized to 
improve biocatalytic utility, in terms of turnover rate and enantioselectivity, 
thermostability and stability in solvents other than water or in detergents, to name a few. 
Directed evolution requires the formation of diverse libraries of mutant variants and 
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screening to identify proteins or enzymes with a desired trait. A review of mutagenesis 
and screening methods, as applied to the improvement of enzymes, is provided below 
and in Appendix A. 
 
Computational Enzyme Engineering 
Successful enzyme turnover requires a complex balance of interdependent 
forces which bring about recognition and binding of substrate and transition state, 
release of product, placement of catalytic residues, control of local environmental 
characteristics (such as pKa) and carefully coordinated entropy trade-offs (e.g. 
desolvation and side chain orientation), not to mention equilibrative forces such as 
conformational flexibility and macromolecular protein dynamics. It is often the case in 
natural enzymes that contributions to catalysis are made by six or more individual amino 
acids53; a thorough search of all combinations would require 206, or 6.4 x 107, variants 
making experimental analysis of all possible combinations impractical. Computational 
methods, though, enable the analysis of large numbers of protein variants. However, 
accurate modeling of active site amino acid positions and their local environment is 
critical for successful engineering of enzyme activity. Many strategies and algorithms 
have been developed which aim to properly predict and stabilize the interaction between 
small molecules and proteins, in both natural and de novo designed enzymes. In 
general, more research has been performed in de novo enzyme design, with notable 
successes. While fewer studies on computational redesign of enzymes exist, there are 
several notable examples and many protein receptors have been the target of substrate 
redesign campaigns. As the interdependent catalytic forces in natural enzymes are pre-
optimized the engineering process is essentially reduced to a binding problem, making 
studies on receptor redesign applicable to enzyme redesign. 
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Initial de novo designed substrate-binding proteins and enzymes were generated 
in four-helix bundles. DeGrado and coworkers introduced O2-dependent phenol oxidase 
activity into a heterotetrameric four-helix bundle hosting a di-iron site utilizing a design 
algorithm based primarily on ab initio calculations54. Later studies constructed a 
homotetrameric bundle capable of binding a nonbiological cofactor55. Control of the 
orientation and placement of histidine residues for coordination of the cofactor was of 
critical importance and accomplished by outlining specific criterion to constrain the 
design. More recently, Koder et al extended this model paradigm resulting in a four-helix 
bundle capable of O2 transport56. Although Koder et al did not utilize computational 
design methodologies, their control of cofactor redox potential and binding orientation in 
such a simple fold-type is nonetheless impressive. 
Enzymatic activity has also been generated by building active sites into existing 
protein scaffolds. Substrates and catalytic residues are first modeled in ideal positions 
followed by placement of secondary residues which appropriately orient the reaction 
center. Bolon and Mayo first applied this strategy to build histidine-mediated nucleophilic 
hydrolysis of p-nitrophenyl acetate into thioredoxin57. They performed their search 
around a covalent histidine/p-nitrophenyl acetate high-energy intermediate. The resulting 
protein catalyst possessed a Km of 170 μM and kcat of 4.6 x 10-4 sec-1, but only a 180-fold 
increase over the uncatalyzed reaction. 
More recently, the Rosetta protein structure prediction and design algorithms 
have been extended to identify potential catalytic sites in novel scaffolds. First, high level 
quantum mechanical calculations are performed to optimally position enzyme functional 
groups which stabilize a modeled reaction transition state. Second, using an inverse 
rotamer search strategy, the RosettaMatch hashing algorithm identifies scaffolds 
capable of hosting functional groups in the idealized positions58. Finally, residues 
adjacent to catalytic sites and transition state are then designed combinatorially to hold 
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catalytic residues in position and form a substrate-specific pocket. Designs are ranked 
based on maintenance of the idealized reaction coordinates and transition state binding 
energies calculated using a knowledge-based potential. Three successful examples 
highlight this approach. 
An enzyme catalyzing the Kemp elimination was generated using this 
approach59. RosettaMatch identified 100 000 scaffolds with potential to host the reaction. 
Subsequent design of the active sites in each scaffold resulted in 59 variant designs in 
17 individual scaffolds. Eight demonstrated detectable activity with kcat/Km values of 6–
160 M-1s-1. One of these candidates, KE07, crystallized readily and became the template 
for a directed evolution campaign in which 7 rounds of random mutagenesis and gene 
shuffling (with cassette mutagenesis of specific sites) produced variants >200-fold 
increased catalytic efficiency (12 to 2 600 M-1s-1). Further characterization indicates that 
the directed evolution process corrected a mistake in the initial design and optimized the 
pKa and electrostatic environment of catalytic residues in the binding pocket60. 
In a comparable approach, a retro-aldol catalyzing enzyme using a Schiff base 
mechanism was developed61. From 181 555 RosettaMatch solutions, 72 designs in 10 
different scaffolds were selected for synthesis and testing. Active designs were produced 
with TIM-barrel and jelly roll folds with the best design catalyzing a 0.74 M-1s-1 turnover. 
In addition to the Kemp eliminase and retro-aldolase, the Rosetta methods have 
been applied to the design of a Diels–Alderase which catalyzes the stereo- and 
regiospecific cycloaddition of 4-carboxybenzyl trans-1,3-butadiene-1-carbamate and 
N,N-dimethylacrylamide62. Greater than 100 scaffolds identified through RosettaMatch 
were winnowed to 84 designs, of which 50 were stable upon expression. Two active 
enzymes were generated in six bladed β-propellor and keto-steroid isomerase scaffolds. 
Iterative saturation mutagenesis of residues adjacent to activating residues (‘catalytic 
residues’) optimized 100- and 20-fold each design. 
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De novo enzyme design provides biocatalytic engineers with additional tools to 
develop synthetic pathways, particularly in cases where the chemistry is not naturally 
catalyzed. Additionally, it tests the basic understanding of enzyme function and catalytic 
principles. However, it is clear that significant improvement in design methodologies is 
required to match the turnover levels of natural enzymes and, furthermore, functionally 
new enzymes are not always necessary to complete a biocatalytic pathway. 
The improvement of enzyme turnover through incorporation of computationally 
predicted mutations has been successfully demonstrated, as have changes in substrate 
preference. To test the ORBIT energy function and HERO design algorithm for 
successful recognition of enzyme-like active sites, Lassila et al simultaneously mutated 
18 residues in the binding site of E. coli chorismate mutase and allowed the algorithm to 
identify the optimal residue at each position. Five variants were constructed, three of 
which contained catalytic efficiency on par to or greater than the wild-type enzyme 
indicating the algorithms ability to recognize and design enzyme active sites63. Further 
probing of the most active mutant, Ala32Ser, indicates this mutation as most optimal for 
this position64. The computationally-identified residue is not in direct contact with the 
substrate but instead forms a hydrogen bond with a critical catalytic residue; this is a 
rare example of successful secondary residue design by computational techniques. 
More intense QM/MM calculations were performed to predict mutations 
necessary to improve the catalytic efficiency of a cocaine hydrolase65. An impressive 
2 000-fold improvement was found with a variant containing five mutations. Prescreening 
of all possible mutations with a very simple hydrogen bond-based function enabled 
timely execution of the protocol despite its reliance on high-level calculations. 
Alteration of the substrate preference of GrsA-PheA, the phenylalanine activating 
domain of the NRPS gramicidin synthase, was accomplished with an ensemble-based 
scoring algorithm, K*, which relies on a Boltzmann-based scoring function to efficiently 
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prune mutations and conformations from the available search-space. Initial application 
found a double mutant that switched the binding specificity to leucine66. The algorithm 
was extended to predict mutations outside the binding pocket resulting in a further 2-fold 
improvement in catalytic efficiency67. To my knowledge, this is the first case of 
successful in silico prediction of distal residues which affect activity. 
Algorithms within the Rosetta framework were utilized to predict the length and 
amino acid make-up of an active site loop in a guanine deaminase with the end-goal of 
generating cytosine deaminase activity68. The removal of two residues and a complete 
change in local sequence identity were necessary to control the precise placement of a 
catalytic asparagine residue. The new variant was able to catalyze deamination of 
ammelide, a structural intermediate of guanine and cytosine, with turnover improved 
over the wild-type by 2 orders of magnitude to 0.15 M-1s-1. While the new activity has 
been introduced, turnover is still seven orders of magnitude lower than guanine 
deaminase with guanine. 
 
Directed Evolution of Biocatalytic Function 
Directed evolution is the embodiment of natural selection in the laboratory, where 
variation in the enzyme population is first introduced through mutagenesis and improved 
variants are identified and selected based on specific functional criteria. By reproducing 
natural search strategies directed evolution can, in theory, identify solutions to the 
catalytic problem in the absence of complete biochemical or structural characterization 
or other knowledge-based biases. In practice though, structural and functional data are 
frequently garnered to guide directed evolution experimental designs and increase the 
likelihood of success. 
Proteins and enzymes have been evolved to possess a number of traits not 
present in the wild type enzyme. Variants have been generated which catalyze new 
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reactions; or the same reaction with increased rate of turnover under specific conditions; 
or with a new substrate or broader substrate scope; to generate conformational stability 
under specific conditions; and more. Many successes have been published and recently 
reviewed48, 49, 69, 70; however, a few selected cases are outlined here to illustrate the 
potential of directed evolution. 
P450 monooxygenases have been developed by Arnold and coworkers for the 
biochemical fermentation of alcohols from straight chain alkanes. Using a medium chain 
fatty acid oxidase as a progenitor enzyme, directed evolution methodologies introduced 
catalytic competence for the oxidation of successively shorter and less oxidized alkyl 
chain precursors, first octane71 and later to propane72. Step-wise improvements via 
mutagenesis throughout the individual domains of the monooxygenase variants 
ultimately resulted in an efficient P450, propane monooxygenase73. Furthermore, one of 
the variants resulting from these campaigns was evolved to convert ethane to ethanol, 
currently an important biofuel for use in automobiles74. Zhao and coworkers have 
demonstrated how the cofactor regeneration problem may be addressed using directed 
evolution of phosphite dehydrogenase. Through a combination of multiple mutagenesis 
methods over several generations the t1/2 of phosphite dehydrogenase at 45°C was 
improved greater than 23 000-fold from the parent enzyme without sacrificing catalytic 
efficiency, providing a useful biochemical method for NADH cofactor regeneration75, 76. 
Impressive results have also been reported in the area of improving enzyme 
enantioselectivity for new substrates through the process of iterative saturation 
mutagenesis and Combined Active site Saturation Testing (CASTing).50 To demonstrate 
the utility of these methods, Reetz applied iterative saturation mutagenesis to 
Pseudomonas aeuriginosa lipase, a well studied enzyme, to increase the 
enantioselectivity for a selected chiral ester, succeeding in generating a mutant with an 
enantiomeric ratio (E-value) 594-fold improved over the original enzyme. In comparison, 
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previous efforts using conventional mutagenesis protocols (epPCR, saturation 
mutagenesis of hot spots, gene shuffling and recombination) identified a lipase 
possessing a comparatively lower E-value of 5177. 
Every directed evolution campaign has a varied and specific goal but each one 
shares two common elements: the introduction of sequence variety and the identification 
of enzyme variants possessing the desired trait through screening and selection. The 
first step in directed evolution is the generation of a mutant library from a template 
protein. Most mutagenesis protocols fit into three categories: random mutagenesis, 
genetic recombination and site-directed, or targeted, mutagenesis (Figure 1-4). Random 
mutagenesis, as the name implies, introduces variation throughout the target gene 
without any methodological prejudice which controls the outcome. Common random 
mutagenesis methods include error-prone PCR, irradiation with ultraviolet light or 
plasmid replication in mutator strains. Error-prone PCR can be accomplished using 
mutation-prone polymerases, by the addition of noncanonical nucleic acids capable of 
‘wobble’ base pairing, or chemical modification of the parent DNA such that the 
hydrogen bonding pattern is altered. In each case, polymerases are used which do not 
possess an error-checking function. Gene shuffling aims to capture and combine 
desirable traits from multiple templates. Recombination can occur at random points, as 
in the protocols utilizing DNAse and developed by Stemmer or in StEP (STaggered 
Extension Process) which was initially introduced by Arnold and coworkers. ITCHY 
(Incremental Truncation for the Creation of Hybrid Enzymes) and SHIPREC (Sequence 
Homology Independent Protein Recombination) protocols allow for controlled crossover 
at domain boundaries and between secondary structure elements. 
Targeted mutagenesis protocols use knowledge-based criteria to thoroughly and 
systematically alter the residue identity at particular locations. In site-directed saturation 
mutagenesis proteins are mutated at a single site to all possible amino acids with 
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primers containing randomized codons. As a first step, site-directed saturation 
mutagenesis is most effective when residues contacting the substrate, or in a second 
shell, are targeted. As a second round of evolution, saturation mutagenesis is often 
targeted to sites identified through random mutagenesis, enabling the refinement of 
mutational hotspots. Occasionally, every residue in a protein is individually saturated to 
find the single best mutation at any position. In many more cases, saturation 
mutagenesis has been performed iteratively, at one site followed by a second and then a 
third. While step-wise improvement is frequently found through iterative saturation 
mutagenesis, the evolutionary landscape can become stuck in local minima identified in 
early rounds; furthermore, the order of mutagenesis is often arbitrary and it is possible 
that a different result could be identified if sites were mutated in another fashion. To 
bypass such concerns, Reetz and coworkers introduced the combinatorial active site 
saturation test, or CASTing, which applies primer cassettes with multiple randomized 
codons to mutate several proximal residues simultaneously50. CASTing requires that 
larger libraries are screened to ensure complete coverage of the mutant library but also 
ensures that the evolutionary process is not biased by local minima or order of mutation. 
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Figure 1-4. Mutagenesis methods for the generation of variant enzyme libraries. 
Methods target single sites or the whole gene. Iterative application of a method allows 
for accumulation of improved mutations. Recombination of the most improved mutants 
from a single round is frequently accomplished through gene shuffling and “hot spots”, 
positions identified through random mutagenesis, are further probed by saturation 
mutagenesis. 
 
 
 
Identification of improved variants is a second element shared by all directed 
evolution studies. Selection-based methods and biochemical screening-based 
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approaches represent the two primary techniques for identification of improved mutants. 
Aside from differences in the mechanism of improved variant identification, screening 
and selection methods can be differentiated by the number of variants the procedure can 
screen in a realistic time period (Figure 1-5). Larger library sizes allow for the activity of 
more variants to be probed and benefit from increased sequence coverage. A short 
description of screening and selection methods is given here to provide context for the 
following sections. Screening and selection methods in directed evolution have been 
rigorously reviewed78-82 and a more detailed analysis is found in Appendix A.  
In selection-based methods, a desired enzymatic activity, such as amino acid 
synthesis, is linked to host cell survival through growth under selective conditions, such 
as in minimal medium lacking the particular amino acid. Typical examples include the 
synthesis of an essential amino acid83-85 or nucleotide81, 82 or degradation of an 
environmental toxin86-94. Positive selections can be performed on agar plates or rely on 
enrichment of cells harboring enzymes of the desired activity in a liquid culture95. 
Negative selection methods, in which the desired activity results in cell death, often 
entail that cells must be sorted and replicated into both library reference and assay 
microtiter plates to facilitate backtracking and resurrection of the desired library variants, 
thereby making them lower throughput96, 97. In general, selection methods provide the 
capability to screen 106 or more variants; however, it is often difficult to link cellular 
response to molecule production, correlate the response in concentration-dependent 
manner, and ensure products are impermeable to the cellular membrane. 
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Figure 1-5. Screening and selection methods for directed evolution. Representative 
methods for identification of improved enzyme variants are classified by throughput 
capacity. Examples of methodologies capable of selecting or screening ultra large 
libraries include FACS, enrichment, and phage display. High throughput methods 
include selection or screening on agar plates. Many biochemical assay methods can be 
modified to 96-well format, but require that colonies are picked into individual wells prior 
to screening. Some plate-based colorimetric screens require secondary analysis in this 
format. 
 
 
In screening-based methods, the rate of substrate turnover is determined via 
biochemical assay, often via colorimetric or fluorometric measurements. In vitro (cell-
free) activity assays generally require the isolation of individual colonies into 96- or 384-
well plates, followed by lysis and multiple reagent transfers. Thus, screening-based 
methods are frequently limited by cost and time to less than 106 mutants (103-104 is 
more common). Just as it is challenging to link enzymatic reactions to cell viability, it is 
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also difficult to contrive reporter systems that induce a change in color or fluorescence in 
vivo, or in compartments. Such systems often require an enzymatic assay for activity in 
cell lysates from colonies isolated in microtiter plates. Although these assays require the 
growth of individual cultures for assay, there is no limit to the varieties of instrumental 
analysis that can be performed, and most assays can be implemented in a 96-well 
format and auto-sampling technologies. Examples of these methods include analytical 
HPLC98, mass spectrometry87, TLC99, 100, radioactivity101, and UV/Vis spectroscopy (e.g. 
NADH reduction)102-104. 
Some colorimetric screens can be modified and applied to agar plate colony 
screening. Here, colonies displaying a desired color within a certain time window are 
selected as active. Frequently, the colorimetric agar plate assay is used as a primary 
screen to identify enzyme variants with functional turnover. Subsequently, a secondary 
and sometimes tertiary activity assay is performed in a 96-well microtiter plate to confirm 
and identify the most active clones105-107. Colorimetric agar plate colony screening 
methods benefit from the larger library sizes assayable via the initial agar plate screen 
before encountering the time and cost limitations of single colony isolation techniques. 
Flow cytometry and phage display methods also permit the assay of larger 
mutant libraries, without requiring that product formation is linked to cell growth. 
Fluorescence activated cell sorting (FACS) is a type of flow cytometry in which a mixture 
of cells is sorted, one cell at a time, based upon the specific light scattering and 
fluorescent characteristics of each cell. In phage display screening, the DNA of a gene 
library is fused to a viral coat protein gene, and combined in a phagemid (a vector 
containing both plasmid and phage origins of replication). The phagemid DNA then 
becomes packaged in the phage capsid that displays the protein. The phage are 
subjected to chromatographic separation (affinity binding) to select for desired activity108. 
Very rarely is phage display connected directly to enzyme activity although an increase 
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in a biosynthetic enzyme activity can be identified through tighter binding to a tethered 
transition state analog109. Other display methods, such as cell surface display, provide 
the advantage of a large library size in addition to facile subsequent screening 
capability110. 
 
 
Statistical Analysis of Directed Evolution Methods 
With the large number of available methods for stochastic improvement of 
enzyme function it is difficult to know which methods offer the best chance for success. 
While there are many impressive success stories, a cursory survey of the literature also 
reveals a substantial number of studies in which the enhancements are more modest. 
Also, complicating the comparison of the success of many studies is that many articles 
report improvement in properties that do not refer directly to kinetic parameters (e.g. total 
yield of reaction). Presumably, this is not an intentional obfuscation. Rather, many 
directed evolution studies are simply goal oriented, and the goal is a desired phenotype. 
Desired phenotypes may be “an organism survives”, “a colony changes color”, or that “a 
percent conversion is achieved”. Indeed, almost all reported studies to date appear to 
succeed in generating their desired phenotype or chemo-phenotype and by these 
criteria, can be viewed as bona fide successes in directed evolution. Therefore, it is 
difficult to identify and emulate a particular strategy during the enzyme evolution 
process. 
Given the substantial body of literature describing successes in directed 
evolution, the diversity of the methods employed and the variety of enzyme classes 
improved, it would be interesting to perform an objective assessment of success of the 
methods in directed evolution for the creation or optimization of discreet biosynthetic 
enzymes; in particular, those studies which aimed to improve activity for a non-native 
substrate. To accomplish this, articles from the last ten years were selected using 
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objective selection criteria, and classified each study, primarily, by the mutagenesis 
method and protocol for selection or screening of variant function. Mutagenesis 
protocols were categorized into four basic subsets: random mutagenesis, gene shuffling, 
targeted mutagenesis, and studies which used a combination of methods. Screening 
and selection methods were generally classified by the number of mutants which could 
be screened in a reasonable time frame (~1–2 weeks). 
Examples of improvements in biocatalytic enzyme activity for non-native 
substrates were collected from ~3,500 total articles discussing directed evolution. As 
part of this objective comparison, it was required that improved turnovers were not due 
to protein stabilization or improved production levels. Only articles reporting velocities 
normalized to enzyme concentration were included in the analysis; normalization to total 
protein content of cell free extract was also accepted. Furthermore, only articles that 
report improvements in biotransformation reactions were collected. Articles with the goal 
of improving protein stability under non-native reaction conditions (e.g. 
thermostablization) were not included. Studies reporting on the optimization of restriction 
enzymes, DNA/RNAzymes, catalytic antibodies or protein:protein interactions were 
excluded as they did not generally report on the improvement of a small molecule 
biosynthetic enzyme. Reported improvements in activity for the natural substrate (or 
other common substrate, as is the case for guaiacol and cytochrome c peroxidases) 
were considered improvements in native reaction conditions parameters and therefore 
were not included. The directed evolution process is defined by randomized mutation of 
a gene and screening for a desired new activity; as such, it was required that more than 
one site be mutated, whether it be simultaneously (e.g. epPCR or CASTing) or through 
an iterative process (iterative saturation mutagenesis). This study also required that a 
selection scheme or activity screen be employed as the primary method to identify 
improved mutants and that the compound used during screening was also the 
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compound used for catalytic characterization (determination of Vmax, kcat, kcat/Km); in 
some cases substrate derivatives which enabled high throughput screening and/or 
selection (i.e. biotinylation111 or fluorescent tagging112) were included.  
Studies reportedly aimed at broadening substrate specificity were excluded by 
the requirement that the substrate in the employed selection is the most faithful reporter 
of improvements in activity. Many studies report mutants functional on multiple 
substrates and it was often unclear how a given mutant was identified through screening 
with a particular substrate. Additionally, studies that reported on the generation of 
enantioselective enzymes were typically not included on the grounds that the desired 
function was not strictly increased turnover of a desired substrate but a ratio of turnovers 
for two enantiomers. Where studies aiming to generate enantioselectivity were able to 
screen or select for improved activity on a particular enantiomer in a single step (one 
assay per mutant, as opposed to an assay with each enantiomer), and additionally meet 
the remaining conditions, they were included112, 113.  
Using the GoPubMed.com semantic server114, the top 20 research journals 
publishing articles with the search phrases “directed evolution” or “directed molecular 
evolution” were identified. Additionally, all citations comprised studies that 1) reported 
improvements in a small molecule biotransformation enzyme, 2) reported kinetic 
parameters, including kcat/Km and/or kcat (or Vmax) and/or Km, for both the progenitor 
enzyme and the evolved enzyme, 3) are target-based studies; in other words, the 
reported improved turnover was for the substrate used in the screen and 4) more than 
one site was mutated, reflecting a departure from single site saturation mutagenesis. 
Database searches for the terms “directed evolution” and “directed molecular 
evolution” were performed in the PubMed and ISI Web of Knowledge databases 
resulting in the accumulation of ~3,500 unique articles. Patents, conference 
proceedings, and non-English language listings were removed. To focus these results, a 
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search was performed with the GoPubMed.com semantic analysis web-server114 to 
identify the top 20 journals publishing articles on “directed evolution” or “directed 
molecular evolution” during the last 10 years (2000 to present). Journals that primarily 
published review articles (Current Opinions in Biotechnology, Current Opinions in 
Chemical Biology, and Trends in Biotechnology) or methods (Methods in Molecular 
Biology) were excluded from the top 20 list. Including commentaries and review articles, 
these 20 research journals have published ~1,275 articles since the year 2000. The 
journals included in this study were: Protein Engineering, Design and Selection, Journal 
of Molecular Biology, Proceedings of the National Academy of the Science, 
ChembioChem, Nucleic Acids Research, Angewandte Chemie International Edition in 
English, Applied Environmental Microbiology, Applied Microbiology and Biotechnology, 
Biochemistry, Journal of Biotechnology, Nature Biotechnology, Journal of Biological 
Chemistry, Journal of the American Chemical Society, Biotechnology and 
Bioengineering, Chemistry & Biology, Protein Science, FEBS Journal, Nature, Science, 
and Biochemical and Biophysical Research Communications. 
Using these criteria the ~1,275 articles in the GoPubMed database were 
scanned, first by title, then abstract, and finally the full text, and extracted information on 
enzyme class, screening method, mutagenesis protocol and enzyme turnover 
parameters. Initially, the database was limited to articles reporting kcat and Km; finding 
only 32 articles the criteria was expanded to include articles reporting Vmax, kcat, Km or 
kcat/Km. The final database contains 81 improved enzymes from 77 papers published in 
18 journals, and is listed in Table 1 of Appendix B, with references contained therein. 
The pruning results are depicted in Figure 1-6. 
Our initial goal was to identify articles that reported a fold improvement in kinetic 
parameter for wild-type enzyme and evolved enzyme. As the preceding discussion 
demonstrates, this ultimately was not always a clear cut process. Thus an important 
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caveat to be mentioned here is that while every effort was made to identify articles within 
the 1,275 member pool that met the stringent selection criteria, it is doubtless the case 
that some qualifying articles were overlooked. 
 
Figure 1-6. Article selection criteria for meta-analysis of directed evolution 
methodologies. The number of articles remaining after each round of pruning is labeled.  
 
 
 
While all enzyme classes (EC 1–7) are reported to have been optimized by 
directed evolution methods, the majority of the 77 articles meeting the selection criteria 
fell into three E.C. classes, (1) 23 oxidoreductases, (2) 22 transferases and (3) 28 
hydrolases (Figure 1-7A). Within the oxidoreductase category six enzymes were P450 or 
other heme based oxidases and only one was a cofactor-dependent reductase. The 
prevalence of hydroxylation enzymes in recent directed evolution campaigns (7 cases) 
may be reflective of the importance of hydroxylation in the alternative energy industry 
and the difficult nature of C–H bond activation reactions in the context of preparative 
organic synthesis. Additionally, formal oxidation of an amino or hydroxyl group to a keto 
group was well represented with 6 instances of class 1. The transferase category is the 
most functionally diverse and included members with such assorted activities as 
aminotransferase, kinase and glycosyltransferase. Within the dominant class, the 
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hydrolase category, the leading representatives were lipases, glycosyl hydrolases and 
esterases representing 3, 6, and 9 experiments respectively. The poorest represented 
enzyme class overall was that of ligase enzymes (e.g. synthetases). The low population 
of this class may be a result of the inherent difficulty in evolving multi-substrate 
enzymes, the lack of identification of interesting targets for evolution within this enzyme 
class, or absence of reported kinetic parameters meeting the criteria of this analysis. 
 
Figure 1-7. Statistical analysis of selected directed evolution experiments by enzyme 
class (A), mutagenesis method (B) or screen (C). Methods are described in detail in the 
text and in Appendix A. 
 
 
 
As previously discussed, there are a great variety of methods for introducing 
mutations into progenitor genes. In practice, most studies employed a combination of 
methodologies over several generations to achieve an optimized enzyme (Figure 1-7B). 
The workhorse of directed evolution appears to be error prone PCR, and it was this 
methodology that was responsible for the origination of many mutations and/or the 
determination of hot spots within a progenitor gene. Of the cases in this study, 51 used 
epPCR at some point in the evolutionary process. Saturation mutagenesis comprised 
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the second largest category, being used 36 times, revealing the importance of using 
structural and/or experimental prescience of active site residues to guide the directed 
evolution experiment. Gene shuffling was the least employed as a stand-alone method 
for introducing diversity. However, it was most frequently applied as the last step to 
combine beneficial mutations, and to remove deleterious or neutral changes. 
A popular aphorism of directed evolution is “you get what you screen for”80. To 
those practicing in the field, this may be prefixed with the qualification, “if you get 
anything…”. Indeed, it is impossible to determine the statistics for failed directed 
evolution experiments, although many campaigns reported null or minimal improvements 
in some rounds of mutagenesis and screening. In these cases, alternative mutagenesis 
strategies were devised to generate mutants with the desired improvement115, 116. Of 
successful reported experiments meeting the selection criteria, microtiter well-based 
assays were identified as the most common method of activity screening, although agar 
plate based selection and screening was also frequently employed (Figure 1-7). Liquid 
culture enrichment and FACS were each used in only a small fraction of the selected 
articles. This distribution of methods may be a reflection of the limited range of 
enzymatic activities that can be tied to cell survival or a fluorescent signal in whole cell 
imaging. Microtiter well-based assays in clarified cell lysate allow analysis via tracking 
changes in absorbance in the UV or visible light range and permit the use of tandem 
enzyme assays that may be required to link the desired reaction to a measurable 
parameter. Additionally, assays designed for microtiter plates can be subsequently 
analyzed by using autosamplers and HPLC, MS or capillary electrophoresis for direct 
product quantitation, making these approaches the most broadly applicable methods the 
for analysis of a wide variety of enzymatic reactions, albeit with substantially lower 
throughput. 
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The success of directed evolution studies can be measured in a variety of 
fashions, most typically by the attainment of the desired phenotype or the desired 
reaction yield. While providing valid criteria for success, these results form a difficult 
basis for evaluating these success in the context of the degree of improvement (i.e. 
almost all publications report success in the attainment of a desired chemo-phenotype). 
Correspondingly, selected papers were evaluated in the context of kinetic parameters, 
specifically kcat, Km and/or kcat/Km, the last parameter being the most frequently cited 
parameter. Interestingly, while the average fold improvement for kcat, Km, and kcat/Km 
were 366-, 12-, and 2 498-fold respectively, the median fold improvements were 
significantly lower at 5.4-, 3-, and 15.6-fold respectively. This disparity is a result of the 
small number of extremely large fold rate enhancements (see Table 1 in Appendix B, 
and discussion below). In both statistics, the improvements in Km were relatively low; this 
may be reflective of the lower dynamic range for Km values (often 10 μM to 10 mM) and 
the difficulty in selecting for improved binding during catalysis using common activity 
screening. 
The prevalence of a given classification or method may not predict its ultimate 
success. Figure 1-8 illustrates the relationship of the parameter kcat/Km to the 
classification schemes presented herein. Significant trends between the enzyme class, 
mutagenesis method or screening paradigm and the fold improvement were not 
identified. Enzymes with the greatest fold improvement (>100) were represented in every 
enzyme class, excepting lyases, using each mutagenesis method, and from every 
screening method. 
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Figure 1-8. Breakdown of enzymes improved by directed evolution studies by catalytic 
efficiency and turnover rate. A. Enzyme classification; B. Screening method; C. 
Mutagenesis method; D. Application.  
 
 
 
Of note, 7 out of the 14 cases that were identified reporting >100-fold 
improvement for a new substrate employed a form of saturation mutagenesis in their 
directed evolution strategy (Figure 1-8B). This correlation may be expected as it has 
been demonstrated that mutations closer to the binding pocket have a greater impact on 
enzymatic activity.117 There are numerous examples of studies comparing saturation 
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mutagenesis of residues in the binding site to whole-gene random mutagenesis. In each 
case, targeted mutagenesis strategies allow for smaller library sizes and equal, or better, 
levels of improvement. While this has been thoroughly documented77, 118, 119, this data 
suggests that saturation mutagenesis is not the only method resulting in large fold 
improvements, and it also does not guarantee a high level of success. 
An assumption of directed evolution is that a more complete search of the 
mutational space may allow for identification of more improved variants. While large 
library screens have been reported (e.g. >107 by FACS), the fold improvements did not 
scale with the size of the library screened. For instance, screening of only 300 clones in 
each of two rounds identified a carboxylesterase with 840-fold improved catalytic 
efficiency99 whereas a similar FACS based study resulted in a modest 5.5-fold 
improvement.120 
Finally, in the context of the generation of new biocatalytic enzymes the intent of 
each directed evolution study was examined and sorted each case into three types: 1) 
biocatalytic or biotechnological application studies; 2) studies which aimed to answer a 
scientific question, such as the evolutionary process; and 3) enzymes which were 
evolved to remove toxins for survival, for bioremediation, or to study drug resistance 
mechanisms (Figure 1-8D). Despite making up >50% of the cases, only one study out of 
14 with >100-fold improvement in enzyme function has biocatalytic application as the 
ultimate goal. Overall 41 studies of 81 were enzymes with potential biocatalytic 
application. 
The magnitude of rate enhancements may be perceived as modest from a 
biophysical perspective, with a median value of 5.4-fold for kcat. However, this 
improvement, and the improvements frequently observed as a result of improved protein 
production levels, may be deemed highly significant from a biotechnological perspective 
as the time and/or cost savings scale with increased turnover. 
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Biocatalytic Synthesis of Nucleoside Analogs 
To demonstrate the feasibility and utility of de novo biosynthetic pathways in 
reducing the cost of complex unnatural compounds, the chemo-enzymatic synthesis of 
2´,3´-dideoxyinosine has been studied. In terms of chemical structure, didanosine is the 
simplest dideoxynucleoside drug and representative of the broader class of 
dideoxynucleoside analogs (Figure 1-9)121. As a close analog of inosine, extensive 
biochemical and structural studies exist for both de novo biosynthesis and purine 
salvage pathways of inosine122, 123. Since a large fraction of nucleoside analogs are 
variants of 2´,3´-dideoxynucleosides, methods developed for ddI can be applied to the 
generation of biocatalytic pathways and biosynthetic production of many other analogs. 
 
Figure 1-9. 2´,3´-Dideoxynucleosides for treatment of HIV include didanosine, 
zalcitabine, stavudine, abacavir, zidovudine, and the experimental compound 
apracitabine. 
 
 
 
Nucleoside analogs have long been recognized for their utility in the treatment of 
viral infections and cancer. Since the synthesis of the first analogs in the 1950s, 
nucleoside analog drugs have become indispensable as therapeutic molecules in the 
treatment of the herpesviruses, HIV, papillomavirus, polyomaviruses, adenoviruses, 
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poxviruses, hepatitis B, and hepatitis C viruses and in the treatment of carcinomas such 
as leukemias, colorectal, pancreatic, bladder, breast, and non-small cell lung cancers. 
Furthermore, nucleoside analogs are utilized in DNA sequencing methodologies and 
other biotechnological techniques. As such a critical class of compounds the synthesis 
and biological activity of nucleoside analogs is a major area of study. 
Despite the broad efficacy of nucleoside analogs, high prices prohibit broad 
therapeutic application in some geographical areas with significant need, such as 
treatment of the AIDS epidemic in Sub-Saharan Africa. The cost of the manufacturing of 
the active ingredients of some drugs in this class comprise up to 55–99% of the final 
therapeutic price.16 These costs can be attributed to low yield chemical steps, many 
requiring chromatographic separation, and expensive starting materials. To illustrate 
this, a discussion of chemical synthetic methods for ddI is shared below. Because of the 
difficulty in synthesis even modest improvements in process yields or a switch to a less 
expensive starting material will facilitate broad distribution of critical drugs worldwide. 
 
Chemical Synthetic Methods for Production of Dideoxyinosine 
Webb et al first reported the synthesis of ddI in the literature in 1988124. Efficacy 
towards treatment of HIV was first reported in 1986 by Mitsuya and Broder125, who used 
commercially available sources for their studies17. It was approved for clinical use in 
1991 and remains a component in highly active anti-retroviral therapies and drug 
cocktails. Since then, a number of syntheses have been developed for ddI, falling into 
three general strategies, each utilizing a different starting material. Initial syntheses of 
ddI, and many of the other dideoxynucleosides, were accomplished from inosine and 
deoxyinosine126. Webb et al treated 5´-benzoyl protected 2´-deoxyinosine with 1,1´-
thiocarbonyldiimidazole to form a 3´-O-imidazolothionocarbonate derivative. Subsequent 
reduction with tributyltin oxide and AIBN/polymethylhydrosiloxane, followed by 
 41 
 
ammonolysis for deprotection, affords the final product in 33% yield (Figure 1-10).124 
This same process was previously reported for the synthesis of 2´,3´-dideoxyadenosine, 
2´,3´-dideoxyguanosine, 2´,3´-dideoxythymidine, and 2´,3´-dideoxycytosine.127 
 
Figure 1-10. Chemical synthesis of ddI by Barton deoxygenation of 2´-deoxyinosine and 
inosine. Reaction intermediates are shown from the syntheses of Webb et al124 and Torii 
et al133. A variety of thiocarbonyl derivatives have been demonstrated in this process. 
 
 
 
The Barton deoxygenation process has been improved upon128, 129 and also 
utilized with phenoxythionocarbonate130, 131 derivatives of 2´-deoxyinosine and β-
cyanoethyl-dithiocarbonate derivatives of inosine132. The application of 1-
ethylpiperidinium hypophosphite (EPHP) as a reducing agent and triethylborane as 
radical initiator by Torii et al avoids the necessary removal of tin oxide by silica 
chromatography and avails the Barton deoxygenation process to large-scale processes 
where remaining tin is toxic133. Torii and coworkers report a 60% yield from inosine to 
ddI. Where inosine is the starting material, a frequent intermediate is 2´,3´-didehydro-
2´,3´-dideoxyinosine; this intermediate is easily reduced by hydrogenation with palladium 
on carbon126. The Corey–Winters reduction of cyclic thiocarbonates, utilizing triethyl 
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phosphite, has been successfully applied, generating the unsaturated 2´,3´-didehydro-
2´,3´-dideoxyinosine intermediate and, subsequently, ddI132, 134. 
Figure 1-11. Chemical synthesis of ddI through application of the Mattocks reaction 
performs direct reduction of the bromoacetate to generate a mixture of deoxy- and 
dideoxy- products. Reductive elimination of the 2´ and 3´ functional groups to form the 
unsaturated nucleoside prior to hydrogenation forms the desired product, alleviating 
purification steps. 
 
 
 
A second method utilizing inosine as the starting material takes advantage of the 
specific reaction of 1,2-diols with α-acetoxyisobutyryl bromide, known as the Mattocks 
reaction, and depicted in Figure 1-11. The resulting acetoxy bromide can be directly 
reduced by catalytic hydrogenation although this frequently results in a mixed product 
composition of 2´- and 3´-deoxyinosine and ddI and a lower yield of pure ddI128. 
Reductive elimination processes with zinc or copper catalysts have generated the 2´,3´-
didehydro-2´,3´-dideoxyinosine species and hydrogenation with Pd/C generates ddI135. 
Modifications of the Eastwood olefination process, whereby a five-membered cyclic 
orthoformate fragments in the presence of an acid catalyst, has been used to generate 
2´,3´-dideoxyuridine, 2´,3´-didehydro-2´,3´-dideoxyadenosine, and 2´,3´-didehydro-2´,3´-
dideoxythymidine. This process is not widely applicable to generation of 
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dideoxynucleosides though, as the compounds are prone to elimination of the 
heterocyclic base and cleavage of the glycosidic bond under acidic conditions126. 
De novo synthesis of the unnatural sugar followed by addition of the nucleobase 
offers an alternative to inosine and deoxyinosine as the starting material. In 1989, Farina 
et al136 published the synthesis of ddI from glutamic acid and hypoxanthine (Figure 1-
12A). Deamination and cyclization of glutamic acid can be accomplished 
stereospecifically and reduction of the carboxylate results in a five carbon cyclic lactone. 
Upon protection of the 5-hydroxyl, further reduction of the lactone and acetylation affords 
the acetyl lactol as a mixture of anomers. Treatment with trimethylsilylbromide and 
addition of bis-silyladenine forms a racemic mix of ddA anomers upon deprotection. 
Dideoxyinosine is generated by enzymatic reaction with adenosine deaminase, which is 
selective for the β-anomer. The product can be purified through recrystallization in 
methanol and ddI is collected in <10% overall yield from glutamic acid136. Precedence for 
the use of adenosine deaminase to generate ddI from ddA comes from studies on the 
application of ddA as a prodrug137, 138.  Acid cleavage of ddA in the stomach, however, 
generates high levels of adenine which causes nephrotoxicity upon crystallization in the 
kidneys17. Dideoxyinosine has been synthesized directly, without the use of adenosine 
deaminase, in a method similar to Farina et al136. The generation of a 2-selenophenyl 
acetyl lactol  allows for stereocontrolled addition of the nucleobase (Figure 1-12B), 
providing the β-anomer as the major product. ddI is formed through reduction of the 2´-
selenophenyl-ddI through reduction with tributyltin hydride and triethylborane in 44% 
total yield139. This strategy, whereby the unnatural sugar is first synthesized, often results 
in the generation of enantiomeric products resulting in the loss of significant material or 
requiring chromatographic purification. 
Semi-synthetic methods for production of ddI have also been reported. In 
addition to the use of adenosine deaminase136-138, E. coli BL21 was studied as a 
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biocatalyst for production of nucleosides and nucleoside analogs by feeding uridine 
derivatives as the sugar-donor and either adenine or hypoxanthine as the base acceptor 
but found E. coli BL21 to be an inefficient catalyst for formation of ddI140. A screening 
program identified E. coli AJ 2595 cells that were capable of synthesizing 32 mM ddI 
from 100 mM hypoxanthine and 100 mM dideoxyuridine, which had been chemically 
synthesized, over 24 hours at optimal conditions141. Additionally, several patents address 
methods of ddI synthesis that use immobilized adenosine deaminase or whole cell 
cultures142, 143. 
 
Figure 1-12. De novo sugar synthesis for the chemical production of ddI often results in 
an anomeric mixture of product. Methods reported by Farina et al136 (A) and Beach et 
al139 (B) are highlighted. 
 
 
 
Bioretrosynthetic Design of a Chemo-enzymatic Pathway for ddI 
A biocatalytic pathway for ddI synthesis was designed using retrosynthetic and 
bioretrosynthetic principles. Potential transformations were chosen based on the 
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structure and reactivity of each molecule while matching those characteristics to other 
studies involving molecules of some similarity. This process, as applied to the design of 
a chemo-enzymatic pathway for ddI, will be outlined here, using the KEGG database to 
identify enzymes which catalyze the desired reaction on substrates similar to the target 
enzyme. Numerous pathways are possible, with some having steps with high risk levels 
or unlikelihood and others having the advantage of fewer steps. Several possible 
pathways are illustrated in Figure 1-13 and their benefits and challenges, in terms of 
available literature and engineering probability, will be discussed. 
Nucleosides are generated intracellularly through two pathways: de novo 
construction of nucleotides from phosphoribosyl pyrophosphate (PRPP), amino acids 
and folate and through the nucleoside and nucleotide salvage pathways. The de novo 
pathway is made up of 11–13 enzymes for purines and 6–14 for pyrimidines, making it 
an energy-expensive mechanism for nucleotide generation. Because of its length, 
modification of the de novo pathways to optimally synthesize ddI, from a simple sugar 
precursor, would be a tremendous undertaking, likely requiring the improvement of >10 
enzymes. 
 46 
 
 
Figure 1-13. Bioretrosynthetic analysis of ddI for identification of potential biocatalytic 
pathways. Enzymatic transformations which generate molecules similar to ddI (e.g. 
inosine or inosine monophosphate) are collected and compared. Each backward step 
brings about a simpler molecule. Analogous molecules for ddI synthesis are shown to 
the left of the red line. HGPRT – hypoxanthine-guanine phosphoribosyl transferase; PNP 
– purine nucleoside phosphorylase; PRPPS – phosphoribosyl pyrophosphate synthase; 
PPM – phosphopentomutase. 
 
 
 
In nature, salvage enzymes exist to scavenge exogenous sources of sugar and 
nucleobase to bypass the de novo synthesis process. Hypoxanthine-guanine 
phosphoribosyl transferase (HGPRT, EC 2.4.2.8) generates inosine monophosphate 
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from hypoxanthine and PRPP, an early precursor in nucleotide synthesis. Alternatively, 
inosine is formed by purine nucleoside phosphorylase (PNP, 2.4.2.1) from ribose 1-
phosphate and hypoxanthine, which is then phosphorylated to form the metabolically 
useful monophosphate. HGPRT and PNP are well-studied enzymes, each having been 
crystallized and with significant literature background available. To generate ddI utilizing 
a PRPP analog, however, will require dephosphorylation of the final product; if 
necessary, this could be accomplished by certain nucleotidases144. Potential substrates 
for these enzymes include 5-phospho-2,3-dideoxyribose α-1-pyrophosphate and α-2,3-
dideoxyribose 1-phosphate.  
Along this line, PRPP is formed intracellularly from other ribose phosphates, 
namely ribose 1,5-bisphosphate and ribose 1-phosphate. Ribose 1,5-bisphosphate 
phosphokinase (EC 2.7.4.23) and phosphoribosyl pyrophosphate synthetase (PRPPS, 
EC 2.7.6.1), utilize ATP to form PRPP and ADP or AMP, respectively. PRPPS from 
multiple species have been studied extensively, crystallized numerous times, and 
characterized with numerous substrates and through mutagenesis. An abundance of 
data makes PRPPS a promising target for enzyme engineering. Ribose 1,5-
bisphosphate phosphokinase, on the other hand, has only recently been described as a 
gene product in an E. coli NAD salvage pathway145, making a difficult and risky enzyme 
to work with. Ribose 1,5-bisphosphate, in turn, is synthesized from ribose 5-phosphate 
by phosphoribokinase (EC 2.7.1.18), another enzyme which has been minimally studied. 
Ribose 1-phosphate can be formed directly from ribose 5-phosphate by 
phosphopentomutase (EC 5.4.2.7), a second enzyme in the nucleoside salvage 
pathway. Phosphopentomutases (PPMs) have been identified in mammalian and 
bacterial species and activity for dideoxyribose phosphates shown to exist in certain 
bacterial isolates146. However, minimal structural data is available on PPMs and there 
are certain inconsistencies in the required cofactors and likely mechanism. (These 
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inconsistencies are described and explained in Chapter 4.) The formation of ribose 5-
phosphate from the general precursor ribose can be afforded by application of 
ribokinase (EC 2.7.1.15) and ATP. Ribokinase has been extensively studied and its 
mechanism of action described for many species. 2,3-dideoxyribose is, therefore, a 
potential precursor for ribokinase on the way to ddI. Thus, the pathway going through 
PRPP requires 3–4 enzymes to reach inosine monophosphate and the equivalent of 3 
molecules of ATP. Incorporation of PPM into the pathway affords the use of a single 
molecule of ATP and three total enzymes. 
Other enzymes are available to phosphorylate cyclic sugar derivatives outside of 
those for ribose described above. S-Methyl-5-thioribose kinase (EC 2.7.1.100) acts in 
the bacterial methionine salvage pathway enabling the consumption of S-methyl-5-
thioribose and S-methyl-5´-thioadenosine147. S-Methyl-5-thioribose kinase has been 
crystallized with S-methyl-5-thioribose and nucleotide substrates enabling the 
determinants of substrate specificity to be elucidated. Incorporation of S-methyl-5-
thioribose kinase would allow for direct biosynthesis of dideoxyribose 1-phosphate from 
dideoxyribose and thus, yield a short, two enzyme pathway to ddI. However, in addition 
to mutations required for changes of the substrate at the 2- and 3-position, mutations 
which allow the kinase to bind 5-hydroxy sugars will be necessary, making this a higher-
risk pathway.  
Dideoxyribose is a simple sugar derivative which can be chemically synthesized 
from glutamic acid using methods similar to the synthesis of ddI by Farina et al136. As 
stated previously, this strategy maintains the stereochemistry of the starting material. 
Glutamic acid, a commodity material with application in flavorings, cyclizes under acidic 
conditions in the presence of NaNO2 to form (S)-γ-butyrolactone-γ-carboxylic acid. Step-
wise reduction of the carboxylic acid and the lactone will form the desired (S)-γ-
hydroxymethyl-γ-butyrolactol. Modification of the Farina et al synthesis pathway to utilize 
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enzymes earlier in the process alleviates the generation of α-nucleosides, immediately 
increasing the yield by reducing the amount of side products formed. 
 
Figure 1-14. Biocatalytic pathway for directed biosynthesis of 2´,3´-dideoxyinosine 
starting from glutamic acid and utilizing ribokinase (RK), phosphopentomutase (PPM) 
and purine nucleoside phosphorylase (PNP) 
 
 
 
Each of the previously described enzymes naturally functions on ribose or a 
ribose-like molecule and activity is likely to be low for the dideoxy derivative. Because of 
this, enzyme engineering will be a necessary part of the pathway optimization. Despite 
great effort and years of study, some reported here, a limited understanding of enzyme 
mutagenesis on structure and function makes the outcome of mutagenesis studies 
difficult to predict, even under ideal conditions. For this reason, the shorter pathway 
utilizing S-methyl-5-thioribose kinase carries a certain element of risk. A pathway 
involving PNP, PPM, and ribokinase was chosen as a probable pathway for synthesis of 
ddI. The resulting pathway is depicted in Figure 1-14. 
 
Dissertation Statement 
The main topic of this dissertation is the generation of a de novo biocatalytic 
pathway for ddI. A three enzyme pathway for biosynthesis of ddI from glutamic acid and 
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hypoxanthine has been designed using a bioretrosynthetic approach. Stereo- and 
regioselective properties of enzymes will greatly simplify the synthesis of ddI. Production 
of this critical anti-HIV compound from commodity materials could provide a significantly 
less expensive method for ddI synthesis as compared to the natural nucleoside 
precursors likely used in chemical production. Since a significant portion of nucleoside 
analog drug cost is accrued during production of the active ingredient, even a small 
decrease in price will alleviate the financial burden placed on HIV-infected individuals in 
poor countries. An in vitro demonstration of the pathway is discussed in chapter 5. 
For biocatalytic production to be feasible at process levels, the turnover of each 
enzyme in the pathway must be improved. Rational active site redesign involving site-
directed mutagenesis based on structural, functional and binding data and directed 
evolution are methods which enable tuning of enzymatic properties to the required task. 
The application of computational design tools and directed evolution to improve the final 
enzyme in the proposed pathway, human purine nucleoside phosphorylase, is 
demonstrated in chapters 2 and 3, respectively. 
Chapter 4 focuses on the biochemical and structural characterization of 
phosphopentomutase, the penultimate enzyme in the proposed pathway. Rational 
design requires knowledge of the substrate binding mode within the enzyme. Prior to this 
work, no crystal structures of a bacterial phosphopentomutase had been described in 
the literature. Furthermore, the catalytic cycle had not been fully described. This work 
identifies critical enzyme-substrate interactions and clarifies the turnover cycle of PPM. 
Microbial factories make possible efficient production of complex molecules 
utilizing environmentally friendly reaction conditions and offer many advantages over 
large-scale chemical syntheses. The work presented in this dissertation provides a base 
for subsequent in vivo pathway demonstration, improvement of each enzyme in the 
proposed pathway and metabolic engineering of organisms for microbial ddI production. 
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Chapter II 
 
RATIONAL AND COMPUTATIONAL DESIGN OF THE SUBSTRATE BINDING 
POCKET OF HUMAN PURINE NUCLEOSIDE PHOSPHORYLASE1 
 
Introduction 
Nucleoside analog drugs are primary therapeutics in the treatment of viral 
infections including HIV2 and hepatitis3. Indeed, it has recently been reported that of the 
25 drugs currently approved in the USA for the treatment of HIV, eight are nucleoside 
analogs2. Nucleoside analogs are also currently in advanced stage clinical trials for the 
treatment of various cancers including leukemia4. The broad efficacy of these 
compounds contrasts with their price. The cost of the manufacturing of the active 
ingredients of some of these drugs comprise up to 55–99% of the final therapeutic 
price5, a fact which has spurred the continuing development of new methods for the 
synthesis of nucleoside analogs. 
Currently, there is great interest in developing biocatalytic and chemo-enzymatic 
alternatives for the synthesis of nucleoside analogs, which will enable regio- and 
enantioselective synthesis of these critical compounds. Toward this aim, 2´,3´-
dideoxyinosine was targeted for directed biosynthesis as a representative of the broader 
class of dideoxynucleoside drugs. Dideoxyinosine (ddI) is a nucleoside reverse 
transcriptase inhibitor and is a close analog of the primary metabolite inosine. Both de 
novo biosynthesis and purine salvage pathways for inosine have been extensively 
characterized in biochemical and structural studies6, 7. As a large fraction of nucleoside 
analogs are variants of 2´,3´-dideoxynucleosides, methods developed for ddI may have 
broader application2. 
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Enzymes with new or improved functions are increasingly generated from 
existing enzymes or scaffolds by a 2-fold strategy consisting of (i) rational mutational 
active site remodeling, to modify binding specificity for a desired reaction or substrate, 
followed by (ii) optimization of global protein function by more stochastic methods such 
as directed evolution. Prerequisites to the first stage are the identification of a progenitor 
enzyme or scaffold with a suitable starting activity and acquisition of some knowledge of 
the active site geometry from structural data or homology models. If a suitable enzyme is 
identified, first or second shell interacting active site residues are selected for mutation 
and functional assessment8-10. As even the most prudently selected active site mutations 
may result in unexpected catalytic consequences, the complete complement of amino 
acids at targeted active site residues is often generated by saturation mutagenesis11. 
To focus these efforts, it would be desirable to identify a subset of potentially 
beneficial mutations, particularly in cases in which permutations of several active site 
residues may be required simultaneously. Many computational protein design strategies 
have been developed to engineer alternative ligand specificity into proteins and generate 
enzyme variants with improved activity on non-cognate substrates12. Recently, methods 
incorporated in the Rosetta program have been developed to estimate relative ligand–
protein interaction energies with conformational flexibility. RosettaLigand employs a 
Monte Carlo-based search algorithm with protein side chains replaced by residues from 
a rotamer library13, 14. It is easily combined with RosettaDesign15 allowing for redesign of 
binding pockets16. Indeed, the Rosetta framework has been extended to the design of 
enzymes catalyzing both natural (retro-aldol17) and nonnatural (Kemp elimination18) 
reactions in the context of novel protein scaffolds19. The protocol identifies critical 
interactions between transition state models and catalytic residues. Subsequently, 
adjacent amino acids are placed in the binding site to optimize stability of the catalytic 
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residues and specificity for the ligand. The initial computational designs displayed low 
catalytic activity and were further improved through directed evolution and screening. 
Herein, the identification of human purine nucleoside phosphorylase (hPNP) as 
an engineering candidate for nucleoside analog biocatalysis is described. Human PNP 
catalyzes the reversible synthesis or phosphorolysis of 6-oxopurine (deoxy)nucleosides. 
As PNPs play a critical role in human and pathogen physiology, numerous studies have 
been performed to biochemically and structurally characterize this class of enzymes. 
This knowledge permitted the identification of a single first shell active site residue, Tyr-
88 (Y88), as a potential modulator of ribose substrate selectivity20, 21. Additionally, 
computational design of the hPNP binding site in the presence of inosine and ddI 
suggested Y88 as critical for differentiation of the two substrates. This result 
demonstrates that the computational method is generally applicable to focus 
experimental studies on specific sites and selected mutants thereby reducing 
experimental effort and accelerating research. RosettaLigand was used to predict 
changes in transition state binding free energy, or activation energy, upon mutation of 
this position to all genetically encoded amino acids except glycine and proline. Mutation 
to phenylalanine was consistently predicted to increase catalytic activity with respect to 
ddI. Experimental testing finds Y88F is 23.6-fold more efficient for ddI phosphorolysis 
than wild type hPNP and 2.9-fold less efficient for inosine. Systematic experimental 
analysis of all Y88X single mutants finds good agreement of Rosetta predictions with 
experimental data for all but negatively charged amino acids. 
The present study differs from previous enzyme designs in that Rosetta is tested 
in a limiting setup where scaffold, binding mode and even a single site of mutation are 
predetermined. Thereby success hinges on accurate prediction of binding free energy 
changes for mutations at the Y88 site. The results demonstrate the general ability of 
Rosetta to identify favorable mutations in enzyme catalytic sites and enabled a 
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customization of the Rosetta energy function to improve correlation between predicted 
and experimentally determined transition state binding affinities to R = 0.65. However, 
these results point also to inaccuracies in handling electrostatics, in particular for 
charged amino acids, where further improvement of the Rosetta energy function is 
needed. 
The Y88F variant then became the starting point for a directed evolution study. A 
high-throughput assay was developed and combined with error-prone PCR (epPCR) to 
generate and test libraries of PNP mutants. Three rounds of mutation and selection 
resulted in an enzyme with a modest 3-fold improvement in turnover compared with 
Y88F in in vitro assays. The directed evolution of PNP is described in Chapter 3. 
To the best of our knowledge, this study comprises the first engineering of a 
nucleoside phosphorylase for the biosynthesis of an unnatural dideoxynucleoside. This 
work demonstrates that a combination approach of targeted active site mutation and 
directed evolution may find future application in nucleoside analog biosynthetic pathway 
engineering. 
 
Methods 
Transition State Model 
Transition state models for docking and calculation of binding energies 
incorporate critical characteristics of the mechanism and transition state. The binding 
modes of substrates (PDB ID 1m73, 1a9s, 1rct, 1v2h, 1pwy, 1rfg), substrate analogs 
(PDB ID 1a9t, 1v41, 1v3q, 1v45, 1rt9) and transition state analog inhibitors (PDB ID 
1pf7, 1rsz, 1rr6, 1b8o) crystallized with human and bovine PNP were studied for their 
resemblance to the experimentally-derived transition state (Figure 2-1A)22. Coordinates 
of ligands with characteristics matching the known transition state were used as internal 
coordinates of the transition state model. Phosphate coordinates are derived from ribose 
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1-phosphate crystallized in bovine PNP (PDB ID 1a9t) as OP is oriented appropriately for 
nucleophilic attack (Figure 2-1B). The P–OP bond in this structure is ~0.22 Å longer than 
the other P–O bonds recapitulating the known bond lengthening of ~0.23 Å as the 
reaction coordinate progresses23. The purine of DADME-Immucilin-H (PDB ID 1rsz) is 
the aromatic base for both inosine and ddI transition state models (Figure 2-1C)24. 
Separate coordinates for the sugar residues of inosine and ddI transition state models 
(Figure 2-1D,E) were taken from Immucilin-H (PDB ID 1pf7) and ddI (PDB ID 1v3q), 
respectively. The ring shape in ddI is flatter than that of nucleosides with hydroxyls at the 
2´ or 3´ positions. Internal coordinates of the Immucilin-H sugar moiety were used for the 
inosine transition state model to best replicate the position of the 5´-OH over the 4´-O. 
The O5´-C5´-C4´-C3´ dihedral of Immucilin-H in 1pf7 is 62.72°. For ddI, the 5´-OH of the 
dideoxyribose moiety was rotated manually to match that of Immucilin-H. The ddI 
transition state model has an O5´-C5´-C4´-C3´ dihedral angle of 65.41°. The sugar 
moiety was aligned with the average C3´, C4´, and C5´ position from the aligned 
structures and a point directly between N9 of the purine and OP of the phosphate which 
put the anomeric carbon 2.56 Å from N9 and 2.66 Å from OP, both of which are shorter 
than the known value of 3 Å calculated from kinetic isotope effect22. 
 
Computational Mutation and Docking 
Trimeric hPNP coordinates were obtained from the Protein Data Bank (PDB ID 
1rct, 1pf7, 1rr6, 1v3q) and relaxed using a combination of Monte Carlo rotamer 
replacement and gradient based minimization25 to generate an ensemble of ten energy 
minimized models for each parent structure. Inosine and ddI transition state models 
were placed in the binding site of the minimized backbone ensemble for the ensemble 
derived from 1pf7 for docking and design. 
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Figure 2-1. Construction of inosine and dideoxyinosine transition state models. A. The 
human PNP transition state structure consists of a highly dissociative ribooxocarbenium 
ion transition state. Transition state models for inosine (D) and ddI (E) were generated 
through combination of the purine coordinates from Immucilin-H (C, PDB ID 1pf7) and 
the phosphate coordinates of ribose 1-phosphate (B, PDB ID 1a9t). 
 
 
 
Residues in the hPNP binding site involved in substrate selectivity of inosine over 
ddI were identified by redesigning the binding pocket around each transition state model. 
As shown in Figure 2-2, 23 residues with Cα or Cβ atoms within 8 angstroms of the 
ligand and Cα/Cβ vectors oriented toward the binding site were allowed to mutate. To 
facilitate an unbiased design process the amino acid identity for all 23 residues was 
converted to alanine. The position of inosine and ddI transition state models was 
optimized during design of these 23 residues along with concurrent repacking of 
additional side chains in the vicinity of the bindsite. Three iterative rounds of design were 
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performed to pare down the list of mutable residues. Residues that Rosetta filled with the 
wild-type amino acid were converted back to the original identity after each round and 
fixed in this identity for subsequent rounds along with residues that lack interaction with 
substrate transition state models.  
 
Figure 2-2. Identification of selectivity modulating amino acids in the hPNP binding site 
by computational design. The Cα and Cβ atoms of residues undergoing design are 
represented as blue spheres and sticks. The transition state analog Immucilin-H and 
sulfate are depicted as sticks (PDB ID 1pf7). This image copyright of Oxford University 
Press. Reproduced with permission. Adapted from Nannemann, et al.1 
 
 
 
To identify sites for which enable differentiation of inosine and ddI the Rosetta-
suggested mutations for the remaining six sites were compared for each substrate. 
These sites were computationally analyzed for predicted selectivity and ddI transition 
state binding energy in single mutations by docking and by a comparison of the 
information-weighted Euclidian distance for the design results of the final round. For 
each position the Euclidean distance di between substrate A  and substrate B (in this 
case inosine and ddI, respectively) at design position i is calculated as 
𝑑𝑖 = �∑ �𝑏𝑖𝐴𝑣𝑖𝑘𝐴 − 𝑏𝑖𝐵𝑣𝑖𝑘𝐵 �2𝑛𝑘=1 . The vector of amino acid frequencies at position i is 
represented by vi and bi is the total number of bits of information at that position, 
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calculated as 𝑏𝑖 = log2 𝑛 +  ∑ 𝑣𝑖𝑘 log2 𝑣𝑖𝑘𝑛𝑘=1 . The position with the greatest information-
weighted Euclidian distance is implicated as a primary selectivity controlling position. 
Based on this computational analysis and biochemical data Y88 was identified as 
a likely modulator of substrate selectivity; therefore, the identity of Y88 was altered to 
each possible amino acid (excluding Pro and Gly). All side-chains in the active site were 
optimized using a backbone-dependent rotamer library26, 27 while all other amino acids 
were held in their minimized conformation. High-resolution docking of transition state 
models and optimization of side-chain interactions was achieved through Monte Carlo 
minimization of side-chain rotamers and intense sampling of the ligand orientation. 
Energies for the unbound and bound forms of the enzyme were calculated using 
the Rosetta energy function. The function is a linear combination of weighted scores 
including a Lennard–Jones attractive and repulsive potential, an orientation dependent 
hydrogen-bonding potential, Coulomb electrostatics and an implicit solvation model. 
Transition state binding energy is calculated as ∆∆𝐺 = ∆Gbound − ∆Gunbound28-30. Weights 
for individual parameters of the energy function were established using multiple linear 
regression. The correlation to the experimental activation energy 
(∆G𝑇𝑆‡ = −𝑅𝑇 ln(𝑘cat 𝐾m⁄ ))31 of each mutant with each substrate was optimized in a 
leave-one-out (LOO) cross-validation scheme. For each substrate/mutant/backbone 
combination the scores of the top ten models were averaged to minimize noise in the 
predicted binding free energy32. 
 
Cloning, production and purification of hPNP and site directed mutants 
Expression vector pCRT7/NT-TOPO-PNP, containing wild-type hPNP, was 
generously provided by Prof. Vern Schramm22 and NdeI/HindIII restriction sites were 
added to facilitate cloning into pET28a (forward primer: 5´-CATATGGAGAACGG-
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ATACACCTATGAAGATTATAAG-3´, reverse primer: 
5´-AAGCTTCAAGTGGCTTTGTCAG-GGAGTG-3´). Site directed mutations at position 
88 were generated using the Quikchange-II system (Stratagene, La Jolla, CA) (forward 
primer: 5´-GCAGGTTCCACATGXXXGAAGGGTACCCACTCTGG-3´, reverse primer: 
5´-CCAGAGTGGGTACCCTTCXXXCATGTGGAACCTGC-3´, where XXX was the 
variable codon). Mutations were verified via DNA sequencing.  
Individual PNP mutants were over-expressed as N-terminal hexahistidine tagged 
constructs in E. coli BL21(DE3). Strains harboring mutant PNP constructs were grown 
with shaking in 500 mL of LB broth with 50 μg/mL kanamycin at 37 °C. At OD600 ≈ 0.6 
cultures were induced with 1 mM isopropyl-β-D-1-thiogalactopyranoside and allowed to 
incubate for an additional 6–10 h. Cells were harvested by centrifugation and cell pellets 
were frozen at -80 °C until immediately before purification. Cells were resuspended in 
Binding Buffer (50 mM Na2HPO4, 300 mM NaCl, 10 mM imidazole, pH 8), disrupted by 
passage through a French pressure cell and centrifuged to remove cellular debris. The 
soluble proteins were purified in a single step via Ni-affinity chromatography using a 
HisTrap FF column on an AKTA FPLC (GE Healthcare Life Sciences). Proteins were 
eluted using a linear gradient from 100% Binding Buffer to 100% Elution Buffer (50 mM 
Na2HPO4, 300 mM NaCl, 500 mM Imidazole, pH 8). The sample was desalted and 
stored in Exchange Buffer (100 mM Tris HCl, 0.1 mM EDTA, 0.1 mM DTT, pH 7.5) at -80 
°C23. All enzyme concentrations were determined via λ280 measurements and extinction 
coefficients were estimated using Accelrys DSGene 1.5. 
 
Biochemical Assays of PNP 
PNP assays were performed in the phosphorolysis direction by continuously 
monitoring the formation of hypoxanthine33. A catalytic excess of xanthine oxidase was 
used in a tandem assay converting hypoxanthine to uric acid with concomitant reduction 
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of iodonitrotetrazolium chloride (INT) to form a formazan chromophore (λmax: 546 nm). 
Assay Mix buffer contained 50 mM potassium phosphate saturated with O2, 50 mM 
HEPES, 0.075% Triton X-100, 1 mM INT, and xanthine oxidase from buttermilk (Sigma). 
Substrates were dissolved in Assay Mix at concentration ranges of 20–200 μM or 100–
1000 μM inosine and 250–2500 μM or 750–7500 μM ddI (Fluka and 3B Medical 
Systems, Inc.) depending on preliminary substrate concentration response curves. For 
each mutant, the concentration of enzymes diluted in Assay Mix were adjusted to 
produce rates within the dynamic range of the assay and < 15% consumption of 
substrate was observed over time course measurements. Correspondingly, PNP 
concentration ranges of 0.006–2 μM for measuring inosine rates and 0.02–10 μM for 
measuring ddI rates were used with substrate ranges spanning the Km region, wherever 
possible. The assays were performed as follows: 100 μL of substrate dissolved in Assay 
Mix was transferred into wells of a flat bottomed 96-well plate, equilibrated at 25 °C, 
followed by addition of 100 μL of assay mix containing PNP. The rate of hypoxanthine 
formation was observed by monitoring tandem formazan formation by its unique 
absorbance at 546 nm over 5 minutes. A hypoxanthine standard curve was performed in 
parallel with each concentration series to convert absorbance numbers into molar 
turnover values. 
 
Results 
Progenitor Identification and Design Rationale 
An understanding of the effects of enzyme structure on activity and substrate 
preference is critical to enzyme selection for biocatalytic application and subsequent 
rational redesign. Nucleoside phosphorylases have been studied extensively because of 
their role in human disease and potential for drug development. Deficiencies in PNP 
result in a marked effect on T cell and cellular immune function, while B cell and humoral 
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immunity remain unaffected21. Thus, inhibition of the enzyme shows potential in 
treatment of T-cell and auto immune diseases34. Since nucleoside phosphorylases play 
a critical role in metabolism of nucleoside and nucleotide analog drugs the enzyme is a 
target for treatment of pathogens, such as Plasmodium falciparum22 and Mycobacterium 
tuberculosis35, 36. For these reasons, the mechanism has been studied in detail. 
Nucleoside phosphorylases have one of two folds which are broken down into 
the NP-I and NP-II families. NP-I family members possess an α/β-subunit fold while the 
NP-II family forms a dimeric quaternary structure consisting of an α-domain and a mixed 
α/β domain. In this work, the purine nucleoside phosphorylases (PNPs), which are NP-I 
family members, are of primary interest. PNPs of the NP-I family exist in either trimeric 
or hexameric quaternary structures but maintain a strikingly similar tertiary fold 
throughout the family (Figure 2-3A–D). PNPs from higher organisms and prokaryotic 
PNPs have the trimeric quaternary fold while lower organisms primarily possess the 
hexameric form. As such, trimeric and hexameric PNPs are typically represented by 
human (hPNP) and E. coli (ecPNP) variants. 
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Figure 2-3. Structural overview of purine nucleoside phosphorylases in the NP-1 fold 
family. Human and E. coli PNP represent trimeric (A) and hexameric (B) quaternary 
structures of the NP-1 family (PDB ID 1rct and 1pr0, respectively). Fold diagrams for 
trimeric (C) and hexameric (D) PNP demonstrate a similar tertiary fold within each 
monomer. Quaternary structure differences are reflected in the binding site of trimeric 
(E) and hexameric (F) PNPs. Critical interactions between protein and sugar are shown 
in blue. 
 
 
 
Differences in the quaternary fold are reflected in the binding site and 
significantly affect the substrate selectivity (Figure 2-3E,F). Trimeric PNPs are specific to 
the 6-oxo purines hypoxanthine and guanine whereas hexameric PNPs are 
indiscriminate at the nucleobase. Each fold orients phosphate in a similar manner with 
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the trimeric PNPs having an additional Glu-His diad which serves to activate phosphate. 
The target compound, ddI, and the natural substrate, inosine, differ only in the atomic 
make-up of the sugar, so this region is of particular importance to a rational redesign 
effort. Both trimeric and hexameric PNPs utilize backbone and side chain contacts to 
orient substrate. Each PNP forms a hydrogen bond between the 2´-hydroxyl and the 
backbone nitrogen of a methionine. The fact that both quaternary forms utilize 2´-
deoxynucleosides as substrate is an indication that this backbone – side chain 
interaction is not critical for function. Because of this, and that it is currently difficult to 
engineer changes in backbone–substrate contacts, interactions between protein side 
chains and the substrate have been targeted. In hPNP, a hydrogen bond is present 
between Y88 and the 3´-hydroxyl of inosine while ecPNP forms a bidentate interaction 
between Glu-181 and ribosyl nucleosides (Figure 2-3E,F). Human PNP has been 
chosen as a starting point for development of dideoxynucleoside phosphorylase catalytic 
activity for two reasons: first, side chain interactions are limited to one hydroxyl on the 
substrate; and second, mutations at Y88 of hPNP are tolerated to a greater degree than 
mutations at Glu-181 of ecPNP (Erion et al20 and unpublished results). 
Upon identification of hPNP as an ideal starting point for engineering, a full 
understanding of the hPNP mechanism and knowledge of the contributions of each 
residue in the binding pocket is necessary for application of computational bindsite 
optimization. Overall, the transition state for nucleoside phosphorolysis is highly 
dissociative37 and there is strong ribooxacarbenium ion character24. Throughout the 
reaction coordinate of hPNP the purine ring is positioned via hydrogen bonding 
interactions with Asn-243 and Glu-201. The nucleophilic phosphate is positioned by a 
complex network of hydrogen bonding interactions (Figure 2-3E) and activated for 
addition to C1´ by a His-86/Glu-89 diad. As noted earlier, there appear to be relatively 
few significant ribose binding interactions, namely His-257 contacting O5´ and Y88, 
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which forms a hydrogen bond with O3´. The O3´ hydroxyl is also implicated in 
coordinating to the phosphate ligand and has been suggested to play a role in optimizing 
the geometry of the transition state.20 As side chain contacts between the ligand and 
substituted sugar atoms are limited to Y88, this residue is a primary contributor to 
substrate selectivity in the ribose binding region and, thus, a main target for rational 
redesign. 
 
Binding Energy Calculations  
An initial gradient-based energy minimization25 of the experimental protein 
structure was carried out in the absence of substrate to obtain an unbiased starting 
conformation of the protein that occupies a minimum in the energy landscape. The 
lowest energy structure had a Cα-rmsd of 0.64 Å from the experimental coordinates 
(PDB ID 1pf7). The average Cα-rmsd of the ten lowest energy minimized structures was 
~0.86 Å. 
Transition state models for inosine and ddI were constructed based on 
experimental and crystallographic data (see methods section and Figure 2-1). Docking 
of the transition state models allows for calculation of transition state binding energies 
and prediction of enzymatic activity. For this purpose the transition state models were 
placed into the minimized protein structures and the position and orientation of the 
transition state model was optimized together with the conformations of residues near 
the binding site using the RosettaLigand energy function13, 14.  
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Figure 2-4. Identification of hPNP substrate selectivity residues through differential 
analysis of designed residues and binding energies. Results of active-site redesign of 
residues in Figure 2-2 for inosine and ddI are shown as the frequency of a given 
mutation at each position by plotting information content using the WebLogo server38. 23 
residues were allowed to design during the first round (a), 13 during the second round 
(b) and 6 during the third round (c). Mutations altering substrate selectivity were 
identified through calculation of the information-normalized Euclidean distance (d), the 
predicted binding energy (∆∆G) for ddI (e) and substrate binding preferences (∆∆∆G) (f). 
This image copyright of Oxford University Press. Reproduced with permission. Adapted 
from Nannemann, et al.1 
 
 
 
To demonstrate the applicability of the docking protocol to the identification of 
specificity encoding sites the RosettaDesign algorithm was used to identify amino acids 
in the binding site that maintain tight binding upon mutation but display a differential 
mutation profile in the presence of inosine and ddI. There are 23 amino acids that have 
Cα or Cβ atoms within 8 Å of the transition state analog ImmucilinH (PDB ID 1pf7) and 
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point toward the binding site (Figure 2-2). Each of these amino acids was allowed to 
mutate to any other amino acid in the presence of ddI or inosine transition state analogs. 
The frequency of each amino acid in each position was evaluated using the publicly 
available WebLogo server38. Residues populated by Rosetta with the wild-type identity 
are not expected to affect a change in substrate binding characteristics. Similarly, 
residues designed by Rosetta to interact with neighboring amino acids or turned toward 
solvent would not be expected to alter the substrate activity profile. With such an 
analysis 17 residues had been reverted to wild-type after two rounds of iterative 
refinement (Figure 2-4A-B). Five of the six remaining residues (F159, Y88, A116, F200, 
M219 and V245) interact with the sugar moiety of the transition state models. The 
obtained mutation profiles were rather similar suggesting that minimal differentiation 
between the two ligands will be achieved (Figure 2-4C). Suggested mutations for Y88 
indicate that tyrosine is ideal for this location; secondary predictions, however, differ 
significantly for inosine and ddI (His and Asn, respectively) indicating the potential for 
modulating the substrate selectivity and specificity by mutating this position. The 
information-normalized Euclidean distance for each design position was calculated to 
quantify the impact of each residue on selectivity. This analysis further points to Y88 as 
a selectivity-modulating residue. 
Next, step-wise analysis of all proposed single mutants was performed. All six 
positions were mutated sequentially to all amino acids proposed by Rosetta and affinity 
for the ddI transition state model as well as preference for the ddI transition state model 
above the inosine transition state model was computed (Figure 2-4D-E). Y88 remains as 
the only site that fulfills criteria for both tight binding to transition state models and 
displays a differential mutation profile. Consequentially, Y88 was mutated in silico 
through replacement of the wild-type side chain to all possible amino acids (except Pro 
and Gly) and the transition state models were re-docked.  
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Using this protocol a first round of seven single mutants was initially 
characterized: Y88F/A/C/I/L/W/K. These mutants were selected for predicted high ddI 
activity, a range in predicted activity and variety in the side-chain character. In a second 
round of experiments all Y88X mutants were generated, purified, and characterized to 
comprehensively analyze the ability of RosettaLigand to rank individual mutations (Table 
2-1). Mutants predicted to form tight complexes with the ddI transition state model 
include Y88F, Y88L, and Y88M as well as the negatively charged amino acid mutations 
Y88D and Y88E (Figure 2-5). 
Table 2-1. Kinetic Characteristics for hPNP-Y88Xa 
Variant kcat (s-1) Km (µM) kcat/Km ( s-1 M-1) 
 Inosine ddI Inosine ddI Inosine ( x 102) ddI 
Wild-type 43.9 ± 0.6 0.9 ± 0.01 48 ± 2 1030 ± 20 9210 ± 140 875 ± 8 
Y88F 28.3 ± 0.7 10.5 ± 0.1 73 ± 4 450 ± 10 3890 ± 110 23140 ± 230 
Y88H 8.6 ± 0.2 2.5 ± 0.1 74 ± 3 675 ± 20 1160 ± 23 3670 ± 60 
Y88W 5.6 ± 0.1 0.09 ± 0.01 500 ± 25 980 ± 40 113 ± 3 91 ± 2 
Y88A 17.6 ± 0.4 2.8 ± 0.05 80 ± 3 1670 ± 50 2190 ± 51 1670 ± 22 
Y88V 2.4 ± 0.1 0.6 ± 0.01 1200 ± 60 4410 ± 160 19.6 ± 0.7 144 ± 3 
Y88L 15.9 ± 0.3 6.1 ± 0.05 94 ± 4 391 ± 8 1690 ± 34 15670 ± 130 
Y88I 1.3 ± 0.1 0.5 ± 0.02 1420 ± 55 4670 ± 270 9.4 ± 0.3 115 ± 4 
Y88M 12.8 ± 0.1 5.2 ± 0.1 345 ± 7 645 ± 20 371 ± 3 8090 ± 90 
Y88C 5.5 ± 0.2 2.5 ± 0.1 170 ± 10 810 ± 30 321 ± 13 3070 ± 60 
Y88S 8.8 ± 0.1 2.7 ± 0.1 430 ± 10 4060 ± 110 203 ± 3 652 ± 10 
Y88T 2.3 ± 0.1 0.4 ± 0.01 1200 ± 70 8160 ± 280 19 ± 1 44 ± 1 
Y88N 9.7 ± 0.2 1.5 ± 0.1 845 ± 25 9530 ± 540 114 ± 2 153 ± 6 
Y88Q 1.4 ± 0.1 0.15 ± 0.01 855 ± 50 860 ± 25 17 ± 0.6 177 ± 2 
Y88D 0.8 ± 0.1 0.02 ± 0.001 2600 ± 120 12700 ± 500 2.9 ± 0.1 1.8 ± 0.5 
Y88E 0.7 ± 0.1 0.01 ± 0.001 4860 ± 410 14900 ± 1200 1.4 ± 0.1 0.9 ± 0.1 
Y88K ND ND ND ND ND ND 
Y88R 0.01 ± 0.001 ND 370 ± 20 ND 0.0184 ± 0.0005 ND 
a. Assay conditions: 50 mM phosphate buffer, pH = 7, 50 mM HEPES, pH 7, 0.075% Triton X-100, 1 mM INT, 
xanthine oxidase. Inosine: 20–200 or 100–1000 μM. ddI: 250–2500 or 750–7500 μM. Enzymes were assayed at 
concentrations which ensure steady state conditions. 
 
 
 
In wild-type hPNP, the phosphorolysis of inosine is three orders of magnitude 
more efficient than that of ddI. The values of Km and kcat reported here are similar to 
those previously reported for inosine20, 21. Each single mutant had decreased kcat and 
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increased Km values for inosine. Positively charged Y88K and Y88R mutants were not 
sufficiently active for kinetic characterization at enzyme concentrations more than five 
hundred times those used for the wild-type enzyme; accordingly, they were not included 
in the in silico analyses. In line with the in silico prediction, the Y88F mutant displayed 
the second highest catalytic activity. 
 
Figure 2-5. Correlation of experimental binding energy to binding energy predicted with 
the standard RosettaLigand weight-set for (A) inosine and (B) ddI. , inosine; , ddI. 
REU are Rosetta Energy Units. Error bars indicate standard deviation of top ten 
transition state bound models. This image copyright of Oxford University Press. 
Reproduced with permission. Adapted from Nannemann, et al.1 
 
 
 
Six mutants demonstrated a higher catalytic efficiency for ddI than the wild-type 
enzyme. A similar profile for toleration of mutations was seen with ddI as with inosine 
however it appears that almost any mutation allows for some improvement in the 
catalytic efficiency ratio relative to wild-type hPNP. As predicted in silico Y88F, Y88L, 
and Y88M displayed the highest catalytic activities. Of these, hPNP-Y88F displayed the 
highest overall catalytic efficiency and the highest turnover rate. Y88D/E mutants did not 
show the predicted high activity. It is expected that addition of a negative charge to the 
binding site disrupts the sensitive arrangements of partial charges in the catalytic site, an 
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effect that is not considered by RosettaLigand as it solely optimizes binding affinity and 
has no means to directly assess catalytic competence of an active site from a 
mechanistic perspective. 
Table 2-2. Predicted and experimental binding energies for PNP-Y88 mutants. 
Variant Experimental Binding Energy (kJ/mol)a 
Predicted Binding Energy 
(REU)b 
Predicted Binding Energy 
(kJ/mol)c 
 Inosine ddI Inosine ddI Inosine ddI 
Wild-type -34.0 -16.8 -7.73 -7.78 -19.82 -23.39 
Y88F -31.9 -24.9 -7.24 -8.46 -29.70 -21.75 
Y88H -28.9 -20.3 -6.71 -7.39 -25.67 -14.08 
Y88W -23.1 -11.2 -5.86 -6.66 -20.40 -18.48 
Y88A -30.5 -18.4 -4.76 -5.78 -22.44 -13.28 
Y88V -18.8 -12.3 -7.01 -7.31 -25.84 -16.30 
Y88L -29.8 -23.9 -7.12 -7.91 -27.03 -15.61 
Y88I -17.0 -11.8 -5.06 -6.83 -21.27 -13.03 
Y88M -26.1 -22.3 -7.57 -8.09 -30.77 -22.41 
Y88C -25.7 -19.9 -5.15 -5.85 -21.81 -9.66 
Y88S -24.6 -16.1 -6.72 -7.44 -27.00 -12.24 
Y88T -18.8 -9.4 -6.62 -7.1 -16.60 -4.15 
Y88N -23.2 -12.5 -6.46 -6.9 -19.99 -13.52 
Y88Q -18.4 -12.8 -5.75 -6.64 -25.41 -16.50 
Y88D -14.1 -1.5 -7.78 -8.73 -20.92 -11.37 
Y88E -12.3 0.3 -8.13 -8.93 -19.12 -12.13 
Y88K n/dd n/dd -9.01 -9.14 n/dd n/dd 
Y88R -7.21 n/dd -7.66 -7.26 n/dd n/dd 
a. Experimental binding energy, ∆G𝑇𝑆‡ = −𝑅𝑇 ln(𝑘cat 𝐾m⁄ ) 
b. Binding energies established using the Protein:Ligand weightset. 
c. Binding energies established using the PNP:Nucleoside customized weightset. 
d. Values for lysine and arginine mutants were not determined with the reweighted scoring function as kinetic data 
was incomplete for these mutants. 
 
 
 
Training of Rosetta Scoring Function for PNP:Nucleoside Interactions  
With a comprehensive dataset in hand, an attempt was made to test which 
fraction of the differences in experimental activation energy and predicted transition state 
binding free energies can be attributed to inaccurate weighting of the energy terms in 
RosettaLigand and which part must be attributed to inaccuracies in the RosettaLigand 
energy function and structural models used. Weights were developed for individual 
components of the Rosetta energy function using multi-linear regression to optimize the 
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correlation of predicted binding energies to experimental activation energies. Activation 
energies were calculated from experimental data as ∆G𝑇𝑆‡ = −𝑅𝑇 ln(𝑘cat 𝐾m⁄ ) while 
predicted binding energies were calculated as ∆∆G = ∑𝑤𝑖 ∙ �𝑠𝑖𝑏𝑜𝑢𝑛𝑑 − 𝑠𝑖𝑢𝑛𝑏𝑜𝑢𝑛𝑑�, where wi 
is the weight applied to a particular score si28-31. Using a leave-one-out cross validation 
analysis weights are generated without the use of one data point and then binding 
energy predictions made for the data point left out (Table 2-2).  
 
Table 2-3. Comparison of established weights for Rosetta applications. 
Score PNP : Nucleoside Protein : Ligand14 Protein : Protein29 Standard39 
Attractive 1 ± 0.05 1 1 1 
Repulsive 0.33 ± 0.02 0.75 0.16 0.91 
Solvation 0.56 ± 0.04 0.63 0.73 0.65 
GBSol 0.37 ± 0.04 - - - 
Hydrogen Bonding - 1.5 1.11 1.74 
Pair Elec. - 0.63 - 0.34 
Rotamer 
Probability 
- 0.4 0.64 0.4 
Phi Psi Probability - 0.4 - 0.51 
 
 
Figure 2-6. Correlation of experimental activation energy to activation energy calculated 
with a customized PNP : Nucleoside weight-set. , inosine; , ddI. REU are Rosetta 
Energy Units. Error bars indicate standard deviation of top ten transition state bound 
models. This image copyright of Oxford University Press. Reproduced with permission. 
Originally published by Nannemann, et al.1 
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Discussion 
We have described the identification of human purine nucleoside phosphorylase 
for biocatalytic synthesis of dideoxyinosine and rational design of the binding site based 
on computational prediction of transition state binding energies. Based on analysis of 
previously reported structures and activity profiles, in addition to computational design 
studies, a single active site residue, Y88, was selected as a likely hotspot for 
improvements in sugar analog binding and created a comprehensive library of 
substitutions at this position. RosettaLigand was used to estimate the binding energies 
of inosine and ddI transition state models to in silico models of these mutations. 
The present experiment evaluates Rosetta in a scenario likely to occur in enzyme 
design – assessing the change of enzyme specificity for a different but related ligand. 
Simultaneously this study evaluates a scenario in which options for computational 
design were limited to a single active site residue, Y88. The accuracy of the Rosetta 
algorithm needs to be sufficiently high to discriminate improved substrate/transition state 
binding properties for a single active site ensemble (hPNP). By comparing Rosetta 
calculated binding energies to energies derived from experimentally measured kinetic 
parameters for every possible mutation the ability of Rosetta to rank substitutions at Y88 
could be assessed. RosettaLigand ranked the Y88F variant in the top three for transition 
state stabilization. However, RosettaLigand generally underestimated energies of 
variants with improved catalytic function and overestimated energies of mutants with 
decreased function; this trend was particularly evident in the case of wild-type hPNP 
which was predicted to process ddI with greater efficiency than inosine. 
Phenomena outside the scope of the method may contribute to errors in the 
prediction of protein variant binding energies. For example, wild-type PNP crystallized 
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with ddI has an ordered water molecule in the binding pocket which forms a hydrogen 
bond with Y88 and is situated proximal to the position of the 3´-hydroxyl in inosine-bound 
structures. The presence of this water molecule was not evaluated in the Rosetta 
calculations and might be one source of error. It is possible that removal of the hydrogen 
bond acceptor by mutation to phenylalanine may be a significant source of improvement. 
Additionally, mutation to β-branched amino acids Y88V/I/T reduced the function of the 
enzyme relative to structurally similar counterparts, such as Y88L/S. Rosetta models 
predicted these mutants to have a destabilizing effect in the enzyme, evident by an 
increase in the total energy score caused by clashing between the Cβ-methyl substituent 
and Pro-198, which resides on an adjacent loop involved in purine binding. This 
destabilization is not revealed by binding energy calculations as the residue-residue 
clash is present in both bound and unbound structures. This has been previously noted 
in the design of protein:protein interfaces40 and is confirmed experimentally in this work. 
The empirical and computational datasets resulting from this experiment 
permitted the optimization of Rosetta parameters resulting in appreciable correlation with 
R = 0.65 (Figure 2-6). Reweighting of the scoring function corrects the gross 
misidentification of charged amino acids as catalytically advantageous and aligns 
inosine and ddI with respect to one another. This reweighting, while advantageous in 
terms of correlating global substrate preference, decreases the quality of ranking 
mutants with a particular substrate. Conversely, the unchanged RosettaLigand score 
function properly identifies the wild type and Y88F variants as most catalytically active 
for inosine and ddI (Figure 2-5A,B). 
In this study, predicted transition state binding energies were correlated to 
experimental data by calculation of the activation energy as ∆G𝑇𝑆‡ = −𝑅𝑇 ln(𝑘cat 𝐾m⁄ )31, 
41.  This term can be rationalized through analysis of a simple, one substrate reaction 
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following Michaelis-Menten kinetics (Figure 2-7A). The free energies involved in the 
unimolecular reaction can be found through the application of transition state theory and 
equilibrium thermodynamics31, 42, 43. Suppose that the difference in energy between the 
ground state, 𝑆, and the transition state of the reaction, S‡, is ∆G‡. From equilibrium 
thermodynamics the following relationship can be established: �S‡� = [𝑆]𝑒−∆G‡𝑅𝑇 . The 
transition state X‡ decomposes to 𝑋 at the same rate as the vibration frequency 𝑣 of the 
bond that is breaking. Therefore, the rate of decomposition of 𝑆 is given by –𝑑[𝑆]
𝑑𝑡
=
𝑣�S‡� = [𝑆] �𝑘𝑇
ℎ
� 𝑒
−∆G‡
𝑅𝑇 , where 𝑣 = 𝑘𝑇
ℎ
. For the Michaelis-Menten reaction, the overall rate 
equation is given by 𝑘𝑐𝑎𝑡 = 𝑘𝑇ℎ 𝑒−∆G‡𝑅𝑇  and the activation energy of the chemical steps of 
bond breaking and bond making is given by ∆G‡ = −𝑅𝑇 ln(𝑘cat). Using equilibrium 
thermodynamics, where 𝐾m =  𝐾𝑠 and 𝐾𝑠 is the association of free enzyme and free 
substrate the substrate binding energy is given by ∆𝐺𝑠 = −𝑅𝑇 ln(𝐾m).  
Following transition state theory the Michaelis-Menten reaction in Figure 2-7A 
can be expressed as the equilibrium between free enzyme and free substrate and the 
transition state complex (Figure 2-7B). The free energies for this process are 
diagrammed in Figure 2-7C and the substrate binding energy and the activation energy 
of the chemical steps are related to the total activation energy ∆G𝑇𝑆‡ , by ∆G𝑇𝑆‡ = ∆G‡ +
∆Gs, where  ∆G𝑇𝑆‡  and ∆G‡ are algebraically positive and ∆Gs is negative42. Substituting 
the above relationship into the overall rate equation gives 𝑅𝑇 ln(𝑘cat 𝐾m⁄ ) = 𝑅𝑇 ln 𝑘𝑇ℎ −
∆G‡ − ∆Gs and relates kcat/Km to the activation energy, ∆G𝑇𝑆‡ , in terms of transition state 
theory. 
Enzymes function by decreasing the activation energy of the chemical steps 
through tighter binding of the transition state than the substrate, effectively lowering the 
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overall activation energy of the transformation31, 42, 44. The current method separates the 
quantum mechanical portion of the free energy of the enzyme-transition state complex 
from the geometrical component. In other words, the high energy of partially formed 
bonds is ignored and becomes implicit in the structure of the transition state. Because 
the enzyme has tighter binding to the transition state the free energy of the enzyme-
transition state complex is effectively lower than the enzyme-substrate complex (Figure 
2-7D). 
 
Figure 2-7. Gibbs free energy diagrams of enzyme catalysis in experimental and 
computational studies. A. Interaction of free enzyme and free substrate to form the 
Michaelis complex and then product. B. Equilibrium between free enzyme and an 
unbound transition state and the enzyme-transition state complex. C. The change in 
energy is shown for the binding of substrate from free enzyme and free substrate and 
the formation of the enzyme-transition state complex from the enzyme-substrate 
complex. The enzyme–transition state complex is high in free energy due to partially 
formed bonds. D. Internal transition state energies are not accounted for in the 
RosettaLigand docking method. Enzymes decrease the overall activation energy (∆G𝑇𝑆‡ ) 
through tighter binding of the transition state over the substrate. Ignoring the high energy 
of partially formed bonds causes a decrease in free energy upon formation of the 
enzyme-transition state complex. 
 
 
  
An ideal design method would be dependent only on the change in activation 
energy (∆G‡) realized upon a change in the binding site. However, by separating the 
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components of the chemical activation energy into quantum mechanical and structural 
portions the value of ∆G‡ is effectively reduced to the difference in transition state 
binding energy and substrate binding energy (Figure 2-7D). This small value of ∆G‡ is 
difficult to differentiate from the noise inherent in the framework of the current method. 
By correlating experimental data to the transition state binding energy, ∆G𝑇𝑆‡ , instead of 
the activation energy, ∆G‡, the substrate binding energy was incorporated into the score 
serving to increase the signal above the noise in the docking calculations.  
By performing the design and docking studies with the transition state models 
mutants with greater predicted binding energy should possess a higher turnover rate. 
Because we have separated the quantum mechanical and structural components of the 
transition state and because RosettaLigand does not directly evaluate the mechanistic 
aspects of turnover one might argue that predicted transition state binding energies 
correlate more accurately with Km, where ∆G𝑇𝑆‡ = −𝑅𝑇 ln(𝐾m). Nonetheless, at least in 
the present studies, this analysis yields somewhat reduced correlation coefficients for 
inosine and ddI, where R = 0.236 and 0.284, respectively, using binding energies 
established with the RosettaLigand weightset and excluding charged residues. These 
values are 0.362 and 0.438 for inosine and ddI, respectively, when correlating predicted 
binding energies to kcat/Km. 
All terms in the RosettaLigand energy function were applied in the generation of 
enzyme:substrate ensembles but the attractive and repulsive, solvation and generalized 
Borne solvation terms were most critical for the final evaluation of binding energy. There 
are several notable differences in the weights developed here with those reported for 
use in protein:protein binding, the RosettaLigand weights used during docking, and the 
standard weight set. Relative to the Lennard–Jones attractive weight the weight for the 
Lennard–Jones repulsive score is twice as large as that used in protein docking but 
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much lower than the original ligand docking and standard weights. The weight for 
solvation is also slightly decreased compared to typical Rosetta weights. Of note is the 
absence of a hydrogen bonding term from the evaluation; while this term was used 
during the docking portion of the experiment its inclusion in the final weight set does not 
improve the correlation to experiment. It is not surprising that the weights of electrostatic 
terms were increased considering the number and role of charged and polar residues in 
binding and catalysis. 
 
Conclusions 
The process outlined herein was applied to improve the catalytic properties of 
hPNP for an alternate substrate, dideoxyinosine. The Rosetta method proved capable of 
identifying mutations which are likely to improve catalysis in a test case made 
particularly difficult by constraint to a single amino acid substitution and high substrate 
similarity. Furthermore, the methods potential for application to systems which, unlike 
hPNP, are not thoroughly characterized has been demonstrated. 
In this case study, charged residues had a major impact on computational and 
experimental results. Addition of an electrostatic term allowed for moderate improvement 
in the results. The makeup of the scoring function highlights the characteristics of this 
particular test and points to the broad scope of applications available for the Rosetta 
algorithm. Indeed, many other nucleoside analogs contain modifications on the sugar 
moiety providing a handle for successful design. 
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Chapter III 
 
DIRECTED EVOLUTION OF HUMAN PURINE NUCLEOSIDE PHOSPHORYLASE1 
 
Introduction 
Structure-based rational design strategies aim to improve protein properties such 
as rate of turnover, substrate acceptance, enantioselecity or protein stability by targeting 
mutations in the enzyme active site. There are numerous accounts proving the efficacy 
of rational active site mutation; however, there are surely just as many unreported 
failures in which the targeted function is not achieved. This is not to say that structure-
based design strategies do not work but, instead, that current models of the complex 
interplay among residues in the active site and with the protein structural framework as a 
whole cannot account for the full function of the enzyme. Additionally, systems which are 
not fully characterized or for which structural data is unavailable are frequently the 
subject of engineering campaigns making rational design a shot in the dark at best. 
Directed evolution methodologies endeavor to fill this knowledge gap through the 
generation of random mutant libraries and subsequent screening for desired traits and/or 
activity. 
Mutagenesis protocols in directed evolution have been developed which target 
the binding site or, alternatively, generate random sequence changes throughout the 
protein. Sufficient structural or sequence data must be available to target critical active-
site residues. If this data is available site-directed saturation mutagenesis enables 
identification of active-site mutations which are difficult to predict or, by multi-site 
saturation mutagenesis, identification of sets of mutually beneficial mutations. On the 
other hand, random mutagenesis protocols can be applied in the absence of sequence 
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or structural data to identify beneficial mutations outside the binding site which are often 
difficult or impossible to predict. 
In this chapter, the directed evolution of hPNP-Y88F, the best point mutant 
identified through computational redesign, is described with the aim of identifying 
mutations outside the binding site which affect ddI turnover. A high-throughput screen 
was developed allowing for the analysis of mutant libraries consisting of several 
thousand variants. Error-prone PCR was used to generate mutations throughout hPNP-
Y88F, with a targeted dead rate of 30–40% resulting in a mutagenesis rate of 1.5–2 
amino acid changes per variant. In vitro selection in cell free extracts allowed for 
identification of variants with improved ddI phosphorolysis. Overall, three rounds of 
directed evolution resulted in a mutant with six mutations and a ddI turnover rate in cell 
free extracts 36 times that of wild-type. 
 
Methods 
Library Generation and Screening 
Mutant libraries were generated via epPCR using MutazymeII (Stratagene, Inc.) 
with forward primer, 5´-GCAGCAGCCATCATCATCATC-3´ and reverse primer, 
5´-GGATCTCAGTGGTGGTGGTGG-3´ flanking the PNP coding region of pET28a-
hPNP template constructs. To ensure efficient restriction digestion prior to ligation into 
pET28a, primers were designed to generate PCR product with overhangs 45 bp 
upstream and downstream of NdeI and HindIII restriction sites. pET28a-hPNP plasmid 
preparations were used as the template for directed evolution and subsequent rounds of 
directed evolution used plasmid preparations from the previous round as template. The 
rate of mutation was adjusted by a) varying template concentration in PCR reactions and 
b) the number of rounds of PCR. The mutation rate was titrated so that ca. 30% of PNP 
mutant subcloned into pET28a demonstrated <5% activity (assay described below). 
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Correspondingly, template concentrations were varied from 0.03–20 ng/μL with 20–30 
cycles. The desired mutation rate was obtained with 20 ng/μL and 20 cycles. DNA 
sequencing of 10 random mutants at the 30% dead rate indicated a mutation rate of 
~1.5–2 base pairs per kb.  
PCR products were gel purified to remove template, digested with NdeI/HindIII 
and gel purified again prior to ligation into correspondingly restricted pET28a. Ligation 
reactions were performed using Promega T4 DNA ligase with 17 ng insert and 100 ng 
vector per 10 μL for 180 minutes. Transformation of the ligation reactions into E. coli 
BL21(DE3) cells was accomplished by electroporation. A random sampling of clones 
indicated all contained PNP insert. 
 
Screening of hPNP variant activities 
hPNP variants were expressed in E. coli BL21(DE3) cells harboring the pET28a-
hPNP plasmid which was introduced by electroporation. The plasmid contains a 
kanamycin resistance marker allowing for selection of positive transformants on 
kanamycin-containing LB-agarose plates. Individual transformants were picked into 300 
μL round bottomed 96-well plates containing 75 μL LB medium with 50 μg/mL 
kanamycin and grown to confluence (24 hours at 37°C with shaking at 220 rpm). 
Glycerol stocks of the library were generated by plate replication in LB medium prior to 
cells being collected by centrifugation at 3000 rpm. Supernatant was removed by 
inversion and the resulting pellets were frozen and stored at -80 °C until ready for assay. 
Directly prior to assay, frozen cell pellets were thawed and resuspended in 200 μL of a 
lysis mixture containing 50 mM phosphate buffer, 0.5 mg/mL egg white lysozyme 
(Sigma), 20 μg/mL deoxyribonuclease I (Sigma) and 0.1–0.125 mg/mL xanthine oxidase 
(to consume endogenous hypoxanthine) followed by a single freeze/thaw cycle from -80 
°C to 37 °C2. Following centrifugation to remove cellular debris, 25 μL of cell free extract 
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from each well was transferred into 384-well flat bottom plates and assayed by addition 
of 50 μL of buffer containing 50 mM phosphate, pH 7, 50 mM HEPES, pH 7, 125 μM ddI, 
0.0375% Triton X-100, 2 mM INT and 0.4–0.6 mg/mL xanthine oxidase. The reactions 
were followed continuously at 546 nm for 60 seconds. Hits from the primary screen were 
replicated from glycerol stocks (1–5 per plate) and assayed alongside cells expressing 
the parent PNP as a benchmark to eliminate false positives. 
Plasmid preps from the best candidates were retransformed by electroporation 
and 1 mL of an overnight culture from the fresh transformants was used to inoculate 50 
mL of LB broth and grown to OD600 ≈ 0.6–0.8 before addition of 1mM isopropyl-β-D-1-
thiogalactopyranoside. After three hours of incubation at 37 °C, 2 mL aliquots were 
pelleted by centrifugation at 13,000 rpm and frozen at -80 °C. Pellets were lysed using 
BugBuster protein extraction reagent (Novagen Inc.) and the resulting cell free extract 
was diluted in Assay Mix to titrate the specific activity within the dynamic range of the 
kinetic assay as described above. Upon addition of substrate (125 μM ddI or 20 μM 
inosine) hypoxanthine release was measured continuously over 60 seconds. Turnover 
rates were calculated and normalized to the cell density (OD600) at the time of harvest to 
yield a per-cell turnover rate for each PNP mutant. The kinetic parameters for selected 
mutant PNPs with high per cell turnover rates (2–3 per round) were established as 
described above. Of the mutants characterized in each round those with the most 
favorable kinetic parameters for ddI were selected as the source of template DNA for the 
next round of epPCR and screening. 
 
Results 
Screen optimization and epPCR mutagenesis 
To further optimize the hPNP-Y88F mutant for turnover of ddI, a 96-well plate 
assay method for screening epPCR generated mutant libraries was designed and 
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implemented (Figure 3-1A). Variants were first cloned into pET28a and subsequent to 
transformation into electrocompetent E. coli BL21(DE3) single colonies were transferred 
into 96-well round bottom plates. The plates were incubated with shaking for 24 h and 
grown to confluence. Cells were harvested by centrifugation and lysed by addition of 
lysozyme and a single freeze/thaw cycle2. Upon removal of insoluble debris by 
centrifugation, cell-free extracts were transferred to 384-well flat-bottom plates to assay 
phosphorylase activity via a modified hypoxanthine formation assay. The assay is based 
on a continuous colorimetric assay for the conversion of hypoxanthine to uric acid via 
xanthine oxidase which is coupled to the reduction of iodonitrotetrazolium chloride to a 
purple formazan dye (λmax: 546 nm)3. Reactions were initiated by addition of 125 μM ddI 
(~1/4 Km) and the amount of enzyme was titrated to assure linearity of the reaction 
during the measurement window (≥60 s). To test the reproducibili ty of the screening 
methodology a single sequence library containing hPNP-Y88F was assayed. As shown 
in Figure 3-1B, under final assay conditions the single sequence library had a coefficient 
of variance of 11.6% within each plate.  
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Figure 3-1. High-throughput screen for increased ddI phosphorolysis activity by PNP (A). 
Evaluation of screen reproducibility was accomplished by screening of a hPNP-Y88F 
single-sequence library (B). A coefficient of variance of 11.6% was calculated for each 
plate. 
 
 
Diverse libraries were generated using an error-prone polymerase (Mutazyme, 
Stratagene, Inc) to amplify hPNP with Y88F hPNP cloned into pET28a serving as the 
template DNA. Primers were designed to be >45 bp upstream and downstream of 
restriction sites (NdeI and HindIII) in order to ensure efficient restriction of PCR products 
prior to ligation reactions. The rate of mutation was adjusted by varying the amount of 
template and number of PCR cycles such that the dead rate (colonies with <5% activity) 
was approximately 30–40% (Figure 3-2). Library sizes of 1 000–2 000 colonies had an 
average mutation rate of 1.5–2 mutations per kb, as established by sequencing 10 
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randomly selected clones. After screening, top hits from each plate were collected and 
re-screened from glycerol stocks of the error-prone library to eliminate false positives. 
 
Figure 3-2. Mutagenesis rates established through variation of the template 
concentration and rounds of PCR. The solid black line indicates the selected epPCR 
conditions. 
 
 
 
Library Screening and Mutant Characterization  
Over three rounds of directed evolution the turnover rate of enzyme in E. coli 
extracts steadily increased, albeit modestly (Figure 3-3). The first round mutant, hPNP-
19E2, has an increased normalized turnover rate for ddI with a concomitant decrease in 
turnover of inosine. Subsequent rounds provided a further increase in turnover of ddI but 
also an increase in inosine turnover. Catalytic constants, however, do not consistently 
improve for ddI throughout the directed evolution process (Table 3-1). The first round 
mutant hit (hPNP-19E2) has a kcat and Km of 5.8 ± 0.1 s-1 and 230 ± 15 μM which is a 
decrease in turnover rate but a significant improvement in Km over the template. The 
kinetic parameters of hits from ensuing rounds of selection (hPNP-30F2 and hPNP-
46D6) do not improve despite a regular increase in turnover in cell-free extracts. The 
final clone, hPNP-46D6, contained five amino acid mutations (G4E, Y88F, M170T, 
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Q172L, T177A) with the gene containing a sixth silent mutation (Table 3-1 and Figure 3-
4). 
 
Figure 3-3. In vitro turnover of ddI increases throughout the directed evolution process. 
Turnover rates are normalized to cell density. Error bars are the standard deviation of 
three assays. Inosine, white; ddI, gray. This image copyright of Oxford University Press. 
Reproduced with permission. Originally published by Nannemann, et al.1 
 
 
Table 3-1. Kinetic characteristics for mutants selected by directed evolution 
Round Variant Acquired 
Mutation 
Codon 
change 
kcat (s-1) Km (µM) kcat/Km (M
-1 s-1) 
    Inosine ddI Inosine Inosine(ddI x102) 
 
ddI 
wild-type - - 43.9 ± 0.6 0.90 ± 0.01 48 ± 2 1030 ± 20 9210 ± 140 875 ± 8 
rational Y88F Y88F TATTTT 28.3 ± 0.8 10.5 ± 0.1 73 ± 4 450 ± 10 3890 ± 110 23140 ± 230 
DE-1 19E2 M170T ATGACG 9.6 ± 0.2 5.8 ± 0.1 26 ± 1 230 ± 15 3710 ± 70 25160 ± 620 
DE-2 
 
30F2 
 
G4E 
Q172L 
C206C 
GGAGAA 
CAGCTG 
TGTTGC 
14.5 ± 0.3 
 
6.1 ± 0.1 
 
37 ± 2 
 
247 ± 10 
 
3970 ± 90 
 
24650 ± 330 
 
DE-3 46D6 T177A ACCGCC 14.7 ± 0.7 4.5 ± 0.1 33 ± 4 235 ± 11 4390 ± 280 19240 ± 320 
 
 
 
In addition to improving the turnover and kinetic characteristics of the mutant 
enzymes a marked improvement in substrate selectivity for ddI was observed. Each 
mutant has an improved specificity ratio (wild-type efficiency / mutant efficiency), though 
none of the variants are selective for ddI over inosine. Wild-type hPNP possesses a 
specificity ratio for inosine of >1000:1 whereas selected hPNP variants attained a 
specificity ratio of 15:1 subsequent the directed evolution process.  
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Discussion 
The turnover rate of hPNP-Y88F was improved by directed evolution resulting in 
a 3-fold improvement in in vitro assays, and an overall 22-fold improvement in catalytic 
efficiency. By applying whole-gene random mutagenesis, mutations distal to the binding 
site that affect ddI turnover were identified. The acquired M170T mutation in hPNP-19E2 
provides significant improvement in binding affinity with a modest decrease in turnover 
rate despite its location ~25 Å from the reaction center. In fact, it has been observed that 
distal, conservative mutations affect the dynamics and catalysis of hPNP and kinetic 
isotope effect studies indicate a significant change in the transition state structure4-7. 
These studies underpin the importance of dynamic motion coupling throughout the 
protein architecture to catalysis. Although the exact effect of the M170T mutation can 
only be speculated upon it favorably alters the PNP reaction coordinate for ddI 
phosphorolysis. 
Successive rounds of directed evolution identified Q172L and T177A mutations 
which occur on the same helix as M170T (Figure 3-4). These may have accumulated to 
counteract any destabilizing effects of the first mutation or this gene region is particularly 
prone to mutation. Based on its location, the G4E mutant may re-orient and stabilize the 
recombinant hexahistidine tag which is not removed prior to screening or 
characterization. For instance, as judged by gel-filtration chromatography of wild type 
PNP, removal of the N-terminal hexahistidine tag used for purification significantly 
decreases the formation of higher-order oligomers (data not shown). Acquired mutations 
may improve expression efficiency or RNA stability as evidenced by the considerable 
increase in turnover of enzyme in E. coli extracts despite nominal improvements in 
catalytic efficiency. 
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Figure 3-4. Mutations selected by directed evolution mapped onto the hPNP structure 
(PDB ID 1rct). Mutations are colored by lineage: orange, rational; red, DE-1; green, DE-
2; blue, DE-3. This image copyright of Oxford University Press. Reproduced with 
permission. Adapted from Nannemann, et al.1 
 
 
 
It is not surprising, however, that mutations in the first or second shell of the 
binding site were not identified in this work considering the moderate library sizes 
employed. However, directed evolution strategies that target residues in the first and 
second shell of the binding site (i.e. CASTing8) have found success in modifying or 
broadening the substrate specificity of enzymes. It is possible that additional mutations 
in the vicinity of Y88F may further improve the turnover of ddI as mutations closer to the 
active site are frequently observed to have greater effect on substrate selectivity9. 
Furthermore, formation of human:bovine PNP chimeras alters enzyme dynamics and 
catalysis, with a significant effect on the reaction profile4-7. A search of this 
conformational space through gene shuffling may identify mutants which utilize a 
reaction coordinate better fit to phosphorolysis of ddI. 
 
Conclusions 
Directed evolution using whole–gene epPCR and an in vitro selection scheme 
allowed for identification of residues distant to the binding site which improve the binding 
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affinity of the phosphorylase for ddI. Individual rounds resulted in modest improvements 
in kinetic parameters and/or turnover. The robustness of the in vitro tandem enzymatic 
assay is demonstrated by its ability to discriminate incremental improvements in 
activities. The final mutant (hPNP-46D6) has a catalytic efficiency 22-times greater than 
the wild-type and the specificity ratio was shifted to 15:1 from a starting point of 1000:1. 
On a per cell basis the turnover rate was 36-fold improved; it is possible that the 
additional improvement originates from increased protein production or a higher 
proportion of active enzyme. As these improvements were products of small libraries, it 
is likely that further rounds of directed evolution can improve the catalytic properties of 
the enzyme and identify residues in other regions of the protein that may enhance 
catalysis of ddI or further shift the selectivity. 
In principle, catalysts for the phosphorolysis and formation of a variety of 
nucleoside analogs can be accessed using the methods described herein. Indeed, 
hPNP-46D6 has been tested for the biocatalytic generation of ddI as a component of 
tandem reactions and found it to be kinetically competent in the synthesis direction (to 
be presented in Chapter 5). Several nucleoside analogs with ribose substitution at 2´ 
and 3´ positions are of significant clinical importance as are nucleoside analogs with 
nucleobase substitutions10-12. While hPNP is specific for the 6-oxo nucleosides, 
mutations in the base binding region will likely improve turnover of compounds with 
nucleobase substitutions. For example, mutation of Asn-243 to aspartate has been 
shown to introduce 6-amino nucleoside phosphorolysis activity13. Of note, relatively few 
biotransformation-based approaches have been described for biocatalysis of 
dideoxynucleosides and other analogs14-18. Future experiments will endeavor to generate 
optimized enzymes and pathways capable of generating ribose precursors for PNP 
variants. Engineered pathways for nucleoside analogs have potential to provide 
economical alternatives to chemical synthesis of these valuable pharmaceuticals. 
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Chapter IV 
 
BIOCHEMICAL CHARACTERIZATION, STRUCTURAL ANALYSIS AND DETERMINATION 
OF CATALYTIC CYCLE FOR BACILLUS CEREUS PHOSPHOPENTOMUTASE1 
 
Introduction 
Enzyme-catalyzed phosphoryl transfer forms the basis for many biological, bioenergetic 
and regulatory processes, and is one of the most common cellular reactions2. Numerous 
enzyme families have evolved mechanistically distinct solutions for phosphoryl transfer3. 
Phosphomutases are phosphotransfer enzymes that rearrange the position of phosphate within 
a substrate molecule through either intramolecular (i.e. the phosphate is transferred to a 
different position on the same molecule) or intermolecular phosphoryl transfer (i.e. the 
phosphate is transferred from one substrate molecule to another). 
Bacterial phosphopentomutases (PPMs, EC 5.4.2.7) interconvert α-D-ribose 1-
phosphate (ribose 1-phosphate) and α-D-ribose 5-phosphate (ribose 5-phosphate), which 
bridges glucose metabolism and RNA biosynthesis4. The importance of this reaction has 
recently been underscored by the observation that targeted deletion of the gene encoding PPM 
in the pathogen Francisella tularensis (deoB) results in markedly decreased virulence5. PPMs 
appear to be biochemically and structurally distinct from their human congeners6, 7 making them 
potential targets for antibiotic development. 
Sequence clustering classifies prokaryotic PPMs within the alkaline phosphatase 
superfamily of metalloenzymes, which includes a range of functionally diverse enzymes such as 
cofactor-independent phosphoglycerate mutase, phosphodiesterase, and estrone and aryl 
sulfatases8. The majority of alkaline phosphatase superfamily enzymes catalyze a hydrolase 
reaction; however, both PPM6 and the co-factor independent phosphoglycerate mutase catalyze 
phosphomutase reactions9, 10.  
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All previously-characterized alkaline phosphatase superfamily members follow a unified 
general reaction mechanism11, which is shown in Figure 4-1. In alkaline phosphatase itself12, 13, 
the catalytically competent enzyme has an unphosphorylated catalytic nucleophile, Ser-102 
(Figure 4-1, State 1). Turnover is initiated when the metallocenter activates a phosphoester 
donor substrate (RD-OPO3H-) (Figure 4-1, State 2) to transfer the phosphoryl group to the 
hydroxyl of Ser-102 (Figure 4-1, State 3). This results in a covalent phosphoenzyme 
intermediate (E-OPO3H-) (Figure 4-1, State 4). A second phosphoryl transfer from the enzyme 
to the acceptor water molecule (Figure 4-1, States 5,6) completes the reaction cycle. This 
general reaction mechanism has also been verified for cofactor-independent phosphoglycerate 
mutase9, 10, a phosphomutase in the alkaline phosphatase family. In this case, the incoming 
substrate is also the acceptor molecule, thus defining it as an intramolecular phosphomutase. 
 
Figure 4-1. Generalized catalytic cycle for alkaline phosphatase superfamily proteins. For all 
previously characterized alkaline phosphatase family members, the catalytic cycle begins with a 
dephosphorylated (or desulforylated) enzyme, E-OH, State 1. Donor substrate (RD-O-X, where 
X=PO3H-, SO3H-) binds, and is attacked by the catalytic nucleophile, States 2, 3. The 
dephosphorylated donor substrate, RD-OH is released, leaving a covalently modified enzyme 
intermediate, E-O-X, State 4. An acceptor substrate, RA-OH, attacks the phosphoryl enzyme, 
forming a phosphorylated product, RA-O-X, and returning the enzyme to the dephosphorylated 
state, E-O-H, States 5, 6, 1. 
 
 
 
By comparison, characterization of bacterial PPM has been limited. Biochemical analysis 
of the E. coli enzyme revealed that E. coli PPM catalyzes Mn2+- or Co2+-dependent 
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interconversion of ribose 5-phosphate and ribose 1-phosphate6 and that α-D-glucose 1,6-
bisphosphate (glucose 1,6-bisphosphate) stimulates activity. Given the wealth of information 
available for alkaline phosphatase superfamily members, one might reasonably expect to infer 
the mechanism of bacterial PPM based on its classification within that family. This would predict 
that, like cofactor-independent phosphoglycerate mutase, PPM acts as an intramolecular 
phosphomutase. However, to our knowledge, no study has directly investigated the catalytic 
cycle of PPM. 
This work investigates the biochemical mechanism of Bacillus cereus PPM in the context 
of the alkaline phosphatase superfamily fold. Surprisingly, the data demonstrate that PPM acts 
as an intermolecular transferase, which would require an adaptation of the alkaline phosphatase 
reaction mechanism. In one possible modification, substrate could be acted upon by 
phosphorylated enzyme (Figure 4-1, State 4) and could proceed through the catalytic cycle from 
this altered entry point. These findings expand upon the mechanistic repertoire for the broadly 
conserved alkaline phosphatase scaffold. 
 
Methods 
Protein expression, purification and crystallization 
Genomic DNA for B. cereus ATCC 14579D was purchased from ATCC. DNA encoding 
PPM (accession No. Q818Z9.1) was amplified by PCR using 5´-
GCTAGCAATAAATATAAACGTATATTCCTAGTCG-3´ as the sense primer and 5´-
CTCGAGCTATTTCTTTAGCTCGTTTAAG-3´ as the antisense primer. PPM was ligated into the 
plasmid pET28a (Novagen) between the NheI and XhoI sites to include an N-terminal 
hexahistidine tag and thrombin cleavage site. The resulting plasmid was electroporated into E. 
coli BL21-Gold(DE3) (Stratagene). Cells were grown in LB supplemented with 100 mg/l 
kanamycin at 37 °C with continuous shaking at 250 rev/min until the A600 was between 0.4 and 
0.6. Protein expression was induced by the addition of isopropyl-β-D-1-thiogalactopyranoside to 
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0.3 mM and was continued with shaking at 37 °C for 4 h. Cells were harvested by centrifugation 
at 5 000 g for 15 min at 4 °C and were resuspended in 25 mL buffer A (50 mM Tris–HCl pH 7.5, 
200 mM NaCl, 10 mM imidazole) enriched with 1 μg/mL DNase I, 1 μg/mL leupeptin and 1 
μg/mL pepstatin A. Cells were lysed by sonication on ice for 10 min (60 Sonic Dismembrator, 
Fischer Scientific) and then clarified by centrifugation at 30 000 g for 1 h at 4 °C in an SS-34 
rotor (Sorvall). The supernatant was filtered through a 0.45 μm filter prior to chromatography at 
4 °C. The filtered lysate was passed over a HisTrap HP column (GE) equilibrated with buffer A. 
Nonspecifically bound protein was removed by washing with ten column volumes of buffer A 
supplemented with 50 mM imidazole. Purified protein was eluted by adding buffer A 
supplemented with 300 mM imidazole. The eluant was concentrated to 500 mL using an Amicon 
Ultra 30 000 molecular-weight cutoff centrifugal filter (Millipore) spun in a swinging-bucket rotor 
at 5 000 g at 4 °C. The hexahistidine tag was removed by exchanging into buffer B (50 mMTris–
HCl pH 7.5 and 200 mM NaCl) and cleaving overnight with 50 units of thrombin. The resultant 
protein contained three additional residues, Gly-Ser-His, at the N-terminus. PPM was separated 
from protein aggregates and the cleaved peptide tag by size-exclusion chromatography using a 
Superdex 200 10/300 GL column (GE) equilibrated with 25 mM Tris–HCl pH 7.5 and 1 mM 
MnCl2. The protein was concentrated to between 50 and 75 mg/mL as determined by the Bio-
Rad Protein Assay (Bio-Rad) and was stored at 4 °C prior to use. 
The T85A variant was generated from pET28a-PPM using the Stratagene QuikChange 
Lightning Site-Directed Mutagenesis Kit with oligonucleotide primers 
(5´-CTGGTAAAGATGCAATGACAGGTCACTGG-3´ and 
5´-CCAGTGACCTGTCATTGCATCTTTACCAG-3´). This variant was purified using the protocol 
developed for the wild-type enzyme. Purified PPM was concentrated and stored in aliquots at -
80 °C in 25 mM Tris–HCl, 1 mM MnCl2, pH 8.0. Xanthine oxidase was prepared from raw milk 
using the standard procedure14 and human purine nucleoside phosphorylase was purified as 
previously reported15 and in chapter 2. 
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The structure of PPM was determined alone, co-crystallized with ribose 5-phosphate, co-
crystallized with glucose 1,6-bisphosphate, and following activation with glucose-1,6-
bisphosphate. Crystals of PPM (12 mg/mL buffered in 25 mM Tris–HCl, pH 7.4, 1 mM MnCl2) 
were grown at 18 ºC as described previously16 using the hanging drop vapor diffusion method. 
Protein solution (1 µL) and 1 µL of crystallization reservoir solution were equilibrated over a 
reservoir containing 100 mM Bis(2-hydroxyethyl)-amino-tris(hydroxymethyl)-methane (BisTris), 
pH 5.5, 50 mM MnCl2, 14% polyethylene glycol 3350, and 75 mM NH4CH3COO. Co-crystals of 
PPM with ribose 5-phosphate were prepared by soaking fully-formed crystals in a solution 
containing all of the crystallization components and 10 mM ribose 5-phosphate for 1 hour at 18 
°C. Co-crystals of PPM with glucose 1,6-bisphosphate were prepared with the same procedure, 
but were soaked with 5 mM glucose 1,6-bisphosphate. Crystals of activated PPM were grown 
from purified protein pre-incubated with 5 mM glucose 1,6-bisphosphate for 30 minutes at 22 °C 
before crystallization over a reservoir solution containing 100 mM BisTris pH 5.5, 50 mM MnCl2, 
14% polyethylene glycol 3350, and 50 mM CH3CO2NH4. Prior to data collection, crystals were 
cryoprotected in a solution containing the crystallization components and 30% glycerol, then 
flash cooled in liquid nitrogen. Crystal quality was assessed by diffraction-based feedback at 
both the Advanced Photon Source (APS) beamline 21-ID-G and the Stanford Synchrotron 
Radiation Lightsource beamline 9-2. All x-ray diffraction datasets were collected at APS 21-ID-G 
using a temperature of -173 °C, a wavelength of 0.979 Å and a MAR 225 CCD detector. Data 
were processed using the HKL200017 and CCP418 program suites. Crystals formed in the 
monoclinic space group P21 with unit cell dimensions listed in Table 1. The structure of native 
PPM was determined by molecular replacement with the program PHASER19 using the 
unpublished crystal structure of a putative PPM from Streptococcus mutans (PDB ID 2I09; New 
York SGX Research Center for Structural Genomics) as the search model. Residues 133 to 145 
and 199 to 208 were absent from the search model and were built into 2|Fo|-|Fc| omit maps 
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using COOT20. A careful procedure of omit mapping during refinement was used to avoid model 
bias. 
Model refinement was performed in the programs CNS21 and REFMAC522 with 
Translation/Libration/Screw (TLS)23 groups determined in the TLS Motion Determination 
server24. Superposition of residues 2–393 of the final model of B. cereus PPM with the 
equivalent residues (3–402) of the putative PPM from S. mutans resulted in an overall root 
mean squared (RMS) deviation of 1.0 Å for the core domain (residues 2–99 and 219–393) and 
an RMS deviation of 0.7 Å for the cap domain (residues 102–216).  
Since all crystals of the B. cereus PPM were isomorphous, the refined model of native 
PPM was subjected to rigid body refinement in CNS25 and used as a starting model for the 
remaining structures. Restraint libraries for ribose 5-phosphate and Thr(P) were generated 
using the PRODRG server26. The Rfree test set of data was composed of 5847 (5%) reflections 
randomly-selected in CNS25. The reflections of the Rfree test set were selected to be identical in 
the remaining data sets with additional reflections randomly-selected in the higher-resolution 
structure of PPM in complex with glucose 1,6-bisphosphate (Table 1). Refinement statistics and 
PDB accession codes for each model are listed in Table 1. Root mean squared (RMS) 
deviations between structures were calculated using the program LSQKAB27. Figures 4-2–4-4 
were prepared using PyMol28. The electrostatic surface calculation shown in Figure 2E was 
prepared using the PDB2PQR29 server set to use the CHARMM force field30. Surface maps 
were calculated using the APBS31 tools plug-in for PyMol28. 
Table 4-1. Data collection and refinement statistics  
 PPM 
Ribose-5-phosphate 
soaked PPM crystals 
Glucose-1,6-
bisphosphate 
soaked PPM crystals  Activated PPM 
PDB entry ID 3M8W 3M8Z 3OT9 3M8Y 
Data Collection:     
Wavelength (Å) 0.979 0.979 0.979 0.979 
Beamline  APS 21-ID-G APS 21-ID-G APS 21-ID-G APS 21-ID-G 
Resolution (Å) (last 50-1.85 (1.92-1.85) 20-1.90 (1.86-1.80) 50-1.75 (1.81-1.75) 50-2.1 (2.18-2.10) 
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shell)a 
Unit-cell  a = 91.2 a = 90.6 a = 91.9 a = 91.2 
dimensions (Å) b = 76.6 b = 76.8 b =76.6 b = 76.7 
 c = 106.6 c = 107.1 c = 107.1 c = 107.8 
 α = 90° α = 90° α = 90° α = 90° 
 β = 108.9° β = 108.7° β = 108.7° β = 108.9° 
 γ = 90° γ = 90° γ = 90° γ = 90° 
Total reflections 361062 469857 424368 269649 
Unique reflections 116902 122525 126882 75473 
Reflections in test 
set 5847 5835 6361 5280 
I/σ 13.3 (3.0) 25.7 (2.5) 23.7 (2.8) 14.2 (3.6) 
Completeness (%) 98.6 (99.1) 98.8 (90.3) 94.0 (69.6) 91.8 (71.6) 
Rsymb 0.080 (0.369) 0.063 (0.380) 0.053 (0.298) 0.084 (0.257) 
Model Refinement:      
Rcrystc 0.175 0.177 0.162 0.166 
Rfree  0.216 0.208 0.190 0.213 
RMSD Bonds (Å) 0.018 0.008 0.007 0.009 
RMSD Angles (°) 1.388 1.112 1.076 1.194 
Ramachandran 
Analysis:      
Most favored (%)  90.3 90.4 90.5 90.0 
Additional allowed 
(%)  9.7 9.6 9.5 10.0 
Generously allowed 
(%)  0.0 0.0 0.0 0.0 
Disallowed (%)  0.0 0.0 0.0 0.0 
a. Values in parenthesis are those from the highest resolution shell. 
b. Rsym=∑ |Ii-Imean|/Imean, 
c. Rcryst=∑||Fobs|-|Fcalc||/∑|Fobs| 
 
 
 
Phosphothreonine Western analysis 
Either wild-type or the T85A variant of PPM (at a concentration of 2 µM and buffered in 
50 mM Tris–HCl, pH 8.0 and 0.1 mM MnCl2) were incubated with 0, 1, 2.5, 5, 7.5, 10, 25, 50, 
75, 100 and 1 000 μM glucose 1,6-bisphosphate (wild-type) or 0 and 1 000 µM glucose 1,6-
bisphosphate (T85A) at 23 °C for 30 minutes. SDS sample buffer was added, and each reaction 
was separated by SDS-PAGE and transferred to a 0.45 μm nitrocellulose membrane. Total 
protein was estimated with Ponceau S staining, which was subsequently removed by washing in 
water. The membrane was then blocked with Odyssey blocking buffer (LI-CORP Biosciences) 
 118 
 
overnight and incubated with an anti-phosphothreonine antibody (Cell Signaling) diluted 1:1 000 
in TBS containing 0.5 % BSA and 0.1 % Tween 20 (BSA-TTBS) for four hours at room 
temperature. Binding of the primary antibody was detected by incubation with an 
AlexaFluor680-conjugated goat anti-rabbit antibody (Invitrogen) diluted 1:10 000 in BSA-TTBS 
for 1 hour at room temperature and visualized using an Odyssey Infrared Imaging System. Both 
total protein and anti-phosphothreonine band intensities were determined by plotting lane 
intensities and then measuring the area of the peak corresponding to the band at 44 kDa in the 
program ImageJ32. 
 
Identification of phosphorylation by LC/MS/MS 
Purified PPM (10 µg) was subjected to proteolytic digestion by trypsin, elastase, and 
subtilisin in parallel using a modification of a published procedure33. Data from each digest of 
the sample were acquired with 3 separate 90-minute LC/MS/MS data acquisitions using a 
Thermo-Fisher LTQ-orbitrap equipped with a nanospray source coupled to an Eksigent 1D+ 
nano-LC pump. Peptide tandem mass spectra were extracted from the instrument files 
(Scansifter) and searched against a database containing B. cereus proteins using SEQUEST34, 
considering possible phosphorylation events on serine, threonine, and tyrosine. Search results 
were collated and filtered using IDPicker35. 
 
 
 
Assay for activity 
Enzyme turnover was calculated by coupling the PPM catalyzed formation of ribose 1-
phosphate with human purine nucleoside phosphorylase in the presence of hypoxanthine to 
form inosine. Inosine formation at endpoints was determined via correlating to hypoxanthine 
consumption with a typical hypoxanthine detection assay36 in which xanthine oxidase 
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stoichiometrically converts hypoxanthine into to uric acid, H2O2, and superoxide ion, O2-. 
Superoxide in turn was determined via chemical reduction of iodonitrotetrazolium chloride to a 
formazan chromophore, which has a maximal absorbance at 546 nm. The amount of human 
purine nucleoside phosphorylase required for catalytic excess was determined empirically for 
reactions via a concentration series. In assays containing 50 nM PPM and 750 μM 
hypoxanthine, 1.1 μM human purine nucleoside phosphorylase was determined to be the 
concentration above which no greater rate of product formation was observed. A three-fold 
excess of human purine nucleoside phosphorylase (3.3 μM) was used in all experiments to 
assure catalytic excess. At specified time points, corresponding to <15% ribose 5-phosphate 
consumption, reactions were quenched by either heat denaturation or acidification, as described 
below. Hypoxanthine concentrations were determined by addition of Developer mix and 
comparison of ∆A546 to a standard curve run in parallel to biochemical assays. Developer mix 
contained 25 mM Tris–HCl, pH 8.0, 0.356 % v/v Triton X-100, 7.13 mM iodonitrotetrazolium 
chloride, and 2.4 mg/mL xanthine oxidase. Details of individual assay formats are provided 
below in each study. This assay meets the requirements for a valid tandem assay, which are: 1) 
the first reaction must be zero-order with respect to substrate; and 2) the second stage reaction 
must not be rate-limiting37. 
Endogenous metal ions were removed from affinity-purified PPM by treatment of 100 μM 
stock solutions with 1 mM EDTA for 1 hour at 4 °C. The protein was then exchanged into 25 mM 
Tris–HCl, pH 8.0 using a HiTrap desalting column. To determine metal dependence of PPM, 
chelated preparations were incubated at 23 °C with 1 mM of MnCl2, ZnCl2, NiCl2, MgCl2, or 
CoCl2 for 3 min prior to biochemical assay. Relative turnover assays (100 μl) contained 1 µM 
glucose 1,6-bisphosphate, 10 nM reconstituted PPM, 25 mM Tris–HCl, pH 8.0, 750 μM 
hypoxanthine, and 3.3 μM purine nucleoside phosphorylase, and were initiated by the addition 
of 500 µM ribose 5-phosphate. PPM and purine nucleoside phosphorylase activities were 
quenched after an 8 minute reaction by heat denaturation at 95 °C for 5 min. Product formation 
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was measured via the hypoxanthine consumption assay, performed by adding 20 μL of 
Developer Mix to 75 μL of the turnover reaction. The absorbance at 546 nm was monitored at 
15 s intervals until no further absorption change was observed, which typically occurred within 
10 min.  
The initial velocity of PPM was measured in the presence of increasing concentrations of 
glucose 1,6-bisphosphate in microtiter plates. PPM (10 µl of a 200 nM stock solution) was 
activated by incubating with 80 μL of a solution containing 0, 0.1, 0.25, 0.5 and 1 μM glucose 
1,6-bisphosphate in 25 mM Tris–HCl, pH 8.0, 111 μM MnCl2, 937.5 μM hypoxanthine and 4.1 
μM human purine nucleoside phosphorylase. Turnover was initiated by the addition of 10 μL of 
5 mM ribose 5-phosphate resulting in a final concentration of 0.5 mM. Reactions were quenched 
after 4 min by acid denaturation with 5 μL of a solution containing 1M HCl and 1M CaCl2. 
Reactions were neutralized by the addition of 5 μL 1M NaOH immediately prior to determination 
of the hypoxanthine concentration. Hypoxanthine consumption was measured by removing a 75 
µl aliquot of quenched/neutralized assay mixture and combining with 20 μL Developer Mix. The 
absorbance at 546 nm was monitored at 15 sec intervals until no further absorption change was 
observed, which usually occurred within 10 min.  
Biochemical data for determination of kinetic parameters was determined in 96-well 
microtiter plates. Enzyme Mix was freshly prepared by pre-activating 200 nM PPM in 25 mM 
Tris–HCl, pH 8.0, with 5 µM glucose 1,6-bisphosphate and 100 µM MnCl2 at 23 °C for 10 min 
and maintained at 4 °C until assayed. In the 96-well plate assay, 100 µl reactions contained 10 
μL of Enzyme Mix and 80 μL of Assay Mix comprising 25 mM Tris–HCl, pH 8.0, and 111 μM 
MnCl2, 937.5 μM hypoxanthine, and 4.1 μM human purine nucleoside phosphorylase. Reactions 
were initiated by the addition of 10 μL of the appropriate 10x substrate stock solutions and 
quenched after 4 minutes by addition of 5 μL of a solution containing 1M HCl and 1M CaCl2. 
Reactions were neutralized by the addition of 5 μL 1M NaOH immediately prior to determination 
of the hypoxanthine concentration. Correspondingly, initial velocities of the activated enzyme 
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were measured in a final concentration of 25 mM Tris–HCl, pH 8.0, 100 μM MnCl2, 0.5 μM 
glucose 1,6-bisphosphate, 20 nM activated PPM, and final substrate concentrations of 50, 75, 
100, 170, 220, 270, 350, 500, and 700 µM ribose 5-phosphate. Hypoxanthine consumption was 
measured by combining 75 µl of quenched assay mixture with 20 µl Developer mix as described 
in the preceding glucose 1,6-bisphosphate dependence assay. Hypoxanthine concentrations 
were determined by comparison of ∆A546 to a standard curve run in parallel and initial velocities 
were fit to the Michaelis-Menten equation using non-linear regression analyses in the GraphPad 
Prism software package version 5.01 for Windows. 
Phosphatase activity of PPM was measured during ribose 5-phosphate turnover using 
the Phosphate Sensor based assay (Invitrogen), which monitors the change in fluorescence of a 
fluorophore-labeled E. coli phosphate-binding protein upon phosphate binding. The reaction 
mixture contained 0.1 μM PPM, 0.1 mM MnCl2, 25 mM Tris–HCl, pH 8.0, and 0.5 µM Phosphate 
Sensor. The reaction was initiated with 5 μM ribose 5-phosphate and 5 μM glucose 1,6-
bisphosphate, and the fluorescence was monitored for 10 min at room temperature in a Cary 
Eclipse Spectrofluorimeter with λex = 430 nm and λem = 470 nm. The concentration of phosphate 
formed by PPM was determined by comparison to a standard curve of potassium phosphate in 
0.1 µM PPM, 0.1 mM MnCl2, and 25 mM Tris–HCl. 
 
Isotope relay assays 
Isotopically labeled ribose 5-phosphates were synthesized using ribokinase with ribose 
or [13C5]ribose and ATP or [γ-18O4]ATP (Cambridge Isotope Laboratories). Ribokinase was 
expressed and purified as previously described38 and stored at -80 °C in 25 mM Tris–HCl, pH 
8.0 and 5 mM MgCl2. Preparative reactions contained a final concentration of 1 mM ribose 
(ribose or [13C5]ribose), 1 mM ATP ( [γ-18O4]ATP or ATP), 25 mM Tris–HCl, pH 8, 30 mM KCl, 
0.5 mM MnCl2, 0.5 mM MgCl2 and 0.5 μM ribokinase. Reactions were incubated at 25 °C and 
quenched after 5 min by heat denaturation of ribokinase at 94 °C for 5 min. After centrifugation 
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for 2 min at 15 000 g at 4 °C, the enzymatically-synthesized ribose 5-phosphate species were 
stored at 4 °C until used. 
Labeled ribose 5-phosphates, prepared as described above, were mixed in a 1:1 ratio on 
ice. Reactions in a final volume of 30 μL were initiated by addition of activated PPM to a final 
concentration of 2 μM at 25 °C. PPM (20 μM) was activated with 20 μM glucose 1,6-
bisphosphate in the presence of 0.5 mM MnCl2 and 25 mM Tris–HCl, pH 8.0. After 30 minutes, 
the reactions were quenched with an equivalent amount of ice-cold methanol. In control 
reactions, functional activity of PPM was verified by observing conversion of ribose 1-phosphate 
to inosine by adding 10 μM human purine nucleoside phosphorylase and 1.5 mM hypoxanthine. 
Ribose phosphate species were separated from contaminating salts and other reaction 
components using a Hypercarb porous graphite column (3 x 50 mm, ThermoFisher Scientific) 
and an isocratic flow of 0.2 mL/min of 20 mM CH3COONH4, pH 6, and 0.1% diethylamine. A 
ThermoPal autosampler was used to inject 10 μL of the quenched reaction and a divert valve 
was operational for the first 2.5 min to avoid introducing salts into the ion source. Ribose 
phosphate species typically eluted in the range of 3.5–4.5 min. Isotopologue peak intensities 
were averaged over the 3.5–4.5 min range for the data shown. Ribose phosphate species were 
analyzed on a triple quadrupole ESI–LC/MS (ThermoScientific Quantum Access) equipped with 
an ESI interface outfitted with a 100 μm internal diameter deactivated fused silica capillary. 
Nitrogen was used as the sheath gas and argon as the auxiliary gas, at 54 and 10 (arbitrary 
units), respectively. The mass spectrometer was operated in the negative mode with the 
following parameters: spray voltage, 3 kV; capillary temperature, 200 °C; vaporizer temperature, 
280 °C; tube lens offset, -103 V; skimmer offset, -15 V; capillary offset, -35 V. The parameters 
were tuned by direct infusion of a 500 μM ribose 5-phosphate standard at 10 μL/min. Data 
acquisition and spectral analyses were conducted with Thermo Xcalibur Software, version 2.1. 
 
Results 
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Structure of the B. cereus PPM with and without substrates 
B. cereus PPM folds into two distinct domains: a core domain (residues 2–99 and 219–
393) and a cap domain (residues 102–216) which are illustrated in Figure 4-2A. The core 
domain is organized around an alkaline phosphatase fold (Figure 4-2B,C), and superposition 
with the E. coli alkaline phosphatase (PDB ID 1ALK13) results in a RMS deviation of Cα atoms of 
2.9 Å. The cap domain contains three helices surrounding a 5-stranded mixed β-sheet (Fig. 4-
2A,D) and a homology search using the EMBL DaliLite server39 established that the fold is 
unique to prokaryotic PPMs. 
 
 
Figure 4-2. Structural overview of B.cereus PPM. Panel A shows the overall fold of B. cereus 
PPM. PPM is composed of a core domain and a cap domain. α-Helices are colored in blue and 
β-strands are colored red. The two Mn2+ ions are shown as a CPK representation and are 
colored magenta. The side chain of Thr(P)-85 is shown as a stick representation in orange. A 
comparison of the fold of the B. cereus PPM core domain to that of E. coli alkaline phosphatase 
(PDB ID 1ALK13) is shown in panel B,C. The structures of PPM (panel B, rotated 90° from the 
view in panel a about the black line) and alkaline phosphatase (panel C), were aligned by their 
homologous metal coordinating residues in PyMol28. Panel D shows a topology diagram of the 
cap domain (residues 102–216). The coloring scheme is the same as panel a. Two views of 
electrostatic surface potential mapped onto the surface of PPM are shown in panel E with 
negatively-charged surfaces colored red, positively-charged surfaces colored blue, and 
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contoured from -25 kT/e to +25 kT/e. This image copyright of the Journal of Biological 
Chemistry. Reproduced with permission. Originally published by Panosian, et al.1 
 
 
An electropositive cleft at the interface between the core and cap domains (Fig. 4-2E), 
houses the active site (Fig. 4-3A) and contains electron density consistent with two metals ions. 
Collection of diffraction data at the Mn-edge (λ=1.89 Å) revealed an anomalous signal for both 
metals at this wavelength (not shown). To be consistent with the nomenclature adopted for the 
alkaline phosphatase superfamily, the metals are referred to as Mn-1 and Mn-2. Comparison of 
the active site with E. coli alkaline phosphatase (Fig. 4-3B) and other structurally-characterized 
members of the alkaline phosphatase superfamily revealed that the coordinating ligands to this 
dimetallo center are structurally conserved with the exception of an additional ligand to Mn-1 
that appears to be unique to prokaryotic PPMs (Asp-156 Oδ1).  
Among the coordinating ligands of the dimetallo center is Thr-85, which is structurally 
homologous to the catalytic nucleophile, Ser-102, in the E. coli alkaline phosphatase (Fig 4-3B). 
In accordance with the alkaline phosphatase reaction mechanism (Figure 4-1), Ser-102 is not 
phosphorylated at the start of the catalytic cycle (Figure 4-1, Step 1), but becomes transiently 
phosphorylated as the catalytic intermediate (Figure 4-1, States 3,4,5). This transient 
phosphorylation was challenging to trap for crystallographic studies of the E. coli alkaline 
phosphatase40. As a result, observation of electron density consistent with phosphorylation of 
Thr-85 in the B. cereus PPM was unexpected (Figure 4-3C). The electron density at Thr-85 was 
weaker than expected for a phosphate modification, but could not be explained by a water 
molecule. This suggested that the crystals formed from a pool of protein containing a mixture of 
both phosphorylated and unphosphorylated enzyme. Crystals grown from protein pre-incubated 
with the reported activator glucose-1,6-bisphosphate6 appeared to have stronger electron 
density for the phosphate modification of Thr-85, as shown in Figure 4-3D, suggesting that the 
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activator transfers a phosphoryl group to Thr-85. In the phosphorylated enzyme, two phosphate 
oxygens form a coordinating bridge between Mn-1 and Mn-2 (Figure 4-3E). 
 
Figure 4-3. Active site architecture. B. cereus PPM purifies in a mixed state, with some 
percentage of the protein phosphorylated and some unphosphorylated. Figure panels depicting 
unphosphorylated protein use coordinates from the unphosphorylated population. A. Mn2+ 
coordination in unphosphorylated B. cereus PPM. Coordinating interactions are shown with 
dotted lines. B. Comparison of metal coordination in B. cereus PPM (gray) and E. coli alkaline 
phosphatase (red, PDB ID 1ALK). Comparison was performed with a local alignment in PyMol28. 
Residues are labeled with PPM numbering first and alkaline phosphatase numbering second. C 
& D. Occupancy of the phosphate modification of Thr-85 following incubation of B. cereus PPM 
with glucose 1,6-bisphosphate. 2|Fo|-|Fc| simulated annealing omit electron density maps 
calculated in CNS25 after the removal of Thr-85 from the structure are contoured to 1.25 σ 
(green mesh). C. PPM that was not incubated with glucose 1,6-bisphosphate and D. PPM 
activated with glucose 1,6-bisphosphate. E. The structure of unphosphorylated B. cereus PPM 
(gray) overlaid with the structure of glucose 1,6-bisphosphate activated PPM (blue). A small 
rotation in the χ-1 angle of Thr-85 allows the phosphate modification to bridge the two Mn2+ 
ions. This image copyright of the Journal of Biological Chemistry. Reproduced with permission. 
Originally published by Panosian, et al.1 
 
 
Soaking pre-formed crystals of B. cereus PPM with the substrate, ribose 5-phosphate, 
resulted in the appearance of new electron density within the active site that was not observed 
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in either native crystals or crystals grown from protein pre-incubated with the activator (Fig. 4-
4A,B). This electron density (Figure 4-4C) is not fully explained by the modeling of a single 
ribose 5-phosphate molecule. Since substrate reorientation is a likely event during catalysis, 
multiple binding positions are anticipated. Indeed, the most reasonable explanation of this 
electron density is that it reflects a mixed state, with ribose 5-phosphate binding in two, 
mutually-exclusive positions. 
 
Figure 4-4. Binding sites for substrate and activator in the B. cereus PPM active site. In A–E, 
electron density maps (green mesh) are 2|Fo| - |Fc| simulated annealing omit maps contoured at 
1.0 σ and calculated in CNS25 after the removal of non-protein ligands from the active site 
cavity. A. Active site of purified PPM shows the location of water molecules within the cavity. B. 
Active site of glucose 1,6-bisphosphate activated PPM shows that the location of ordered water 
molecules within the active site does not change upon activation. C. Electron density appearing 
in the active site of crystals of B. cereus PPM soaked with ribose 5-phosphate. D & E. 
Interpretation of the active site density in ribose 5-phosphate soaked crystals. D. Ribose 5-
phosphate (R5P-1; orange sticks) bound in the coordinating position. Only electron density 
consistent with substrate binding at this position is shown. Putative hydrogen bonds are denoted 
with dotted lines. E. Ribose 5-phosphate (R5P-2; orange sticks) bound in the distal position. 
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Only electron density consistent with substrate binding at that position is shown. F. 
Interpretation of electron density of B. cereus PPM crystals soaked with glucose 1,6-
bisphosphate (G16P2; orange sticks). This image copyright of the Journal of Biological 
Chemistry. Reproduced with permission. Originally published by Panosian, et al.1 
 
 
 
In the first binding position of ribose 5-phosphate (Fig. 4-4D), Thr-85 is 
unphosphorylated, and the 5-phosphate of the substrate bridges Mn-1 and Mn-2. As a result, 
this position is termed the coordinating position. In the coordinating position, the substrate is 
additionally stabilized by two hydrogen bonds between Arg-193 Nη and the 1-OH group of the 
furanose ring, and between Asp-286 Oγ and the 3-OH of the furanose ring, and by two water-
mediated interactions with the protein. A similar binding position has previously been observed 
in structures of alkaline phosphatase family members crystallized in complex with products. 
The second binding position of ribose 5-phosphate has markedly clearer electron density 
(Figure 4-4E). While substrate bound in this position is oriented with the 1-OH group of the 
furanose ring toward the phosphate of Thr(P)-85, the distance between Thr(P)-85 and the 1-OH 
group is 8.5 Å, and no part of the molecule directly interacts with the dimetallo catalytic center. 
As a result, this position is referenced as the distal position. In the distal position, ribose 5-
phosphate is stabilized by seven putative hydrogen-bonds to the cap domain of the protein, and 
four water-mediated interactions. Four of the hydrogen-bonds and two of the water-mediated 
interactions are to the 5-phosphate, which binds within a well-defined pocket. The remaining 
interactions are between the Nη1 and Nη2 atoms of Arg-193 and the 1-OH group and 2-OH 
group of the furanose ring, between Ser-154 Oγ and the 3-OH of the furanose ring, and two 
water-mediated interactions to the 1-OH group of the furanose ring. A similar binding position 
has not previously been observed in structures of alkaline phosphatase superfamily members. 
Soaking of pre-formed crystals of B. cereus PPM with glucose 1,6-bisphosphate resulted 
in the appearance of clear electron density within the active site consistent with a single binding 
site for glucose 1,6-bisphosphate (Figure 4-4F). In this binding position, the pyranose ring and 
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the 6-phosphate superimpose closely with the furanose ring and 5-phosphate of ribose 5-
phosphate in the distal position. The 1-phosphate binds within a second phosphoester binding 
pocket at the interface of the core and cap domains and includes contacts to the Nζ atom of 
Lys-240 and the Nη1 and Nη2 atoms of Arg-212. This position of glucose 1,6-bisphosphate is 
stabilized by seven direct contacts to the protein, only one of which is to the pyranose ring 
(between Ser-154 Oγ and the 3-OH of the pyranose ring), and three water-mediated contacts. 
Interestingly, the hydrogen-bonding contacts to the 6-phosphate of glucose 1,6-bisphosphate 
slightly differ from those to the 5-phosphate of ribose 5-phosphate, with one hydrogen bond 
shifting from a direct contact to a water-mediated contact. Steric differences between the 
phosphate orientations on a 5- versus 6-membered sugar ring may underlie this alteration in 
phosphate binding. 
 
Verification of Thr-85 phosphorylation by Western and mass spectral analysis 
Since the phosphorylation of the catalytic nucleophile, Thr-85, was unanticipated, and 
post-translational modifications cannot be unambiguously identified with even the best 
crystallographic data, the phosphorylation of Thr-85 was confirmed with both mass spectral and 
Western analyses. LTQ-orbitrap analysis of B. cereus PPM digested with trypsin, elastase, or 
subtilisin resulted in 82% sequence coverage. Of the peptides analyzed, eight unique peptides 
contained Thr-85, one of which (residues 80–95, STGKDTMTGHWEIMGL, mass of 1 876.76 
Da) deviated from its predicted m/z ratio in a manner consistent with phosphorylation. The 
results of tandem mass spectrometry are shown in Figure 4-5A and confirmed both the 
presence and location of the site of phosphorylation in this peptide. This spectrum shows not 
only the loss of an m/z of 98 (H3PO4) from the parent ion but also from several of the fragment 
ions (e.g. b6, b10, and b12). Localization of the phosphate modification to Thr-85 is evidenced 
specifically with the b5, b6, y10 and y11 fragments flanking the site of phosphorylation. The 
identification of a mixture of phosphorylated and unphosphorylated peptides is consistent with 
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the crystal structure of PPM having only partial occupancy of the phosphate modification (Figure 
4-3C). 
 
Figure 4-5. Phosphorylation of Thr-85. A. Mass spectrum of the phosphorylated peptide 
STGKDTMTGHWEIMGL. A peptide with a mass of 1 876.76 Da was isolated from the pool of 
peptides resulting from elastase digestion of PPM. The spectrum of the doubly charged 
phosphopeptide parent ion (m/z of 938.38) is shown in green. The b and y ions for the 
phosphopeptide are shown in blue and magenta, respectively. T +80, mass of phosphorylated 
threonine residue; M +16, mass of an oxidized methionine residue.  B. Western analysis of 
phosphorylation of B. cereus PPM following incubation with glucose 1,6-bisphosphate. The 
upper image of Ponceau stained nitrocellulose verifies that equivalent amount of total protein 
was loaded in each lane. The lower image shows the Odyssey image of the same nitrocellulose 
membrane following incubation with a phosphothreonine-specific primary antibody and an 
Alexafluor-labeled secondary antibody. The concentration of glucose 1,6-bisphosphate (in μM) 
is indicated above each lane. C. Quantitation of data shown in panel B. Band intensities were 
calculated with the program ImageJ32 and were normalized to the intensity of the band at 1 000 
μM glucose-1,6-bisphosphate in each image. The values are the average of ratios from three 
independent experiments. This image copyright of the Journal of Biological Chemistry. 
Reproduced with permission. Originally published by Panosian, et al.1 
 
 
Western analysis was used to further verify both the phosphorylation of Thr-85 and an 
increase in phosphorylation upon the addition of glucose 1,6-bisphosphate. Both wild-type and 
T85A PPM were analyzed using a phosphothreonine-specific antibody after incubation with 
increasing amounts of glucose 1,6-bisphosphosphate (Figure 4-5B,C). This antibody only 
recognized the wild-type enzyme, consistent with Thr-85 being the only site of phosphorylation. 
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The phosphorylation of the wild-type enzyme increased upon the addition of the activator, 
glucose 1,6-bisphosphate, consistent with the observation that pre-incubation of PPM with 
glucose 1,6-bisphosphate appeared to increase the percentage of protein with phosphorylated 
Thr-85 in the crystal structure (Figure 4-3D). 
 
Figure 4-6. Enzymatic activity of PPM. Panel A illustrates the effect of glucose 1,6-bisphosphate 
concentration on the activity of B. cereus PPM. The calculated velocity is the average of three 
independent experiments. The activity of EDTA-chelated B. cereus PPM in the presence of 1 
mM cations is shown in panel B. Activity is the average of three independent measurements 
and error bars represent the standard deviation of the measurement. Activity was normalized to 
the activity of B. cereus PPM measured after addition of 1 mM MnCl2. In panel C, initial 
velocities of PPM are plotted as a function of ribose 5-phosphate concentration. Data are the 
average of three assays, and a double reciprocal plot of the data is shown in the inset. The 
calculated Km, Vmax, and kcat are 263 ± 34 µM, 12.3 ± 0.7 µM min-1 and 10.25 ± 0.6 s-1. This 
image copyright of the Journal of Biological Chemistry. Reproduced with permission. Originally 
published by Panosian, et al.1 
 
 
 
Activity of PPM 
The crystallographic, Western, and mass spectrometric analyses demonstrated that the 
addition of the glucose 1,6-bisphosphate increased the phosphorylation of Thr-85 in wild-type 
enzyme. To assess the effect of increased phosphorylation on activity, B. cereus PPM was pre-
incubated with increasing concentrations of glucose 1,6-bisphosphate and assessed the 
catalytic turnover (Figure 4-6A). A concentration-dependent enhancement of PPM activity was 
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observed between 0.1 µM and 2.5 µM glucose 1,6-bisphosphate, at which point maximal activity 
was reached. The metal-dependence of B. cereus PPM was confirmed by measuring the 
activity of chelated protein reconstituted with Mn2+, Zn2+, Ni2+, Mg2+, and Co2+. Only the Mn2+ 
incorporated enzyme showed significant enzyme activity (Figure 4-6B). In these optimized 
conditions, the Vmax, kcat, and Km were determined to be 12.3 ± 0.7 μM min-1, 10.2 ± 0.6 s-1 and 
263 ± 34 μM, respectively (Figure 4-6C).  
Having established basic kinetic parameters for the conversion of ribose 5-phosphate to 
ribose 1-phosphate, the presence of intrinsic phosphatase activity, in which the phosphoryl 
group from Thr-85 is hydrolyzed, was determined. While statistically significant phosphatase 
activity was measured, the rate of hydrolysis is near the detection limit of the assay and 
appeared to be ~10 000-fold lower than the rate of ribose 1-phosphate and ribose 5-phosphate 
interconversion (data not shown). 
 
Reaction of PPM with isotopically labeled substrate 
Phosphomutases that are unphosphorylated when active commonly catalyze 
intramolecular phosphoryl transfer (Figure 4-7A), while those that are phosphorylated commonly 
catalyze intermolecular phosphoryl transfer (Figure 4-7B) with respect to substrate41. 
Accordingly, the observed correlation between enzyme phosphorylation and activity in PPM 
suggests that it catalyzes intermolecular phosphoryl transfer; however, this is counter to what is 
anticipated from the alkaline phosphatase general mechanism. In order to unambiguously 
demonstrate intermolecular transfer, an isotope relay assay was performed. In this assay, a 1:1 
stoichiometric mixture of ribose 5-[18O3]phosphate and [13C5]ribose 5-phosphate was incubated 
with PPM under standard reaction conditions (Figure 4-7C). These substrates are labeled with 
heavy-atom isotopes in the phosphoryl group (+6 Da) and the ribose ring (+5 Da), respectively, 
rendering them, and all possible reaction products, distinguishable by mass spectrometric 
analysis. In the event of intramolecular transfer (mutase mechanism) the isotopic distribution of 
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the molecular ions for the two compounds should remain unchanged. Conversely, in the event 
of intermolecular transfer (transferase mechanism), in which the transferred phosphoryl group is 
derived from an antecedent substrate, the isotopic distribution for the molecular ions should 
scramble into four species of unique masses. It is unambiguous from these results (Figure 4-
7D) that intermolecular phosphoryl group transfer is occurring under the PPM reaction 
conditions used in this study, with four isotopologues represented at roughly equal total ion 
current intensities. Moreover, when human purine nucleoside phosphorylase and hypoxanthine 
were added to this reaction, consumption of the ribose phosphates was apparent. Notably, 
newly formed isotopologues were consumed more rapidly than isotopologue masses 
corresponding to precursors, suggesting that the new isotopologues corresponded to 
predominantly ribose 1-phosphate. 
To support the isotope relay results observed in the preceding study, an identical 
experiment was performed with a 1:1 mixture of [13C5]ribose 5-[18O3]phosphate and ribose 5-
phoshate. As in the prior case, the isotopologue distribution of this mixture should remain 
unchanged in the event of an intramolecular reaction, whereas an intermolecular reaction 
should engender isotope relay of [18O3]phosphate to unlabeled ribose and relay of unlabeled 
phosphate to [13C5]ribose (Figure 4-7E). Again, the incubation of substrates with PPM led to the 
generation of isotopologues in equal ratios and the addition of human nucleoside phosphorylase 
to reactions resulted in the disappearance of these newly formed isotopologues (Figure 4-7F). 
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Figure 4-7. Isotope relay assays. A,B. Comparison of phosphoryl transfer scenarios. A 
schematic of intramolecular phosphoryl transfer is shown in panel A. In intramolecular transfer, 
the active form of the enzyme is dephosphorylated (filled star), corresponding to Figure 4-1, 
State 1. Panel B is a schematic of intermolecular phosphoryl transfer. In intermolecular transfer, 
the active form of the enzyme is phosphorylated (filled star), corresponding to Figure 4-1, State 
4. C-F. Mixtures of ribose 5-phosphate synthesized from [U-13C5]ribose (rings with red squares) 
or ribose and [γ-18O4]ATP (blue) or ATP were incubated with PPM for 30 min and the masses of 
the products were measured by LC-MS. C. Theoretical masses for starting materials and the 
predicted products of either intramolecular or intermolecular phosphoryl transfer. D. Mass 
spectra of the experiment outlined in Panel C. In the absence of enzyme (black line) only the 
m/z 234 and 235 peaks corresponding to the starting materials are observed. Following 
incubation with PPM, peaks at m/z 229 and 240 appear (green line). The addition of human 
purine nucleoside phosphorylase to this reaction, which removes the product ribose 1-
phosphate, decreases the intensity of these new peaks (grey line). E. Theoretical masses for 
starting materials and the predicted products of either intramolecular or intermolecular 
phosphoryl transfer. F. Mass spectra of the experiment outlined in E. In the absence of enzyme, 
only the m/z 229 and 240 peaks corresponding to the starting materials are present (black line). 
Incubation of the starting materials with PPM resulted in the appearance of peaks at m/z 234 
and 235 (green line). These new peaks decreased in intensity following incubation with human 
purine nucleoside phosphorylase (grey line), which removes ribose 1-phosphate. This image 
copyright of the Journal of Biological Chemistry. Reproduced with permission. Originally 
published by Panosian, et al.1 
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To determine if ribose could be a discrete intermediate or reversible shunt product in the 
PPM catalyzed reaction, the PPM reaction was performed as described above, with the addition 
of 1 mM [U-13C5]ribose. In these reactions, the initial isotopologue distribution of the reaction 
mixture remained unchanged (data not shown), ruling out ribose as a diffusible intermediate. 
 
Discussion 
Implications for the catalytic mechanism 
Extrapolation of the general alkaline phosphatase reaction mechanism to PPM predicts 
that the enzyme should be active when unphosphorylated (Figure 4-1, State 1), and that 
catalysis should proceed via an intramolecular mutase mechanism. In such a mechanism, the 
reaction would proceed through an intermediate in which the enzyme is phosphorylated, but the 
substrate is dephosphorylated (Figure 4-1, State 4). Indeed, this is exactly what was observed 
for cofactor independent phosphoglycerate mutase9, 10, which is the only other characterized 
phosphomutase in the alkaline phosphatase family. 
Surprisingly, these results are inconsistent with this precedent. It was demonstrated that 
glucose 1,6-bisphosphate both increased enzyme activity (Figure 4-6A) and resulted in 
increased phosphorylation of Thr-85 (Figures 4-3C&D, 4-5B&C), suggesting that glucose 1,6-
bisphosphate activates PPM by phosphorylating the catalytic nucleophile. These data are 
therefore consistent with substrates being acted upon by the phosphorylated enzyme, and 
generally proscribe an intramolecular sequence analogous to phosphoglycerate mutase. 
 To unambiguously demonstrate PPM proceeds via intramolecular or intermolecular 
transfer, a series of isotope relay experiments was performed. Under all assayed reaction 
conditions, the phosphoryl group of the product is indeed derived from an antecedent substrate 
(Figure 4-7D,F). Notably, analogous isotopic labeling experiments performed for 
 135 
 
phosphoglycerate mutase of the alkaline phosphatase superfamily revealed no relay of labeled 
phosphoryl groups (or glyceryl groups), demonstrating the opposite result9, 10. 
Having ruled out a purely intramolecular process, there are several general scenarios 
that may result in the intermolecular transfer of phosphoryl groups (a full range of scenarios has 
been outlined by Britton and coworkers for phosphoglycerate mutase41). As shown in Figure 4-
7B, one limiting case assumes a primed (phosphorylated) enzyme. In this scenario, the 
phosphoenzyme would transfer its phosphoryl group to the 1-position of ribose 5-phosphate, 
resulting in intermediary ribose 1,5-bisphosphate. A phosphoryl group would be subsequently 
transferred from the 5-position of this intermediate to the enzyme nucleophile, concomitantly 
generating the product ribose 1-phosphate, and priming the enzyme for the next reaction cycle. 
Although there are alternatives to this reaction mechanism, a dephosphorylated starting 
enzyme must be invoked, which is inconsistent with the data outlined here. Briefly, to catalyze 
intermolecular transfer with a dephosphorylated enzyme, the dephosphorylation of ribose 5-
phosphate by PPM must be followed by diffusion of the ribose intermediate at a rate competitive 
with phosphoryl transfer over the course of the assay. Despite the evidence that the active 
enzyme is phosphorylated, the possibility of ‘leaky’ mutase activity was assayed by performing 
the PPM reaction with labeled and unlabeled [18O3]ribose 5-phosphates with the addition of a 
molar excess of [13C5]ribose. No transfer of labeled or unlabeled phosphoryl groups to 
[13C5]ribose was observed under these conditions, thereby eliminating the possibility of a 
diffusible ribose intermediate in the context of a leaky mutase mechanism. Given the correlation 
of increased enzyme activity with phosphorylation, and the observation of intermolecular 
phosphoryl transfer between substrates, the most parsimonious interpretation supports the 
mechanism depicted in Figure 4-7B. 
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Figure 4-8. Modification of the alkaline phosphatase mechanism for intermolecular phosphoryl 
transfer. Alkaline phosphatase follows the reaction cycle from State 1 through State 6 (red path, 
red substrates), starting with unphosphorylated enzyme (State 1) and phosphorylated substrate 
(State 2), and proceeding through a transient intermediate where the enzyme is phosphorylated 
(State 4) and the substrate is dephosphorylated (States 3,4,5) before generating a 
phosphorylated product (State 6). The intermolecular transfer catalyzed by PPM can occur 
within the context of this reaction mechanism (blue path, blue substrates) if phosphorylated 
enzyme (State 4) acts on phosphorylated substrate (State 5). PPM could then follow a similar 
path through the same catalytic cycle by proceeding through an intermediate where the enzyme 
is dephosphorylated (State 1) and the substrate is doubly phosphorylated (States 6, 1, 2). To 
complete the reaction cycle, the bisphosphate intermediate could transfer its phosphoryl group 
back to the enzyme, resulting in a singly phosphorylated product (State 3) and a 
phosphorylated, active enzyme (State 4). This image copyright of the Journal of Biological 
Chemistry. Reproduced with permission. Originally published by Panosian, et al.1 
 
To reconcile this intermolecular transferase mechanism with the general alkaline 
phosphatase mechanism (Figure 4-1,8), it is possbile that bacterial PPMs may have adapted to 
favor substrate entry in the catalytic cycle at an alternate point. In this scenario, phosphorylated 
PPM (Figure 4-8, State 4) binds the substrate ribose 5-phosphate (Figure 4-8, State 5), then 
transfers a phosphoryl group from Thr(P)-85 to ribose 5-phosphate, forming a ribose 1,5-
bisphosphate intermediate and a dephosphorylated enzyme (Figure 4-8, State 6). The reaction 
cycle is completed with transfer of the 5-phosphate of ribose 1,5-bisphosphate to Thr-85 (Figure 
4-8, States 2,3), priming the enzyme for the next turnover cycle (Figure 4-8, State 4). 
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The distinct entry point into the catalytic cycle requires that PPM differ from 
characterized enzymes within the alkaline phosphatase superfamily with respect to the stability 
of the phosphorylated catalytic nucleophile. In alkaline phosphatase, the nucleophile, Ser-102, 
is only transiently phosphorylated during the catalytic cycle, and efforts to stabilize this reaction 
intermediate proved challenging. The eventual crystal structure of phosphorylated alkaline 
phosphatase required both that the Zn2+ ions of the dimetallo center be replaced with 
catalytically inactive Cd2+ and that Ser-102 be mutated to threonine40. In peptides, 
phosphoserine has been shown to be more labile than phosphothreonine under alkaline 
conditions42. This cursorily implies that the use of a threonine as the active site nucleophile in 
PPM contributes to the improved longevity of the phosphoenzyme. However, the folded protein 
has a profound influence on the stability of phosphate modifications, and phosphoserines in 
phosphoryl transfer enzymes have measured t1/2 values on the order of years43. While the 
origins of the improved stability of the phosphorylated nucleophile in PPM remain unclear, the 
substrate nevertheless likely encounters phosphorylated enzyme under physiological 
conditions. 
 
Comparison of the structures of the B. cereus and S. mutans PPMs 
The structure of B. cereus PPM was determined by molecular replacement using the 
unpublished coordinates for a putative PPM from S. mutans (PDB ID 2I09; New York SGX 
Research Center for Structural Genomics, unpublished) as a search model. While the backbone 
accuracy was sufficient for use as a molecular replacement search model, the S. mutans 
structure contains numerous errors. For example, four substantial errors at the active site would 
prevent the development of a structure-based reaction mechanism using the S. mutans 
structure as a guide: first, a short frame-shift (residues 218–220) places incorrect residues at 
the active site; second, no metals are included; third, the side chains of three active site 
residues including the catalytic threonine are mis-oriented; fourth, the post-translational 
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phosphorylation of the active site threonine is modeled as a water molecule. It is possible to 
verify that these are model building errors and not differences between PPM from these two 
organisms since both the coordinates and the structure factors were deposited for the S. 
mutans PPM. After the submission of this manuscript, the coordinates for the S. mutans PPM 
were superceded with a newly refined model (PDB ID 3MV7). While this included metal ions 
and corrected some of the errors, incorrectly positioned side chains in the active site would still 
preclude the development of a structure-based mechanism from these updated coordinates. A 
careful procedure of omit mapping was used to prevent these errors from propagating into the 
present study. 
 
Comparison to phosphomutases in the α-phosphohexomutase and haloacid dehalogenase 
superfamilies 
Phosphomutases have long been grouped into cofactor-independent enzymes that 
catalyze intramolecular transfer, and bisphosphate dependent enzymes that catalyze 
intermolecular transfer. The intermolecular transferase mechanism of PPM is shared with 
several well-studied cofactor-dependent phosphomutases within the α-phosphohexomutase and 
haloacid dehalogenase superfamilies44-47. Perhaps unsurprisingly, numerous parallels exist 
between PPM and phosphomutase enzymes within both of these superfamilies. For example, 
PPM and the phosphomutases within the α-phosphohexomutase and haloacid dehalogenase 
superfamilies are multi-domain enzymes with an active site located in a positively-charged cleft 
between domains45, 48-50. Activity is dependent upon divalent cations, the reactions proceed 
through bisphosphate intermediates44, 51, and the enzymes require the continued presence of 
bisphosphate activators46, 47 to counter the slow inactivation that occurs when the reaction 
intermediate prematurely disassociates from the enzyme, or when the phosphoryl group is 
transferred to water2. Taken together, these broad mechanistic parallels suggest that the details 
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of catalysis identified for phosphomutases within the α-phosphohexomutase and haloacid 
dehalogenase superfamilies may guide future studies on PPM. 
 
Conclusions 
The results presented here include the first published crystal structure and structure-
based functional study of a prokaryotic PPM. Although prokaryotic PPMs belong to the alkaline 
phosphatase superfamily, the data presented here provide evidence that the catalytic cycles of 
these enzymes are distinct. This study serves as a reminder that caution should be used when 
extrapolating reaction mechanisms, even in closely related systems. 
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Chapter V 
 
BIOCATALYTIC SYNTHESIS OF 2,3-DIDEOXYINOSINE THROUGH A DESIGNED, 
NON-NATURAL, DE NOVO PATHWAY 
 
Introduction 
the combination of synthetic biology and metabolic engineering protocols to form 
microbial factories has recently found success in biocatalytic production of high value 
compounds such as drugs and biofuels1, 2. For example, a precursor for the anti-malarial drug 
artemisinin has been produced in E. coli3 and yeast4 through co-expression of the non-
mevalonate isopentenyl pyrophosphate biocatalytic pathway and enzymes from the native 
producer, Artemisia annua. Protein scaffolds were utilized to co-localize enzymes of the 
pathway and decrease loss of intermediates to diffusion5. Branched-chain alcohols, which are 
useful in diesel and jet fuels, have been generated through shunting of the amino acid 
biosynthesis pathways6. A de novo designed pathway for glucaric acid was introduced into E. 
coli which decreases the number of enzymatic steps from ten to five7. A second de novo 
pathway generates D- and L-1,2,4-butanetriol, a non-natural precursor to high-energy 
compounds, enantioselectively from D-arabinose or L-lyxose, respectively8. These pathways 
utilize enzymes from various and disparate pathways to generate noninnate high-value 
compounds in excellent yields. 
Given the structural similarity of nucleoside analogs, dideoxynucleosides in particular, to 
natural products it is hypothesized that a biosynthetic pathway for their production can be 
generated by judicious selection of enzymes and/or enzyme engineering and pathway 
optimization. Nucleoside analogs have long been recognized for their utility in the treatment of 
viral infections and cancer. Furthermore, nucleoside analogs are utilized in DNA sequencing 
methodologies and other biotechnological techniques. As such a critical class of compounds the 
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synthesis and biological activity of nucleoside analogs is a major area of study. Chemical 
synthesis of nucleoside analogs, particularly ddI, is achieved from inosine and 2´-deoxyinosine 
through Barton deoxygenation9, 10, Corey-Winters reduction11, 12, the Mattocks reaction13, and 
Eastwood olefination14. Alternatively, addition of nucleobase to synthesized unnatural sugars 
has proven useful in the synthesis of ddI15 and can also be applied to the synthesis of a number 
of nucleoside analogs with sugar variations. A combination of expensive precursors, low yield 
steps, generation of regioisomeric and anomeric products which require chromatographic 
separation and large hazardous waste streams drive the price of manufactory. In fact, 55-99% 
of nucleoside analog drug prices can be attributed to the active pharmaceutical ingredient16. 
Thus, even modest improvements in process yields, reduction in waste stream or a switch to a 
cheaper starting material will likely facilitate broader distribution of dideoxyinosine. 
Recently research has expanded into enzymatic synthesis of nucleosides and 
subsequently extended to generation of nucleoside analogs. This strategy utilizes the stereo- 
and regiochemical control of enzymes to set the orientation of the anomeric carbon along with 
the identity of the C-N bond and provides an advantage over chemical synthetic methods 
through application at aqueous process conditions at standard temperatures. Ribosyl 
transferases or pyrimidine and purine nucleoside phosphorylases (PNPs) have long been 
applied as biocatalysts to transfer unnatural sugars from a nucleoside analog with a facile 
synthetic route to form a second analog which is challenging to synthesize directly17-19. 
Chemical synthesis of the instable sugar-1-phosphate intermediate is avoided through in situ 
generation. Whole cells are frequently utilized to carry out this process, providing a cheap 
source of enzyme and nucleobase and stable environment for enzymatic function20. This 
strategy, however, still requires the chemical synthesis of a nucleoside analog precursor. 
2-Deoxyribonucleosides have been formed through the condensation of D-
glyceraldehyde-3-phosphate and acetaldeyde by 2-deoxyribose 5-phosphate aldolase to form 2-
deoxyribose 5-phosphate21, 22. This product is enzymatically isomerized by 
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phosphopentomutase (PPM) to 2-deoxyribose 1-phosphate and incubated with nucleoside 
phosphorylases and an aromatic base to form the final product. 
Nucleosides and nucleotides have also been formed from ribose, ATP and free base. 
Gross and Whitesides made nucleotides, specifically uridine monophosphate, by first generating 
PRPP using the activity of ribokinase and PRPPS. An ATP regeneration system and 
irreversible, CO2-producing final step helped drive the reaction toward nucleotide product23. A 
similar protocol by Scism et al utilized a mutant HPRT to generate nucleotides with unnatural 
bases24. Chuvikovsky et al generated arabino, xylulo and lyxonucleosides with E. coli 
ribokinase. Thymine, ribothymidine, uridine, 2´-deoxyuridine, inosine and 2´-deoxyinosine were 
generated through reaction of sugar, ATP and nucleobase through tandem catalysis by 
ribokinase, PPM, and PNP25. 
 
Figure 5-1. Chemo-enzymatic synthesis of 2´,3´-dideoxyinosine from glutamic acid proceeds 
chemically through 2´,3´-dideoxyribose and utilizes ribokinase (RK), B. cereus 
phosphopentomutase (PPM) and human purine nucleoside phosphorylase (PNP) to add 
hypoxanthine (Hyp.) to the unnatural sugar. 
 
Here, the generation of a prototype pathway is described for the biocatalytic synthesis of 
dideoxyinosine from dideoxyribose, which in turn can be chemically synthesized from glutamic 
acid, resulting in a complete semi-synthetic route (Figure 5-1). The pathway brings together E. 
coli ribokinase, Bacillus cereus PPM and human PNP. Ribokinase functions as a component of 
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DNA, RNA and critical cofactors while also acting as an energy source26. PNP and 
phosphopentomutase act in nucleoside salvage enabling efficient recycling of nucleosides and 
allowing for catabolism of nucleosides in resource limited conditions27, 28. This pathway 
alleviates the requirement for natural nucleoside precursors, which can cost several hundred 
dollars per kilogram, or synthesis of donator analogs for transferases and provides an entirely 
regio- and enantioselective route for the synthesis of nucleoside analogs.  
Low pathway throughput, despite extensive incubation time, is indicative of poor 
substrate turnover by enzymes in the pathway. Improvement of each enzyme for turnover of the 
unnatural substrate will likely increase the rate of ddI synthesis. With this in mind, PNP-46D6, a 
mutant improved in phosphorolysis of ddI, was tested for an ability to synthesize ddI and 
compared to wild type human PNP activity. Kinetic analysis of B. cereus PPM indicates slow 
turnover and poor binding of the unnatural substrate.   Although low activity of PPM with 
dideoxyribose 5-phosphate has been reported in the literature, a mechanistic explanation has 
not yet been established. The crystal structure of B. cereus PPM has been recently reported 
with ribose 5-phosphate bound in the active site and found that a hydrogen bond is formed 
between Ser-154 and the 3-OH of substrate29. It is possible that the low activity of dideoxyribose 
5-phosphate is due to altered substrate binding resulting in poor turnover of substrate. The 
crystal structure of PPM with the unnatural substrate in the active site is reported here and the 
potential of targeted mutagenesis at residue 154 is explored. 
Finally, the foundation for engineering of ribokinase is laid by docking dideoxyribose into 
the active site. Ribose is oriented by ribokinase through formation of hydrogen bonds to each of 
the substrate hydroxyls. It is expected that loss of two hydroxyls will affect the ability of 
ribokinase to orient the substrate for phosphorylation. Mutation of the many hydrogen bond 
donors and acceptors in the binding pocket may establish an apolar surface for favorable 
interaction with the more hydrophobic dideoxyribose substrate. 
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Methods 
Synthesis of dideoxyribose and dideoxyribose 5-phosphate 
(S)-γ-Butyrolactone-γ-carboxylic acid is formed from L-glutamic acid following the 
method of Okabe et al30. Sodium nitrite (1.5 eq, 37.5 g, 545 mmol) dissolved in water and 5.6 N 
hydrochloric acid (1.4 eq, 90.6 mL, 508.6 mmol) were simultaneously added dropwise over 3-4 
hours to a slurry of glutamic acid (1.0 eq, 53.3 g, 363.6 mmol) in water (170 mL) while 
maintaining the temperature at 15-20 °C. After complete addition of HCl and NaNO2, the 
reaction is brought to ambient temperature and stirred overnight. The solution was concentrated 
in vacuo and further azeotroped with toluene. Ethyl acetate and anhydrous sodium sulfate were 
added and the mixture stirred for several hours. The precipitates were removed, washing with 
ethyl acetate. AG50W-X4 resin was added to the solution and stirred for 30 minutes to remove 
unreacted starting material. After filtration to remove the resin, the solution was concentrated in 
vacuo and recrystalized from dichloromethane. The crystals were separated by filtration, 
washed with DCM and dried to yield pure (S)-γ-butyrolactone-γ-carboxylic acid (18.2 g, 139.9 
mmols, 39%). Recrystallization of the filtrate further increases the yield. 1H NMR (400 MHz, 
DMSO-d6, δ): 4.97-4.93 (m, 1H, CH), 2.54-2.10 (m, 4H, CH2-CH2). 13C NMR (100 MHz, DMSO-
d6, δ): 177.8 (C5), 172.6 (C1), 76.4 (C4), 27.7 (C2) and 26.4 (C3).  
To form (S)-γ-hydroxymethyl-γ-butyrolactone the unpurified (S)-γ-butyrolactone-γ-
carboxylic acid from the previous step is reduced with borane dimethylsulfide30. The reactant 
(1.0 eq, 4.95 g, 38 mmol) was dissolved in 25 mL of anhydrous THF and cooled to 0 °C. Under 
argon, borane dimethylsulfide (10 M, 1.15 eq, 4.375 mL, 43.75 mmol) was added dropwise over 
a 60 min period. The solution was brought to room temperature, monitored by TLC and stirred 
for an additional two hours. Methanol (3 X 2.25 ml) was added to quench the excess reductant 
and the solution concentrated in vacuo, yielding (S)-γ-hydroxymethyl-γ-butyrolactone (3.8 g, 
32.7 mmols, 86%) with sufficient purity for use without further purification. 1H NMR (400 MHz, 
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CDCl3, δ): 4.67-4.60 (m, 1H, CH), 3.62-3.93 (m, 2H, -CH2OH), 2.67-2.10 (m, 5H, CH2CH2, -OH). 
13C NMR (100 MHz, CDCl3, δ): 178.4 (C1), 81.3 (C4), 64.2 (C5), 28.9 (C2), 23.4 (C3).  
2,3-Dideoxyribose was synthesized by reduction of (S)-γ-hydroxymethyl-γ-butyrolactone 
(1.0 eq, 106 mg, 0.9 mmol) with diisobutyl aluminum hydride (1.5 M in toluene, 1.1 eq, 0.67 ml, 
1.35 mmol) in anhydrous dichloromethane (10.6 mL) under argon and at -78 °C31. The reaction 
was monitored by TLC and determined to be incomplete after 1.25 hours of stirring. Additional 
diisobutyl aluminum hydride (2 eq total, 0.55 mL, 0.45 mmol) was added and the solution stirred 
for an additional 30 min. Methanol (5 ml) was added and the solution brought to room 
temperature. The resulting suspension was purified by flash chromatography (9:1 
dichloromethane/methanol). Dideoxyribose (95 mg, 0.8 mmol, 88%) was collected as an oil after 
concentration in vacuo. 1H NMR (400 MHz, D2O, δ): 5.78-4.97 (m, 1H, CH) 4.36-3.35 (m, 3H, -
CH2OH, CH), 2.17-1.47 (m, 4, CH2-CH2). 13C NMR (100 MHz, D2O, δ): 97.93, 97.55, 93.11 and 
92.89 (CH), 80.30, 78.35, 63.95 and 63.42 (CH), 66.85, 66.27, 64.51 and 63.07 (CH2), 32.53, 
32.00, 27.43, 26.99, 25.55, 26.47, 24.2 and 24.12 (CH2). 
To form (S)-γ-Dibenzylphosphomethyl-γ-butyrolactone, (S)-γ-hydroxymethyl-γ-
butyrolactone (1.0 eq, 740 mg, 6.4 mmol) was dissolved in anhydrous dichloromethane (5 mL) 
and anhydrous acetonitrile (1.5 mL). The solution was brought to 0 °C and tetrazole (3 % in 
acetonitrile, w/v, 2 eq, 37.7 mL, 12.75 mmol) was added followed by dibenzyl-(N,N)-diisopropyl-
phosphoramadite (1.4 eq, 3.26 mL, 8.9 mmol) which was diluted in 18.5 mL of dichloromethane. 
After stirring for two hours, tert-butyl hydroperoxide solution (~5.5 M in decane, 1.2 eq, 1.4 mL, 
7.7 mmol) were added and the reaction stirred for an additional hour. Half-saturated sodium 
bicarbonate (20 ml) was used to quench the remaining peroxide and the solution extracted with 
dichloromethane (2 x 20 ml). The organic layers were combined, dried (MgSO4) and 
concentrated in vacuo32. The product was purified by flash chromatography (39:1 
dichloromethane/methanol) and pure (S)-γ-dibenzylphosphomethyl-γ-butyrolactone (1.355 g, 
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3.6 mmol, 56.5%) was collected after two columns. 1H NMR (400 MHz, CDCl3, δ): 5.1-4.99 (m, 
4H, CH2), 4.64-4.55 (m, 1H, CH), 4.17-3.95 (m, 2H, CH2), 2.04-1.93 (m, 2H, CH2-CH2). 13C NMR 
(100 MHz, CDCl3, δ): 176.7 (C1), 135.86 (d, Jcp = 2.32 Hz, CH), 135.8 (d, Jcp = 2.47 Hz, CH), 
128.98 (d, Jcp = 5.36 Hz, CH), 128.39 (d, Jcp = 3.75 Hz, CH), 77.80 (d, Jcp = 8.06 Hz, CH), 69.95 
(d, Jcp = 5.63 Hz, CH), 68.29 (d, Jcp = 5.48 Hz, CH), 28.3 (C2), 23.6 (C3). 31P NMR (200 MHz, 
CDCl3, δ): 0.26 (septet). 
To form 2,3-dideoxyribose 5-(di-O-benzyl)phosphate, (S)-γ-dibenzylphosphomethyl-γ-
butyrolactone (1.0 eq, 270 mg, 0.72 mmol) was dissolved in anhydrous dichloromethane (25 
mL), placed under argon and cooled to -78 °C. Diisobutyl aluminum hydride (1.5 M in toluene, 4 
eq, 1.91 ml) was added dropwise and the reaction stirred for two hours31. The reaction was 
quenched with methanol (12.5 ml) and brought to ambient temperature. The resulting solution 
was poured over Rochelle salts (25 mL) and stirred overnight. The mixture was then filtered with 
the solid dissolved in water and added to the supernatant. The aqueous phase was extracted 
with dichloromethane (3 x 25 ml), dried (MgSO4), filtered, and concentrated in vacuo. 2,3-The 
crude residue was purified by flash chromatography (ethyl acetate) to yield 2,3-dideoxyribose 5-
(di-O-benzyl)phosphate (84 mg, 0.2 mmol, 31%). 1H NMR (400 MHz, CDCl3, δ): 7.34 (s, 10, Ar-
H), 5.53-5.48 (m, 1H, CH), 5.12-4.99 (m, 4 H, CH2), 4.39-4.18 (m, 1H, CH), 4.13-3.88 (m, 2H, 
CH2), 2.14-1.58 (m, 4H, CH2-CH2). 31P NMR (200 MHz, CDCl3, δ): 0.3-0.6. 
The pathway intermediate 2,3-dideoxyribose 5-phosphate was formed by reductive 
deprotection of 2,3-dideoxyribose 5-(di-O-benzyl)phosphate33. 2,3-Dideoxyribose 5-(di-O-
benzyl)phosphate (1.0 eq, 250 mg, 0.661 mmols) was dissolved in methanol (5 mL) followed by 
addition of 10% Pd/C (28 mg). The suspension was flushed with argon and hydrogen then 
stirred overnight with hydrogen in a double balloon. The solution was filtered through celite, 
washed with methanol, and concentrated in vacuo. The resulting compound was dissolved in 
water and 100.5 mg sodium carbonate added to neutralize the solution. The resulting methyl-
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riboside was dissolved in water and hydrolyzed by addition of Dowex-H+ (1.0 g) which had been 
washed with methanol and water. The pH was checked and confirmed to be ~2-3. The solution 
was stirred for 2-3 hours, filtered, concentrated in vacuo, and lyophilized resulting in pure 2,3-
dideoxyribose 5-phosphate (40 mg, 0.2 mmol, 30 % yield). 1H NMR (400 MHz, D2O, δ): 5.58-
5.48 (m, 1H, CH), 4.47-4.22 (m, 1H, CH), 4.02-3.77 (m, 2H, CH2), 1.76-2.20 (m, 4H, CH2-CH2). 
13C NMR (100 MHz, D2O, δ): 98.56, 98.30 (CH), 79.27 (3Jcp = 7.99 Hz, CH), 77.60 (3Jcp = 7.97 
Hz, CH), 68.29 (2Jcp = 5.33 Hz, CH2), 67.07 (2Jcp = 5.25 Hz, CH2), 32.86, 32.28, 24.61, 24.58 
(CH2-CH2). 31P NMR (200 MHz, D2O, δ): 1.79, 1.65, 1.58. 
The concentration of dideoxyribose 5-phosphate solution was determined by a standard 
proton NMR experiment with an attenuated delay time (d1 = 15 s) using 7.5 mM 
dimethylformamide as an internal standard. Concentration was calculated by comparison of the 
peak area for the aldehyde of dimethylformamide (δ=~7.5-8) to the peak area of the anomeric 
hydrogens of dideoxyribose 5-phosphate (δ=~5.5-6), both of which occur in relatively isolated 
regions of the spectra34. 
 
Enzyme Expression and Purification 
B. cereus PPM and human PNP were purified as previously described (as published29, 35, 
36 and in Chapters 2, 3 & 4). To express and purify E. coli ribokinase, pRAS100424 harboring the 
rbsk gene was transformed into electrocompetent E. coli BL21(DE3) cells by electroporation. 
pRAS1004 allows for expression of ribokinase with an N-terminal hexahistidine tag. Successful 
transformations were selected by plating on streptomycin-containing LB-agarose plates. A 
single colony was picked into 5 mL of LB broth with streptomycin and grown overnight at 37 °C 
with shaking. This culture was used to inoculate 500 mL of LB broth containing 50 μg/mL 
streptomycin for protein production. Production cultures were incubated at 37 °C with shaking in 
2.8 L Fernbach flasks. Isopropyl-β-D-1-thiogalactopyranoside was added to a final concentration 
 153 
 
of 1 mM after the culture had grown to an OD600 of 0.6. The cells were harvested by 
centrifugation after an additional 4 h incubation and the cell pellet stored at -80 °C. The frozen 
cell pellet was resuspended in 20 mL of Buffer A (50 mM Tris-HCl, pH 7.4, 300 mM NaCl, 10 
mM Imidazole) supplemented with DNAse I prior to lysis by passage through a French pressure 
cell at 20 000 psi. The cell lysate was purified by centrifugation and the supernatant applied to a 
HisTrap FF crude (5 ml, GE Healthcare) Ni2+-affinity column, which was pre-equilibrated with 
Buffer A. The column was washed with three column volumes of Buffer A followed by 10 column 
volumes of 90:10 v/v Buffer A : Buffer B (50 mM Tris-HCl, pH 7.4, 300 mM NaCl, 500 mM 
imidazole). Ribokinase was eluted by increasing the ratio of Buffer B to 60:40%, which is 
equivalent to ~300 mM imidazole. Fractions containing protein were combined and diluted 1:1 
into Exchange buffer. After concentration with a Millipore centrifugal filter, the remaining 
imidazole was removed by application of the concentrated fractions to a HiTrap Desalting 
column which had been pre-equilibrated with Exchange Buffer (25 mM Tris-HCl, pH 8, 5 mM 
MgCl2). Protein concentrations were established using the BCA Protein Assay Kit (Thermo 
Scientific) and aliquots were stored at -80 °C until use. 
Mutation of Ser-154 to alanine was performed using the Quick Change Mutagenesis 
protocol (Stratagene) using the primers 5´-
CAGGCTCTTTAATCGTTTATACTGCCGCTGATAGCGTATTGCAAATTGCAGC-3´ and 5´-
GCTGCAATTTGCAATACGCTATCAGCGGCAGTATAAACGATTAAAGAGCCTG-3´. 
Expression and purification of the S154A mutant of PPM followed the same protocol as wild 
type PPM. 
 
Detection of Inosine and ddI by LC/ESI-MS/MS 
Inosine and ddI were separated from contaminating salts and other reaction components 
using a Jupiter 5μ C18 column (2.0 mm x 150 mm, Phenomenex) and an isocratic flow of 0.2 
mL/min of 95%:5% v/v H2O:acetonitrile, 10 mM CH3COONH4, pH 6. A ThermoPal autosampler 
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was used to inject 10 μL of the sample onto the column. Under these conditions inosine and ddI 
typically eluted in the range of 2.5-3.5 minutes and 5.0-6.0 minutes, respectively. Samples were 
analyzed on a triple quadrupole ESI–LC/MS (ThermoScientific Quantum Access) equipped with 
an ESI interface outfitted with a 100 μm internal diameter deactivated fused Si capillary. The 
selection reaction monitoring mode was applied with a collision energy of 10 eV. Mass 
transitions of (267137) or (237137) corresponding to the fragmentation of inosine or ddI to 
hypoxanthine, respectively, were monitored. Nitrogen was used as the sheath gas and argon as 
the auxiliary gas, at 54 and 10 (arbitrary units), respectively. The mass spectrometer was 
operated in the positive mode with the following parameters: spray voltage, 4.5 kV; capillary 
temperature, 270 °C; vaporizer temperature, 0 °C; tube lens offset, +35 V; skimmer offset, 0 V; 
capillary offset, 35 V. The parameters were tuned by direct infusion of a 500 μM ddI standard at 
10 μL/min. Data acquisition and spectral analyses were conducted with Thermo Xcalibur 
Software, version 2.1. 
 
PNP forward synthesis rate 
The viability of PNP in the synthesis direction was analyzed by the formation of inosine 
or ddI in the presence of in situ-generated ribose 1-phosphate or dideoxyribose 1-phosphate 
and hypoxanthine. Sugar 1-phosphate is generated by isomerization of ribose 5-phosphate or 
dideoxyribose 5-phosphate by PPM. PPM is first activated29 for 10-15 minutes by the 
combination of 129 μL of 25 mM Tris-HCl, pH 8, 10 μL of 2mM MnCl2, 20 μL of 100 μM glucose 
1,6-bisphosphate, 5 μL of 400 μM PPM and 6 μL of 50 mM hypoxanthine. Upon addition of 20 
μL of 50 mM sugar 5-phosphate the reaction is incubated at 37 °C for 6 h. The reaction is then 
divided into two 95 μL portions and brought to 25 °C. Addition of 5 μL of 1 μM purine nucleoside 
phosphorylase starts the synthesis of ddI or inosine. The final reaction conditions are as follows: 
25 mM Tris-HCl, pH 8, 0.1 mM MnCl2, 10 μM glucose 1,6-bisphosphate, 10 μM PPM, 5 mM 
sugar 5-phosphate, 1.5 mM hypoxanthine, and 50 nM wild type PNP or PNP-46D635, 25 °C. 
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Aliquots of the reactions were removed at 5, 10, 20, and 30 min and the enzyme was denatured 
by heating at 95 °C. Relative amounts of ddI and inosine formed in each reaction were 
compared by LC/ESI-MS/MS. 
 
Initial velocity of PPM and PPM-S154A 
Biochemical data for determination of kinetic parameters of PPM and PPM-S154A with 
dideoxyribose 5-phosphate were collected in microtubes. Activated phosphopentomutase was 
freshly prepared by pre-incubation of 10 μM PPM in 25 mM Tris-HCl, pH 8.0 with 40 μM glucose 
1,6-bisphosphate and 100 μM MnCl2 at 24 °C for 10 minutes and then placed on ice until 
assayed. 21 μL of a standard mix comprised of 25 mM Tris-HCl, pH 8.0, 2.14 mM hypoxanthine, 
15.9 μM PNP-46D6, and 128 μM MnCl2 was added to each microtube along with 6 μL of 
dideoxyribose 5-phosphate which had been dissolved in 500 mM Tris-HCl, pH 8.0. This mixture 
was brought to 24 °C prior to initiation of the reaction by addition of 3 μL of activated PPM. The 
final reaction conditions consisted of 30 μL of 140 mM Tris-HCl, pH 8.0, 0.1 mM MnCl2, 4 μM 
glucose 1,6-bisphosphate, 1.5 mM hypoxanthine, 11.1 μM PNP-46D6 , 1 μM PPM and 0.5, 0.7, 
1.0, 1.4, 2.0, 3.0, or 5.0 mM dideoxyribose 5-phosphate. Reactions were allowed to proceed for 
15 min before denaturing the enzyme at 95 °C for 5 minutes. Samples were centrifuged and 
frozen at -80 °C until analysis. 
The amount of dideoxyribose 5-phosphate turnover was monitored by the amount of ddI 
formed over the time course of each reaction. The concentration of ddI was established by 
HPLC using 2-deoxyguanosine as an internal standard. Hypoxanthine, 2-deoxyguanosine, and 
ddI were separated by a Nova-Pak C18 column (3.9 x 150 mm, Waters) and an isocratic flow of 
1 mL/min of 95%:5% v/v H2O:acetonitrile, 10 mM CH3COONH4, pH 6.0. A calibration curve for 
ddI was established by addition of 5 μL of 80 μM 2-deoxyguanosine to 20 μL of known ddI 
standards at concentrations of 3, 9, 18, 27, 36, 54, 72, 90, and 120 μM. Prior to analysis each 
sample was thawed and centrifuged. 5 μL of 80 μM 2-deoxyguanosine was added to 20 μL of 
 156 
 
each sample and 20 μL of the sample injected onto the HPLC. Initial velocities were fit to the 
Michaelis-Menten equation using non-linear regression analyses in the GraphPad Prism 
software package version 5.01 for Windows. 
 
Crystallization of PPM and PPM-S154A with dideoxyribose 5-phosphate 
Crystals of wild type and S154A PPM were grown from a 12 mg/mL protein mixture in 25 
mM Tris-HCl pH 7.4, 1 mM MnCl2 using the hanging drop vapor diffusion method at 18 °C. The 
reservoir solution for wild type enzyme contained 100 mM BIS-TRIS pH 5.5, 50 mM MnCl2, 75 
mM Ammonium Acetate and 13% PEG 3350 and the reservoir solution for PPM-S154A was 100 
mM BIS-TRIS pH 5.5, 50 mM MnCl2, 50 mM ammonium acetate and 17% PEG 3350. Substrate 
was introduced into fully formed crystals by soaking in a solution that contained all components 
of the reservoir solution along with 10 mM 2,3-dideoxyribose 5-phosphate. Crystals were 
cryoprotected with a solution that was 70% v/v reservoir solution and 30% v/v glycerol before 
flash freezing in liquid nitrogen. X-ray diffraction data were collected at the Advanced Photon 
Source on beamline 21-ID-G and were processed and scaled using the HKL200037 and CCP438 
suites of programs. Initial phases were determined by rigid body refinement of the structure of 
wild type B. cereus PPM (PDB ID 3M8W) in CNS39 and the model was refined with automated 
refinement in CNS39 and REFMAC39 using TLS refinement with TLS groups40 selected using the 
TLSMD server41 and manual refinement in COOT42. A summary of crystallization and model 
refinement statistics is presented in Table 6.1. RMS deviations were calculated with lsqkab and 
figures depicting crystallographic models were generated with PyMOL. 
Table 5-1: Data collection and refinement statistics  
  Wild type PPM bound to 2,3-dideoxyribose 5-phosphate 
S154A PPM bound to 2,3-
dideoxyribose 5-phosphate 
Data Collection:     
Wavelength (Å) 0.979 0.979 
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Beamline  APS 21-ID-G APS 21-ID-G 
Resolution (Å) (last shell)a 50-2.1 (2.18-2.10) 50-2.1 (2.18-2.10) 
Unit-cell  a = 91.5 a = 92.3 
dimensions (Å) b = 76.5 b = 76.6 
 
c = 107.3 c = 107.2 
 
α = 90° α = 90° 
 
β = 108.9° β = 109.0° 
 
γ = 90° γ = 90° 
Total reflections 233118 274095 
Unique reflections 79568 81866 
Reflections in test set 3900 4039 
I/σ 18.1 (3.2) 17.5 (3.1) 
Completeness (%) 96.7 (88.7) 99.0 (95.6) 
Rsymb 0.083 (0.283) 0.087 (0.369) 
Model Refinement:      
Rcrystc 0.167 0.177 
Rfree  0.211 0.215 
a. Values in parenthesis are those from the highest resolution shell. 
b. Rsym=∑ |Ii-Imean|/Imean, 
c. Rcryst=∑||Fobs|-|Fcalc||/∑|Fobs| 
 
 
 
Initial velocity of PPM-S154A with ribose 5-phosphate 
Initial velocity of PPM-S154A with ribose 5-phosphate as substrate was established 
using the assay reported for steady state kinetics in Chapter 4. PPM-S154A was assayed at 
100 nM for turnover of 2 mM ribose 5-phosphate for 10 min. This initial velocity was compared 
to the wild type PPM turnover velocities established with 20 nM PPM and 700 μM ribose 5-
phosphate over 4 minutes. Initial velocities for dideoxyribose 5-phosphate were established 
using the HPLC assay described for the kinetic analysis and 1 μM wild type PPM or PPM-
S154A and 5 mM dideoxyribose 5-phosphate over a 15 minute time period. 
 
Directed Biosynthesis of ddI 
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All reagents are dissolved in 25 mM Tris-HCl, pH 8.0. PPM was freshly activated by pre-
incubation with glucose 1,6-bisphosphate. In a 1.5 mL microtube 14.8 μL of 25 mM Tris-HCl, pH 
8.0, 2.4 μL of 50 mM hypoxanthine, 8 μL of 5 mM MnCl2, 8 μL of 100 μM of glucose 1,6-
bisphosphate, and 2 μL of wild type PPM were combined and allowed to incubate at room 
temperature for 10 min. An equimolar concentration (22.7 μM) of PPM and glucose 1,6-
bisphosphate is present in this mixture. To this same microtube was added 4.8 μL of 500 mM 
KCl, 2.4 μL of PNP, 16 μL of 50 mM ribose or dideoxyribose, 8 μL of 50 mM ATP, and 16 μL of 
ribokinase. For reactions containing ribose, 245 μM wild type PNP was added to the reaction; 
for reactions containing dideoxyribose, 370 μM PNP-46D6 was added. Ribokinase was present 
in Exchange Buffer, which contains 5 mM MgCl2. For an 80 μL reaction, the final reaction 
conditions were 25 mM Tris-HCl, pH 8.0, 1.5 mM hypoxanthine, 500 μM MnCl2, 10 μM glucose 
1,6-bisphosphate, 10 μM wild type PPM, 1 mM MgCl2, 30 mM KCl, 7.35 μM wild type PNP or 
11.1 μM PNP-46D6, 10 mM ribose or dideoxyribose, 5 mM ATP, and 100 μM ribokinase. 
Reactions were incubated at 37 °C for 0, 6 or 12 hours followed by inactivation of the enzyme 
by heating at 95 °C. The denatured protein was pelleted by centrifugation and the supernatant 
frozen at -80 °C. Immediately prior to analysis, the samples were thawed and centrifuged. The 
relative amount of inosine or ddI formed at each time point was analyzed by LC/ESI-MS/MS, as 
outlined above. 
 
Computational docking of ribokinase 
Coordinates for E. coli ribokinase (PDB ID 1rkd) were obtained from the Protein Data 
Bank. The protein backbone and side-chains were energy minimized within the Rosetta energy 
function to make 100 models43; the best scoring model by total energy was carried forward into 
docking. α-D-Ribose and α-D-2,3-dideoxyribose conformations were generated in the Molecular 
Operating Environment version 2009.10 (MOE, Chemical Computing Group) as a fully 
protonated molecule and allowing for all ring conformations. The 22 resulting conformations for 
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ribose and 18 for dideoxyribose were docked using RosettaLigand44 (Rosetta3 r. 39549). The 
docking procedure utilizes 1) a broad search sequence where ligand translation of up to 2 Å and 
360° of rotational freedom is allowed, 2) translation of the ligand, if necessary, to bring it into 
contact with the protein, and 3) a refinement phase with small movement of the ligand (0.1 Å 
translation and 3° rotation) and full side chain and backbone flexibility within 7 Å of the ligand 
along with optimization of all hydrogen-oxygen bond orientations on the ligand. 2000 models 
were generated for ribose and dideoxyribose. Models were filtered according to the 
RosettaLigand interface binding energy and the top 200 models for each ligand were carried 
forward. Stable ligand conformations were identified through clustering of all-against-all rmsd 
calculations for the placement of ribose or dideoxyribose with the bcl::Cluster application45. An 
average inter-cluster distance was calculated as the average pair-wise distance between all 
objects in two clusters with a 2 Å intra-cluster linkage cutoff. Clusters dropping below ten 
members were removed from consideration. 
   
Results 
Ribokinase, phosphopentomutase, and purine nucleoside phosphorylase have been 
collected from E. coli, B. cereus and human, respectively, to form an unnatural pathway for ddI 
from dideoxyribose. The rate of ddI phosphorolysis by hPNP was previously increased through 
computational rational design and random mutagenesis by directed evolution. The improved 
variant, PNP-46D635 (see also chapters 2 and 3), was incorporated into the designed pathway. 
E. coli ribokinase, B. cereus phosphopentomutase and PNP-46D6 were expressed in E. coli 
BL21(DE3) cells and purified to homogeneity by affinity chromatography. 
 
Chemical synthesis of dideoxysugar substrates 
Dideoxyribose was synthesized from glutamic acid through nitrous acid deamination to 
first form (S)-γ-carboxy-γ-butyrolactone with full retention of configuration30 (Figure 5-2). A yield 
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of 39% was sufficient to carry forward, however, yields as high as 85% have been reported and 
up to 93-100% for a two step reaction30, 46. Therefore, the low yield reported here is not an 
indicator of the overall yield potential of the proposed pathway. This compound is then reduced 
with borane dimethyl sulfide to form (S)-γ-hydroxy-γ-butyrolactone in 86% overall yield30. 
(S)-γ-Hydroxy-γ-butyrolactone serves as a branch point for the synthesis of 
dideoxyribose and dideoxyribose 5-phosphate (Figure 5-2). Dideoxyribose is formed with an 
88% yield by reduction of the lactone with DIBAL31, affording the substrate precursor in 
sufficient yields for biochemical testing. 2,3-Dideoxyribose 5-phosphate is synthesized by 
phosphitylation of the 5-OH group and oxidation47 to form a benzyl-protected phospholactone 
intermediate. Reduction with DIBAL31 and hydrogenation32 to remove the protecting groups 
forms the final product. The overall modest yields afforded by this route were sufficient for 
biochemical analysis. 
 
Figure 5-2. Chemical synthesis of dideoxyribose and dideoxyribose 5-phosphate 
 
 
 
Forward rate of ddI synthesis by PNP-46D6 
A 22-fold improved phosphorolysis efficiency of ddI by hPNP-46D6 has been previously 
reported35. However, in this study hPNP-46D6 is applied to the synthesis of ddI and it is not 
clear if these mutations will affect both directions of the reaction in the same way. Therefore, the 
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rate of product synthesis was evaluated through in situ generation of ribose 1-phosphate and 
dideoxyribose 1-phosphate by PPM isomerization of the associated 5-phosphate prior to 
addition of wild-type or mutant PNPs. The amount of nucleoside product formed at varying times 
was analyzed by LC/ESI-MS/MS. As shown in Figure 5-3, the PNP-46D6 turnover rate in the 
synthesis direction was improved for ddI, relative to the wild-type hPNP rate, while the 
mutations simultaneously decrease the inosine synthesis rate. The net effect was a 52-fold shift 
in the selectivity ratio of the mutant for synthesis of ddI (as measured at 20 min) which is 
comparable to a 46-fold shift in the selectivity ratio for phosphorolysis of ddI. 
 
  
Figure 5-3. Comparison of wild-type and mutant PNP product synthesis rates. The amount of 
inosine (A) and dideoxyinosine (B) formed over time is compared upon in situ synthesis of the 
respective sugar 1-phosphate. Synthesis of ddI by PNP-46D6 occurs at a greater rate than that 
of wild type PNP. Error bars are the standard deviation of three independent measurements. 
 
 
 
Binding and turnover of dideoxyribose 5-phosphate 
In this study a PPM from B. cereus that will isomerize dideoxyribose 5-phosphate to 
dideoxyribose 1-phosphate was identified. Barbas and Wong previously reported the 
unsuccessful application of E. coli PPM for the desired rearrangement33. However, 
dideoxyribose 5-phosphate isomerization has been reported for a PPM cloned from Bacillus 
stearothermophilus, which has 88.9 % sequence similarity and 81% sequence similarity to B. 
 162 
 
cereus48. Therefore, the PPM from B. cereus was cloned, expressed and characterized 
structurally and biochemically29, 36 (Chapter 4). Turnover of dideoxyribose 5-phosphate was 
analyzed by linking activity to the generation of ddI from dideoxyribose 1-phosphate and 
hypoxanthine by PNP and subsequent analysis by HPLC. B. cereus PPM, like B. 
stearothermophilus, performs the phosphate transfer reaction on the targeted dideoxy sugar. 
Further analysis of enzyme turnover rates at multiple substrate concentrations established a kcat 
and Km of 7.5 ± 0.6 min-1 and 1 980 ± 350 μM (Figure 5-4). 
 
Figure 5-4. Dideoxyribose 5-phosphate turnover kinetics of phosphopentomutase. Initial 
velocities of PPM are plotted as a function of dideoxyribose 5-phosphate concentration. Data 
are the average of three assays, and a double reciprocal plot of the data is shown in the inset. 
Initial velocities were fit to the Michaelis-Menten equation using non-linear regression analyses 
in the GraphPad Prism software package version 5.01 for Windows. The calculated Km, Vmax, 
and kcat are 1 985 ± 360 µM, 7.5 ± 0.6 µM min-1 and 7.5 ± 0.6 min-1. 
 
 
 
To identify a mechanistic cause for low dideoxy substrate turnover and aid in the 
identification of residues involved in orientation of the dideoxy sugar, fully formed crystals of 
PPM were soaked with dideoxyribose 5-phosphate and the crystal structure was determined. 
Density was identified in the PPM active site consistent with dideoxyribose 5-phosphate and 
analogous to the distal binding site of ribose 5-phosphate (Figure 5-5A). Electron density for the 
phosphate portion of substrate is strong and the molecule is primarily positioned by hydrogen 
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bonds formed with Nη1 of Arg-208, Nη2 of Arg-197, the hydroxyl of Tyr-152 and the backbone 
amide of Gly-132. In contrast, few direct interactions exist with the sugar portion of 
dideoxyribose 5-phosphate and electron density for the sugar ring is weak suggesting a large 
degree of flexibility in the positioning. The density is best interpreted with a rotation of the 
furanose ring relative to the position of ribose 5-phosphate which allows for interaction of the 
hydrophobic C2-C3 portion of dideoxyribose 5-phosphate with two exposed hydrophobic 
residues, Ile-195 and Val-158.  
 
Figure 5-5. B. cereus phosphopentomutase co-crystallized with dideoxyribose 5-phosphate. A. 
Binding in wild type PPM. 2|FO|-|FC| electron density (green mesh contoured at 0.8 σ) calculated 
with residue 154 and the ligand omitted from the calculation shows the strong density for the 
phosphate of 2,3-dideoxyribose 5-phosphate (orange sticks) and weak density for the remaining 
portion of the molecule. Comparison of the structure bound to 2,3-dideoxyribose 5-phosphate 
(dark grey) to the structure bound to ribose 5-phosphate (PDBID 3M8W, light grey) shows that 
the rings are on different planes. B. Binding in S154A PPM. Electron density shown as in panel 
A for the active site of S154A shows that 2,3-dideoxyribose 5-phosphate (orange sticks) adopts 
a different orientation. Comparison of the S154A structure (dark grey) to the structure of wild 
type PPM bound to ribose 5-phosphate (PDBID 3M8W, light grey) shows that the rings of the 
two structures are in plane, but that the phosphates bind differently. 
 
 
 
 164 
 
Ribose 5-phosphate is positioned by hydrogen bonds between the 3-OH and Oγ of 
Ser-154 and between the 2-OH group and Nη2 of Arg-193. The absence of these functional 
groups at the 2 and 3 position of dideoxyribose 5-phosphate likely increases the propensity for 
formation of a non-productive Michaelis complex and, as a result, successful turnover of the 
enzyme occurs much less often (7.5 min-1 with dideoxyribose 5-phosphate versus 10.2 s-1 with 
ribose 5-phosphate). It is hypothesized that the unfavorable polar/non-polar interaction between 
Oγ of Ser-154 and dideoxyribose 5-phosphate forces the non-natural substrate into the 
observed alternative conformation. Therefore, to generate a more favorable interaction the 
polarity of the active site was decreased by mutating Ser-154 to alanine which may allow 
dideoxyribose 5-phosphate to adopt a more favorable ring position by alleviating the polar 
strain.  
Ser-154 was mutated to alanine by site-directed mutagenesis in an effort to decrease 
the polarity of this position and increase the likelihood of a native-like substrate orientation for 
dideoxyribose 5-phosphate. The structure of PPM-S154A was determined after soaking crystals 
with dideoxyribose 5-phosphate. The structure of the S154A mutant is largely superimposable 
with the structure of wild type PPM (RMS deviation for all Cα atoms is 0.5Å). Electron density 
calculated from the refined model clearly demonstrates the presence of a molecule in the distal 
binding pocket (Figure 5-5B). This density is consistent with a molecule of dideoxyribose 5-
phosphate. The phosphate is bound in an orientation typical of the distal binding pocket. The 
orientation of the deoxyfuranose ring, however, is different in PPM-S154A and wild type PPM. 
The C2-C3 portion of the ring is now oriented toward Ala-154 and a hydrogen bond is formed 
between Arg-193 and the 1-OH group of dideoxyribose 5-phosphate. The change in ring 
orientation supports the hypothesis that interactions with Ser-154 provide the impetus for an 
alternative binding conformation of dideoxyribose 5-phosphate in wild type PPM. Hydrogen 
bond formation between dideoxyribose 5-phosphate and Arg-193 is not observed in wild-type 
PPM where the primary interaction of Arg-193 is through a hydrogen bond to Asp-243; 
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interestingly, this interaction is one of two between the cap and core domain. In PPM-S154A, 
Arg-193 hydrogen bonds to the 1-OH group of dideoxyribose 5-phosphate whereas this 
interaction exists with the 2-OH group of ribose 5-phosphate. Despite persistent differences in 
the binding mode of dideoxyribose 5-phosphate in PPM-S154A and ribose 5-phosphate in wild 
type PPM many of the native interactions are recovered. Thus, formation of the S154A mutant 
may be a first step in recovery of the natural substrate orientation and possibly increased 
turnover. 
 
 
Figure 5-6. Comparison of wild-type PPM and PPM-S154A activity. A. Initial velocity of wild type 
PPM and PPM-S154A under near-saturating ribose 5-phosphate conditions. B. Initial velocity of 
wild type PPM and PPM-S154A under near-saturating dideoxyribose 5-phosphate conditions. 
Velocities in A and B are the average of three assays and error bars are the standard deviation. 
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C. Initial velocities of PPM-S154A are plotted as a function of dideoxyribose 5-phosphate 
concentration. Data are the average of three assays, and a double reciprocal plot of the data is 
shown in the inset. Initial velocities were fit to the Michaelis-Menten equation using non-linear 
regression analyses in the GraphPad Prism software package version 5.01 for Windows. The 
calculated Km, Vmax, and kcat are 2070 ± 470 µM, 6.5 ± 0.7 µM min-1 and 6.5 ± 0.7 min-1. 
 
 
 
The activity of PPM-S154A with dideoxyribose 5-phosphate was tested to investigate the 
effect of the new furanose binding orientation. Dideoxyribose 5-phosphate turnover was 
measured in the presence of hypoxanthine and hPNP-46D6 and the product ddI concentration 
established by HPLC and compared to turnover rates of wild type and PPM-S154A established 
at fixed, near-saturating ribose 5-phosphate concentrations, and assayed as described in 
chapter 4. As expected, the loss of the interaction between Ser-154 Oγ and the 3-OH 
decreased turnover of ribose 5-phosphate by PPM-S154A. Preliminary concentration response 
experiments establish near-saturating conditions at 2 mM ribose 5-phosphate. When compared 
to turnover of wild type PPM at 700 μM ribose 5-phosphate PPM-S154A has a 4.4-fold reduced 
velocity per mole of enzyme (Figure 5-6A). In contrast, wild type PPM and PPM-S154A have 
similar velocities at 5 mM dideoxyribose 5-phosphate (Figure 5-6B). Enzyme turnover rates 
established at multiple dideoxyribose 5-phosphate concentrations reveal a kcat and Km of 6.5 ± 
0.7 min-1 and 2 070 ± 470 μM for PPM-S154A (Figure 5-6C). These results indicate that 
although the turnover activity of PPM-S154A has not improved compared to wild type PPM the 
substrate selectivity has increased significantly. 
 
In vitro biosynthesis of ddI 
To demonstrate the viability of the pathway, dideoxyribose and hypoxanthine were 
combined with 11.1 μM PNP-46D6, 10 μM wild type PPM, 100 μM E. coli ribokinase, ATP and 
appropriate co-factors and incubated at 37 °C. Portions of the reaction were removed at 0, 6 
and 12 h and the amount of ddI formed analyzed by LC/ESI-MS/MS. As shown in Figure 5-7, 
 167 
 
ddI is formed in a time-dependent manner pointing to enzymatic activation of dideoxyribose by 
ribokinase and subsequent formation of ddI through the activities of PPM and PNP-46D6. 
 
Figure 5-7. In vitro biocatalytic synthesis of ddI as analyzed by LC/ESI-MS/MS. Incubation of 10 
mM substrate, 5 mM ATP, and 1.5 mM hypoxanthine (hyp) with E. coli ribokinase (RK), B. 
cereus phosphopentomutase (PPM) and human purine nucleoside phosphorylase (PNP) or 
PNP-46D6 forms nucleoside product. The relative amount of product is analyzed by LC/ESI-
MS/MS in the positive mode with selection reaction monitoring for the fragmentation of 
nucleoside to hypoxanthine (inosine: 267  137; ddI: 237  137). 
 
 
 
To check for chemical activation of dideoxyribose, activation through off-target activities 
of PPM or PNP, or contamination in the protein preps, reactions were run in the absence of 
ribokinase or without substrate. In each case mass correlating with product was not observed. 
Incubation of the enzyme mixture with ribose, hypoxanthine and ATP generated >10-fold more 
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inosine attesting to the viability of the enzyme and further pointing to the low rate of turnover of 
dideoxyribose by ribokinase.  
 
Docking of dideoxyribose into ribokinase 
To provide an explanation for the poor levels of dideoxyribose activation, the unnatural 
substrate was docked into ribokinase using RosettaLigand. Ribose was first docked into the 
binding site to provide a benchmark for the procedure. A plot of binding energy against the rmsd 
of the ligand shows a definitive energy funnel (Figure 5-8A). This indicates RosettaLigand 
recognizes models with a native-like configuration of ribose and scores these better than 
models with an alternative conformation. Clustering of the ribose models reveals a total of seven 
conformational groups (Table 5-2). Cluster 359 is populated by at least twice as many members 
as the others and has the best average interface energy between substrate and enzyme. An 
overlay of the best scoring member of cluster 359 is shown in Figure 5-8B. Together, these 
results provide some confidence in the results of docking dideoxyribose into ribokinase. 
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Figure 5-8. Computational docking of ribose and dideoxyribose into ribokinase with 
RosettaLigand. In (A), the interface binding score of ribose docked into ribokinase is plot against 
rmsd to the native binding conformation. Evidence of an energy funnel confirms that native-like 
models are recognized in the RosettaLigand energy function. B. The best scoring model of 
ribose (black sticks) is overlaid with the crystal structure (PDB ID 1rkd, gray sticks). C-H. Each 
cluster is overlaid with the crystal structure; C: 387, D: 377, E: 381, F: 376, G: 367, E: 368. 
 
 
 
Dideoxyribose was then docked using the procedure established for docking of ribose. A 
total of 2 000 models were generated and the top 10% were identified based on interface 
binding energy. Clustering of these models reveals that six binding configurations are stably 
recognized upon docking of dideoxyribose to ribokinase. Two of the clusters are clearly larger 
than the others, possessing 56 and 40 members each (Table 5-3). Two other cluster size 
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ranges exist at ~20 and at <15. Each cluster was further analyzed by comparison of the average 
interface binding score and interface binding score of the best scoring cluster member. In 
general, the larger clusters have a lower average interface binding score and in most cases the 
best scoring models in the larger clusters have a better interface binding score than the smaller 
clusters. This is perhaps unsurprising as configurations which score well are likely to be 
enriched during the docking process. Furthermore, the lowest populated clusters have a poorer 
interface binding score than the more populated clusters indicating a preference for the other 
binding modes. However these binding modes must be sufficiently favorable as to be partially 
populated, albeit at low levels. 
Table 5-2. Conformational clusters of ribose docked into ribokinase.  
Cluster Cluster Size Linkagea Cluster Interface 
Binding Scoreb 
Best Interface 
Binding Score 
Cluster RMSD to nativec 
359 40 1.26 -18.43 ± 2.77 -26.05 0.81 ± 0.35 
378 24 1.79 -15.86 ± 1.32 -18.73 2.13 ± 0.46 
383 24 1.95 -16.91 ± 2.37 -21.69 2.54 ± 0.25 
368 19 1.49 -15.38 ± 1.34 -17.09 3.77 ± 0.17 
367 16 1.49 -18.04 ± 2.14 -21.49 3.49 ± 0.21 
382 16 1.93 -16.66 ± 2.06 -20.21 4.11 ± 0.11 
374 10 1.68 -15.53  ± 1.24 -17.74 3.86 ± 0.19 
384 10 1.96 -15.53 ± 0.80 -17.29 2.48 ± 0.23 
a. Linkage is calculated as the average pair-wise distance between all objects in two sub-clusters 
b. Reported values are the average interface binding score for all models in the cluster ± standard deviation 
c. Reported values are the average rmsd to native for all models in the cluster ± standard deviation 
 
Table 5-3. Table of conformational clusters of dideoxyribose docked into ribokinase by 
RosettaLigand.  
Cluster Cluster Size Linkagea Average Interface 
Binding Score 
Best Interface Binding 
Score 
387 56 1.61 -13.74 ± 1.47 -17.35 
377 40 1.25 -13.29 ± 1.03 -15.81 
381 20 1.39 -13.87 ± 1.52 -17.37 
376 20 1.24 -13.41 ± 1.03 -16.70 
367 13 1.02 -12.68 ± 0.56 -13.61 
368 10 1.06 -12.80 ± 0.37 -13.52 
a. Linkage is calculated as the average pair-wise distance between all objects in two sub-clusters 
b. Reported values are the average interface binding score for all models in the cluster ± standard deviation 
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To assess the substrate binding mode prevalent in each cluster, clusters were 
represented by the cluster member with the best predicted binding energy (Figure 5-8C-H). 
Cluster 387 forms hydrogen bonds between the 5-OH group and both Asp-16 and Asn-46 while 
the 1-OH group is bound by Asn-14 and Glu-143 (Figure 5-8C). Cluster 377 resides in a 
conformation almost exactly opposite that of cluster 387 (Figure 5-8D), with the 1-OH group 
bound to Asp-16 and Asn-46 and the 5-OH group bound to Asn-14 and Glu-143. Cluster 381 
(Figure 5-8E) and cluster 376 (Figure 5-8F) are found with the 5-OH group positioned in the 
Asp-16/Asn-46 pocket with the 1-OH group bound on either side of Lys-43 with Asp-255 or Glu-
143, respectively. Cluster 367 (Figure 5-8G) binds opposite of cluster 376, bridging between 
Glu-143/Lys-43 at the 5-OH group and Asp-16/Asn-46 at the 1-OH. The smallest cluster, cluster 
368, adopts a conformation most similar to ribose (Figure 5-8H). The 1-OH group is bound by 
Glu-143 and Asn-14 while the 5-OH group forms a hydrogen bond with Asp-255. The ring is 
further oriented by a hydrogen bond between Lys-43 and the furan oxygen. 
 
 
Discussion 
A chemo-enzymatic pathway for directed biosynthesis of nucleoside analogs has been 
outlined and its potential has been demonstrated through biocatalytic synthesis of 
dideoxyinosine (Figure 5-1). Dideoxyribose is synthesized in three steps from glutamic acid. A 
refined synthetic process will likely increase the yield of dideoxyribose to levels sufficient for 
manufacturing processes. The chemically synthesized precursor is transformed into ddI through 
tandem catalysis of ribokinase, PPM and PNP. However, the low levels of product formed over 
24 h highlight the necessity for optimization of each enzyme in the pathway. 
Toward this end human PNP was improved for phosphorolysis of dideoxyinosine 
resulting in the mutant PNP-46D6 which has a phosphorolysis efficiency 22-fold greater than 
wild type PNP. Previously, however, the viability of PNP-46D6 in the synthesis direction was not 
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confirmed because dideoxyribose 1-phosphate was not available. Here, the improved forward 
synthesis rate is confirmed by formation of the precursor through isomerization of dideoxyribose 
5-phosphate by PPM. Because the concentration of dideoxyribose 1-phosphate in the reaction 
is not known and difficult to ascertain the present experiment does not establish a definitive 
forward rate. Instead, the ratio of turnover rates under these conditions is compared for wild 
type PNP and PNP-46D6. There is a marked improvement in synthesis of dideoxyinosine by the 
mutant and a concomitant decrease in synthesis of inosine (Figure 5-3). Overall, the mutations 
introduced to form PNP-46D6 provide a 52-fold improved substrate selectivity ratio in the 
synthesis direction. This value agrees well with the 46-fold improved selectivity ratio measured 
for phosphorolysis. Given the improved Km for dideoxyinosine it is possible that PNP-46D6 also 
possesses an improved Km for dideoxyribose 1-phosphate; this would be of great benefit in a 
tandem reaction sequence limited by poor turnover of enzymes earlier in the pathway as large 
precursor pools are not necessary for efficient turnover. 
Dideoxyribose 1-phosphate is generated from dideoxyribose 5-phosphate by transfer of 
phosphate by PPM. It is interesting to note that E. coli PPM is reported not to accept 
dideoxyribose 5-phosphate as substrate despite a significant sequence similarity. Unlike with 
the study of PNP, the PPM reaction can be studied in the desired direction through synthesis of 
dideoxyribose 5-phosphate. The chemically synthesized pathway intermediate was utilized to 
establish kinetic constants for turnover of dideoxyribose 5-phosphate by PPM (Figure 5-4). The 
natural substrate is turned over 80-fold faster and has a 7.5-fold greater Michaelis constant.  
To explain this disparity PPM was crystallized and dideoxyribose 5-phosphate was 
soaked into the binding site (Figure 5-5A). In wild type PPM the 3-OH of ribose plays a key role 
in positioning the substrate for catalysis through formation of a hydrogen bond with Ser-154. 
This handle is not available in dideoxyribose and has been exchanged for a much smaller 
hydrophobic methylene. To compensate for the largely polar active site of PPM the substrate is 
forced to adopt an alternate conformation. Rotation of the sugar moiety likely decreases the 
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interaction of the C2-C3 portion of dideoxyribose 5-phosphate with the multitude of polar 
residues in the active site. 
To test this hypothesis Ser-154 was mutated to alanine, the activity compared to wild 
type PPM and the structure of dideoxyribose 5-phosphate-bound PPM-S154A solved. Removal 
of the polar residue caused a significant change in the conformation of the furanose ring (Figure 
5-5B). Testing of the activity indicates that this mutation does not improve the turnover of 
dideoxyribose 5-phosphate, with PPM-S154A turnover on par with wild-type PPM turnover 
despite the ring migration (Figure 5-6B,C). Interestingly though, natural activity is reduced ~4-
fold, increasing the substrate selectivity ratio of the mutant (Figure 5-4A). 
The directed biosynthesis of ddI is demonstrated by phosphorylation of dideoxyribose by 
ribokinase and subsequent turnover by PPM and PNP (Figure 5-7). Overall, the reaction occurs 
at a rate which precludes its use in preparative syntheses. The ribokinase concentrations 
required for generation of detectable levels of ddI (100 μM in these experiments) are extreme 
and implicate ribokinase as the rate-limiting step in the pathway. 
Docking studies with RosettaLigand were performed to identify interactions in the 
binding pocket for targeted engineering of the enzyme. Ribose and dideoxyribose were docked 
into the binding pocket. Successful recapitulation of the native binding pose provides confidence 
that the method will identify dideoxyribose configurations existing in nature. Ribose is oriented in 
the binding pocket by hydrogen bonds to each of the hydroxyls and the furanose oxygen, a 
hydrophobic overhang generated by Ile-100, Ile-110, Ile-112, and Ile-251, and the bottom of the 
pocket is lined by Gly-41 and Gly-42, which forms a hydrogen bond to the 3-OH of ribose with 
its backbone nitrogen (Figure 5-8B). A total of eight hydrogen bonds, occurring between Asn-14 
and the 1- and 2-OH, Asp-16 and the 2- and 3-OH, Lys-43 and the furan oxygen, Asn-46 and 
the 3-OH, Glu-143 and the 1-OH, and Asp-255 and the 5-OH, are formed in the binding pocket. 
The large number of hydrogen bonds provide a strong binding force for the small molecule. 
Furthermore, the hydrophobic overhang forces the substrate into the polar residues which 
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reside in the lower part and bottom of the binding pocket while selecting for phosphorylation of 
the 5-OH group by enforcing the downward orientation of the 2- and 3-OH in the binding pocket. 
The predominant conformations generated during docking are formed through satisfaction of the 
many hydrogen bond donors and acceptors in the binding pocket. In phosphopentomutase, the 
hydrophobic portion of the tetrahydrofuranose ring controls the orientation of the substrate, in so 
far as it is free to move with the 5-phosphate anchor. Contrastingly, in ribokinase the C2-C3 
portion is oriented to solvent in clusters 385 and 381 and toward polar side chains in clusters 
386 and 376. These unfavorable interactions are tolerated in favor of formation of hydrogen 
bonds to the 1- and 5-OH group at the highly negative Asp-16 and Glu-143. Only cluster 371 
and 360 orient this region toward hydrophobic residues. Cluster 367 abuts C2 and C3 to Ile-251 
(not shown) while the native-like orientation of cluster 368 comes at the expense of unfavorable 
interactions with Asp-16. These results point to the formation of a stable, non-productive 
substrate binding complex which results in slow turnover of the enzyme. 
Clearly, removal of polarity in the ribokinase binding pocket will increase the likelihood of 
native-like binding and decrease the impetus for mis-orientation of the residue. Targets for 
mutagenesis include Asp-16, Asn-46, Asn-14 and Gly-41. Because of the proximity of Asn-46 to 
the site of catalysis mutations are likely to have a pronounced affect. Similarly, Asn-14 is 
involved in orientation of the 1-OH. Mutation of Gly-41 may serve to fill space vacated by 
removal of the 2- and 3-OH of ribose. 
  
Conclusions 
In this study, a proof-of-principle for directed biosynthesis of nucleoside analogs is 
provided. Differences in substrate makeup clearly affect function of each enzyme in the 
pathway. Modifications in the binding pocket of PNP along with identification of sequence 
changes throughout the protein improved both synthesis and phosphorolysis rates of ddI; a 
similar strategy will likely improve the other enzymes in the pathway. Furthermore, it has been 
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shown that improvements made to reversible enzymes in one direction transfer, to some 
degree, to catalysis in the reverse direction. 
Structural studies of PPM docked with dideoxyribose 5-phosphate provide a basis for 
subsequent engineering, identifying Ser-154, Ile-159 and Val-195 as targets. Mutation of 
Ser-154 to alanine has a marked effect on the orientation of the dideoxysugar but only a 
minimal effect on turnover of the unnatural substrate. However, because of the strong increase 
in the substrate selectivity ratio an engineered mutant should contain the S154A mutation. 
Further probing of the active site will identify the optimal amino acid identity at this position. 
Ribokinase is likely the rate limiting step in the current set-up of the biocatalytic pathway. 
Docking of dideoxyribose into ribokinase implicates Asp-16 and Gly-41 as likely residues for 
mutagenesis. Because of their proximity in the binding pocket, mutations in these sites may be 
mutually exclusive. Strategies for a simultaneous search of the combinatorial sequence space 
include computational design or multi-site saturation mutagenesis. 
It is possible that other nucleoside analogs could be generated with this pathway. 
Furthermore, analogs need not be limited to 6-oxopurines. For instance, a point mutation in 
hPNP alters the specificity to 6-aminopurines like adenosine and hPNP also shows off-target 
phosphorolysis activity for nucleosides with unnatural bases49. Additionally, nucleosidyl 
transferases can be incorporated in the pathway to switch the hypoxanthine base with 
pyrimidine bases18. 
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CHAPTER VI 
 
DISSERTATION SUMMARY AND FUTURE DIRECTIONS 
 
Synopsis 
Microbial factories have provided an environmentally friendly means to 
synthesize complex organic molecules. Historically, native producers were engineered to 
increase the yield of innate products; more recently, however, heterologous expression 
methodologies applied by metabolic engineers and synthetic biologists have enabled the 
generation of microbial factories for non-innate molecules, including pharmaceuticals, 
commodities, fuels and other fine chemicals. Copying or replicating pathways permits 
simple manipulation of the pathway and host DNA and host metabolism and bypasses 
control of the pathway by the producing organism. The combination of sub-pathways 
from multiple source organisms also allows for control of pathway flux and frequently 
generates a fully integrated system for biosynthesis of the product from simple 
feedstocks. Non-natural molecules have been generated by directing alternative 
substrates through known pathways. Metabolic flux through these appropriated 
pathways has been increased through the generation of mutant enzymes with increased 
activities on and selectivity for the alternate compounds. The generation of novel 
pathways from disparate and unrelated enzymes, or de novo pathway design, allows for 
long pathways to be re-routed down more economical routes and for biosynthesis of 
molecules for which there is no naturally-available pathway. 
A de novo pathway has been designed for ddI, a reverse transcriptase class 
nucleoside analog drug, which will allow for directed biosynthesis of the compound 
within a hosted system. The pathway decreases to three the number of required 
enzymes from the >10 enzyme steps required for biosynthesis of natural nucleosides. 
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Furthermore, ddI is not known to be synthesized in nature. A bioretrosynthetic analysis, 
in which the product is broken down to simpler molecules in a reverse step-wise manner, 
was employed in the design of the pathway. Ribokinase, phosphopentomutase, and 
purine nucleoside phosphorylase were chosen for directed biosynthesis of ddI from 2,3-
dideoxyribose, a five carbon dihydroxypentanal analog of ribose. Enzymes from E. coli, 
B. cereus and human, respectively, were initially chosen for incorporation into the 
pathway. 
In addition to a pathway design paradigm, a bioretrosynthetic approach was 
adopted for incorporation and optimization of enzymes into the pathway. 
Bioretrosynthesis minimizes to one the number of assays required for optimization of the 
pathway. Despite the use of multiple analytical techniques (UV/Vis, HPLC, LC/MS) 
during the study of this pathway, a single assay linked to the production of ddI or 
consumption of hypoxanthine was used for the ddI pathway.  
Chemical synthesis of the pathway precursor 2,3-dideoxyribose from glutamic 
acid and heterologous expression of each enzyme allowed for in vitro demonstration of 
the pathway functionality. Turnover of the pathway was extremely low, generating only a 
few picograms of product per milliliter in a 12 hour time period. In comparison, an order 
of magnitude more inosine is formed in only an hour of incubation. Clearly, pathway flux 
is significantly affected by the change in substrate structure. This poor turnover is 
mirrored upon characterization of the individual enzymes in the pathway with the dideoxy 
substrate congener. Rational mutagenesis, guided by protein structure/function studies 
or computational prediction, and directed evolution were utilized to improve the function 
of enzymes in the pathway. 
Mutation of active site residues in the first or second shell has a significant 
impact on specificity and substrate selectivity. Active site residues within PNP which 
control sugar selectivity were identified through calculation of substrate transition state 
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binding energies for inosine and ddI using the RosettaLigand small molecule docking 
algorithm. Computational design of the binding site and analysis of biochemical data 
narrowed the list of likely mutations to a single site, Y88. The complete complement of 
amino acid mutations were made at this position and kinetically characterized for 
comparison to predicted binding energies. Successful ranking of mutant activity was 
achieved within each substrate using the native RosettaLigand scoring function. Wild 
type PNP and PNP-Y88F were each correctly predicted as the most active mutants for 
inosine and ddI, respectively. Inaccuracies are observed in the relative prediction of 
substrate activity for each mutant and in the prediction of binding energies for mutants 
with charged residues. Re-weighting the score terms in the Rosetta energy function 
corrects the gross errors in prediction of substrate turnover, but at the expense of 
ranking ability. In particular, the reweighting results point to poor handling of electrostatic 
interactions, accounted for by the addition of a Generalized Borne solvation term, and 
difficulties in ranking of highly similar substrates. Despite this, the success in ranking is 
indicative of the methods applicability in systems where design is limited to a small 
number of amino acid positions. hPNP-Y88F has a 9-fold improved kcat and 2-fold KM 
over the wild type enzyme. 
To further improve the ddI turnover rate, hPNP-Y88F became the template for a 
directed evolution study. A high-throughput screen was developed to improved variants 
from a library of mutant enzymes, which were generated by error-prone PCR (epPCR). 
Upon transformation of the library into E. coli BL21(DE3) for protein expression, 
individual colonies were picked into 96-well plates and grown for 24 hours in LB media. 
The cells were replicated, pelleted and lysed by addition of lysozyme and a single 
freeze/thaw cycle. The cell-free extract was transferred to a 384-well plate and assayed 
for ddI phosphorolysis activity. Hits were re-grown from glycerol stocks and validated. A 
secondary screen normalized the turnover rate to cell density and aided in the removal 
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of false positives. Kinetic characterization of the mutants identified those with improved 
binding and substrate turnover number. The mutant with the most improved catalytic 
efficiency was carried into the next round as the template for mutagenesis and selection. 
After three rounds of directed evolution a mutant was identified with 36-fold 
improved turnover in E. coli extracts when compared to wild type hPNP, and 3-fold 
compared to hPNP-Y88F. Of note is a 2-fold improvement in Km identified after the first 
round of directed evolution. Subsequent rounds of directed evolution did not improve the 
catalytic efficiency despite increases in turnover in cell free extracts. This, and the 
location of acquired mutations, indicates that directed evolution identified mutants with a 
greater concentration of active enzyme, likely brought about by increased expression 
levels, protein stabilization or stabilization of mRNA transcripts. Overall, the final mutant 
is 22-fold improved in phosphorolysis and 36-times more active in cell free extracts. 
It is not necessarily the case that improvements in phosphorolysis efficiency will 
translate to improvements in the rate of nucleoside analog synthesis. To test this 
scenario dideoxyribose 1-phosphate was synthesized in situ through isomerization of 
dideoxyribose 5-phosphate with PPM and the rate of ddI synthesis compared for wild 
type PNP and PNP-46D6. The mutant enzyme possesses a 52-fold improved selectivity 
ratio in the synthesis direction. Since the selectivity ratio is 46-fold improved in the 
phosphorolysis direction, in this case improvements in one direction did replicate to the 
reverse direction. 
Enzyme engineering studies are aided by basic knowledge of an enzymes 
structure and mechanism. In particular, a map of the interactions between substrate and 
product, coming in the form of substrate-bound crystal structures, is desirable. Structural 
studies of both ribokinase and PNP are abundant and substrate-bound crystal structures 
are available for each. In contrast, very little literature exists on the structure of PPMs 
Based on sequence comparison, the enzyme was classified as a member of the alkaline 
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phosphatase superfamily and early studies with E. coli PPM reinforced the classification, 
as the enzyme is dependent on divalent metal cations for activity. Like the PPM from E. 
coli, B. cereus PPM activity is dependent on Mn2+ and crystallization of the enzyme 
confirmed that the protein contains the core domain shared by alkaline phosphatase 
super-family members. In addition to the core domain a cap domain is formed by 
residues 102-216 and is unrelated to any known fold. Soaking of B. cereus PPM crystals 
in a solution containing ribose 5-phosphate revealed the presence of two substrate 
binding modes. The first utilizes a phosphate binding pocket distal to the catalytic center 
made up of cap domain residues while the second is coordinates the divalent metion 
ions and is positioned for reaction with Thr-85. The two positions, along with the 
orientation of monomers in the asymmetric unit, indicate a significant potential for 
domain re-orientation throughout catalysis. Significant plasticity would be required to 
allow for positional rearrangement of the bisphosphate intermediate during enzyme 
turnover. Hydrogen bond contacts between the enzyme and ribose sugar are limited to 
the upper substrate orientation and occur between the 3-OH of ribose and Ser-154 and 
between the furanose oxygen and Arg-193. 
Of note is the requirement for phosphorylation of the catalytic nucleophile prior to 
turnover of ribose phosphates. This requirement is in stark contrast to all other alkaline 
phosphatase superfamily members which have been described to date. Together, the 
activation by sugar bisphosphates and presence of a stable phosphothreonine 
intermediate indicate the use of an intermolecular transferase mechanism whereas 
cofactor-independent phosphoglycerate mutase, a member of the same superfamily, 
proceeds through intramolecular transfer. Isotopically labeled ribose 5-phosphates were 
synthesized enzymatically from universally labeled [13C5]ribose and γ-[18O4]ATP to test 
the transferase mechanism.  These studies confirmed an intermolecular catalytic cycle 
for bacterial phosphopentomutases. 
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Crystallization of PPM with ribose 5-phosphate allowed for identification of Arg-
193 and Ser-154 as likely participants in orientation of substrate. To supplement this 
data PPM was crystallized with dideoxyribose 5-phosphate bound in the active site. 
These structures reveal an inability of PPM to orient the sugar for catalysis, as 
evidenced by decreased electron density for the sugar portion of the molecule. In 
addition, a rotation of the sugar toward Ile-195 and Val-158 occurs, which serves to 
decrease interactions between polar sidechains, specifically Ser-154, and the 
hydrophobic methylenes of dideoxyribose 5-phosphate. This alternative binding mode of 
dideoxyribose 5-phosphate represents a non-productive interaction resulting in an 82-
fold decrease in kcat and a 7.5-fold decrease in Km. 
Mutation of Ser-154 to alanine causes a shift in orientation of the dideoxyribose 
5-phosphate furanose ring. Although turnover activity for dideoxyribose 5-phosphate did 
not correspondingly increase with the change in substrate orientation, ribose 5-
phosphate activity decreased 4-fold. This change in activity increases the selectivity of 
the mutant for the unnatural substrate and serves as a first step in engineering of PPM. 
Finally, to explain the poor phosphorylation of dideoxyribose by ribokinase 
dideoxyribose was docked into the ribokinase active site with RosettaLigand. These 
results indicate the importance of hydrogen bonding to substrate orientation. 
Dideoxyribose adopts a number of conformations in an effort to satisfy the many 
hydrogen bond donors and acceptors. In particular, Asp-16 is involved in misorientation 
of dideoxyribose 5-phosphate through formation of hydrogen bonds to the 1- and 5-OH 
group and by disfavoring orientations that favor turnover through unfavorable polar/non-
polar interactions with the C2- and C3-methylenes. Mutation of Asp-16, and additionally 
Gly-41, may decrease the size of the binding pocket, thereby selecting for the smaller 
substrate and orienting it more appropriately for phosphorylation. 
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Significance 
Pathway and enzyme engineering 
This work demonstrates the potential for directed biosynthesis of nucleoside 
analogs, in particular dideoxyinosine. Biocatalytic production of ddI has social 
implications in its potential to decrease the manufacturing price of ddI. Synthesis of 
nucleoside analogs via biocatalysis benefits from the inherent stereo- and 
regiospecificity of enzymes. Classical synthetic methods for nucleoside analogs require 
many protecting group manipulations and are plagued by the generation of racemic or 
enantiomerically impure products which require chromatographic or other purifications. It 
also provides for processes which utilize environmentally friendly reaction conditions, 
such as ambient temperature and pressure and physiological pH, in an aqueous 
environment without the necessity of toxic or expensive catalysts. Altogether, these 
process improvements alleviate the large waste streams generated through classical 
chemical synthesis of pharmaceuticals. It is estimated that the pharmaceutical industry 
uses between 25 kg and 100 kg of solvent per kg of drug produced1. By reducing the 
amount of solvent waste generated in production, the pharmaceutical industry can save 
millions of dollars in solvent purchase and disposal expenses. Additionally, the proposed 
pathway utilizes a cheap starting material. Glutamic acid is a commodity material 
available in the dollar per kg range. Current manufacturing techniques likely utilize 
adenosine or inosine as the primary starting material. In comparison, adenosine and 
inosine have a median price of several hundred dollars per kg (data not shown). These 
cost savings can be passed to persons requiring antiretroviral treatment, many of which 
live in low-income countries. 
This thesis utilizes a bioretrosynthetic analysis for design of the biocatalytic 
pathway. Additionally, bioretrosynthesis is introduced as an engineering paradigm. The 
work presented here provides a strong base for testing of this novel pathway 
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engineering mechanism. For example, subsequent work hypothesized that increased 
concentrations of PPM would be required to maximize pathway activity when PNP-46D6 
is incorporated into the pathway (work by William R. Birmingham). In fact, the contrary is 
true! Because the affinity of PNP-46D6 is improved for the dideoxy substrate congener, 
dideoxyribose 1-phosphate precursor pools need not accumulate for similar activities to 
increase alleviating the requirement for increased concentrations of the penultimate 
protein. In terms of pathway flux optimization in a microbial factory the improved Km will 
reduce the probability of intermediate diffusion and loss of starting materials to other 
metabolic processes. 
It has been demonstrated that PPM is structurally homologous to alkaline 
phosphatase superfamily members. However, PPM was found to utilize a catalytic cycle 
that is different from other alkaline phosphatase superfamily members despite 
possessing the same core mechanism as the other superfamily members (covalent 
nucleophilic catalysis stabilized by two divalent cations). This observation has basic 
science implications. Understanding how enzymes have evolved a specific function has 
been a topic of study for decades. A common practice is the extrapolation of a common 
mechanism from a well-studied enzyme to evolutionarily related enzymes. This work 
serves as an example of a unique function evolved in an evolutionarily related 
superfamily of proteins. The PPM phosphotransfer cycle is most similar to that of α- and 
β-phosphoglucomutases which are unrelated in both sequence and structure and is an 
interesting case of convergent evolution. 
Computational docking studies were a major part of Chapters 2 and 5. Very few 
enzyme re-design studies have been reported. The work presented in Chapter 2 
benchmarks the RosettaLigand algorithm and provides confidence in the results of 
subsequent studies. Furthermore, computational studies enable quick prediction of 
enzyme-substrate interactions and analysis of mutant activities. Their utility lies in an 
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ability to quickly and cheaply identify positive research directions and also intractable 
lines of inquiry. 
 
Best practices in directed evolution 
Several significant conclusions can be drawn from the meta-analysis of directed 
evolution studies presented in Chapter 1. Directed evolution studies containing 
comparable kinetic data over the last 10 years were surprisingly sparse. However, 
despite a relatively small sample from which to draw conclusions, the summary provided 
by this study hints at some putative best practices to consider when implementing 
contemporary directed evolution methodologies:  
Identify a progenitor enzyme acting on a substrate as similar as possible to the 
new substrate. This point is somewhat facile, but most of the new substrates identified 
by the retrospective analysis in Table 1 are closely structurally related to the parent 
enzyme’s natural substrate. In many cases, natural enzymes performing a desired 
chemistry on a target substrate may be unavailable. In such cases, the next best option 
is to select a progenitor enzyme performing a desired functional group transformation. 
As previously noted, saturation mutagenesis methods are over-represented in 
the high-fold improvement bins, pointing to a greater potential in targeting particular 
sites. When possible, it appears that structure or homology based site directed 
mutagenesis methods should be attempted first. When structural data for progenitor 
enzymes is unavailable, error prone PCR and gene shuffling are the next alternative. 
Expect to use combinations of mutagenesis methods in a single campaign. While 
it is clear that mutation of active site residues provides a clear benefit, it is also clear that 
distal mutations serve to improve the activity (and/or stability) of enzymes. 
Recombine identified mutations using site-directed mutagenesis and gene 
shuffling2, 3. While individual mutations are rarely 100% additive, recombination 
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frequently provides additional improvement in activity. Furthermore, recombination of the 
top mutants enables further mining of already-screened libraries. 
The steep triage from over 1200 articles to only 81 qualifying cases is primarily 
reflective of a lack of uniformity in reporting standards for enzymes improved by directed 
evolution studies. To provide clearer data to guide improvements, it would also be 
helpful for practitioners of directed evolution studies to report complete biochemical 
kinetic data for progenitor enzymes and throughout each selection exercise. 
Where biocatalysts for a particular reaction system are not available in the 
natural repertoire, directed evolution methodologies allow for generation of new 
enzymes with non-native reaction characteristics such as increased rates of catalysis or 
altered substrate and/or product profiles while functioning in a wide range of reaction 
conditions. As drug development continues to rely on the generation of chemically 
complex small molecules, the development of biocatalysts for regio- and stereoselective 
production of these complex entities will become an important tool for the medicinal and 
process chemist. 
The retrospective assessment provided by this perspective aims to assist 
researchers interested in applying existing directed evolution methods for the 
development of new biocatalysts for transformation of non-native substrates. It is evident 
that directed evolution methodologies continue to contribute to significant improvements 
in enzyme catalysis, although a single and generalized route towards the most improved 
enzyme is frequently unclear. The numeric assessments provided here may be useful in 
expectations management for both investigators and reviewers of directed evolution 
studies. The disparity between the average and median fold improvements in 
parameters is striking, suggesting that the median value may represent a more equitable 
standard for performance improvements. However, numeric assessments fail to fully 
capture the successes and failures of directed evolution methodologies. Comprehensive 
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knowledge of the failures, which may or may not outnumber the reported successes, is 
lacking but regardless this would reduce the median fold improved values further. 
However, the success from a biocatalytic perspective must ultimately not be defined by 
fold improvements in biochemical parameters but by the attainment of goals for a given 
study. Based on this broad survey, it was clear that these criteria were met by the 
majority of campaigns reported in recent literature, underlining further the ongoing 
contribution of directed evolution methodologies to engineering of biocatalysts for new 
and existing substrates. 
 
Future Directions 
A chemo-enzymatic pathway for ddI production was constructed which generates 
the target molecule. However, the low levels of turnover leave much room for 
improvement. Rates of nucleoside phosphorolysis and synthesis were improved for 
hPNP but turnover rates are still significantly lower than those of inosine. This activity 
may be further improved through subsequent rounds of directed evolution. It is possible, 
though, that equivalent activities will not be reached with ddI: the hydrophobic nature of 
the molecule may repel approach by phosphate or purine base. Furthermore, the 
dideoxyribose moiety may be inherently less reactive. 
The dataset provided here, and the plethora of binding and turnover data 
available for hPNP, hPNP mutants and homologs, may enable extension of 
computational prediction of beneficial mutations to residues distal to the binding pocket. 
Here, mutagenesis of residues >15 Å from the binding site affect substrate turnover 
preference. Similar datasets are available for binding of transition state analogs4. 
Furthermore, computational bench-marking to this rich data set will advance the 
understanding of RosettaLigand as it relates to complex, multimeric systems which 
utilize multiple substrates and generate multiple products.    
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The efficiency of PPM turnover of dideoxyribose 5-phosphate is 620-fold worse 
than ribose 5-phosphate. Crystallographic studies have suggested Ser-154, Arg-193, Ile-
195 and Val-158 as targets for mutagenesis. Mutation of Ser-154 to alanine increased 
the selectivity for dideoxyribose 5-phosphate by decreasing turnover of the natural 
substrate without significantly affecting the turnover rate of the target molecule. 
Saturation mutagenesis at this position, and the others, will help to identify the optimal 
residue identity. It is possible that other amino acids may orient the furanose portion of 
dideoxyribose 5-phosphate in a more catalytically active conformation. 
Dideoxyribose phosphorylation by ribokinase is currently the rate limiting step of 
the biocatalytic pathway. Docking studies with RosettaLigand pointed to Asp-16 and Gly-
41 as potential targets for mutagenesis. Because of their proximity, amino acid 
substitutions may be mutually beneficial or mutually exclusive. Simultaneous saturation 
mutagenesis should be performed to identify the optimal combination of residues at 
these positions. A step-wise approach may lead to selection of an amino acid at the first 
position which precludes a better combination from occurring. Alternatively, 
computational design of the active site can be used to predict combinations of mutations 
which stabilize a productive binding orientation. 
A primary advantage of microbial factories is the stable environment they provide 
for enzyme function. It is possible that low pathway turnover is a consequence of 
enzyme degradation during the long incubation time of the reaction. Incorporation of the 
pathway into E. coli and feeding of dideoxyribose will demonstrate production of the 
compound in vivo and is a major step toward high-volume production of ddI. 
Furthermore, extension of the pathway to a simpler precursor will improve the viability of 
the proposed chemo-enzymatic pathway. Currently, formation of dideoxyribose requires 
reduction at -78 °C, a temperature which is impractical and expensive on production 
scale, to stop reduction at the lactol. To alleviate this requirement, (S)-γ-butyrolactone-γ-
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carboxylic acid could under reduction to (S)-1,4,5-pentanetriol, or dideoxyribitol. 
Subsequent formation of dideoxyribose could be accomplished by enzymatic oxidation 
with mannitol 1-dehydrogenase (EC 1.1.1.255). This enzyme has been previously been 
evolved to generate L-ribose from ribitol5. Further evolution would generate an enzyme 
useful in the current pathway. 
Finally, this pathway can be applied to the synthesis of numerous other 
nucleoside analogs, such as azidothymidine, vidaribine, clofarabine, or apricitabine to 
name a few. Evolution of pyrimidine nucleoside phosphorylases or 
nucleosidyltransferases would provide access to each of the natural nucleobases. In 
addition to the natural bases, many nucleoside phosphorylases, nucleosidyltransferases, 
phosphoribosyltransferases possess off target activities for unnatural bases. It is likely 
that directed biosynthesis of these compounds will streamline the synthesis of these 
compounds, in addition to increasing their availabity. 
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Appendix A 
 
DIRECTED EVOLUTION METHODS 
 
Library Generation and Mutagenesis 
Random mutagenesis methods aim to identify mutations throughout the gene 
coding region and include error prone polymerase chain reaction (epPCR), chemical 
mutagenesis, UV irradiation, and mutating bacterial strains. The most common is 
epPCR,1 of which there are several variations. Typical early experiments used an error 
prone, thermostable polymerase lacking proofreading ability, such as Taq, to amplify a 
gene of interest, incorporating random mutations along the entire length of the gene.2 
The error rate of the polymerase alone was titrated through addition of Mn2+ to stabilize 
mismatched base pairs, and by manipulation of the number of thermocycles and 
template and dNTP concentrations. More recently, polymerases have been engineered 
to possess a higher inherent mutation rate, with less bias (e.g. balancing transitions vs. 
transversions) than wild-type Taq polymerase; Mutazyme (Stratagene Inc.) is frequently 
used, commercially available engineered error-prone polymerase. Alternatively, the 
addition of unnatural nucleotide analogs to the PCR reaction gives a similar end-result. 
Once incorporated, alternative pairings are generated as the nucleotide analogs are 
capable of pairing with multiple canonical nucleotides.3 Similarly, chemical mutagens 
may be employed to modify template DNA and foster mutation. Reaction of template 
DNA with nitrous acid, formic acid, hydrazine or ethyl methane sulfonate can result in 
chemical changes in nucleotide bases, altering their hydrogen bonding properties and 
increasing the propensity for the formation of non-canonical pairings.4, 5 Mutator strains 
and whole cell mutation by UV irradiation have been used to generate mutations in vivo.6 
In this way, low yield ligation steps can be avoided but at the expense of possibly 
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deleteriously mutating the host genome, resistance genes, copy number control 
sequences or promoter regions of the heterologous plamids. To balance the bias of 
transitions (AG, TC) and transversions (A/G  C/T), some researchers have used 
multiple epPCR methods thereby increasing the mutational diversity in the library.7-9 
Wong and coworkers performed a statistical analysis of the mutational spectrum 
achieved through the application of 19 random mutagenesis experiments to three genes. 
Using this data they developed a web application, the Mutagenesis Assist Program 
(MAP), to aid researchers in choosing an optimal method for a given target gene.2 The 
MAP analysis takes into account the codon usage of the template and, for each random 
mutagenesis method, provides data on the expected number of stop codons, number of 
available mutations from each codon, incorporation of destabilizing glycines or prolines, 
number of preserved amino acids and the propensity for mutation to amino acids with 
alternative chemical properties. 
The preceding “random” mutagenesis methods can facilitate the identification of 
advantageous mutations or tunable sites located throughout a protein sequence and can 
be successfully applied in the absence of structural data. Saturation mutagenesis 
protocols test all 20 amino acids at a targeted site or sites and enable a controlled and 
comprehensive search of mutational sequence space via degenerate oligonucleotide 
primers. Although saturation mutagenesis can be applied to every position in a gene, as 
in Gene Site Saturation Mutagenesis,10 the method is most commonly targeted to 
potentially beneficial sites using structural data or through homology modeling. 
Saturation mutagenesis can be applied to a single site, to multiple sites in an iterative 
fashion, or to multiple sites simultaneously. Cassette mutagenesis,11 involves 
simultaneous saturation mutagenesis of multiple, proximal residues. In this category, 
Reetz and coworkers introduced a method dubbed the combinatorial active-site 
saturation test, or CASTing, in 2005.12 Most often, CASTing has been applied to alter the 
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shape of binding sites for the purposes of changing the enantioselectivity of an 
enzyme.13 Overall, saturation mutagenesis methods have the advantage of substantially 
reducing library size requirements by focusing on a subset of ‘hotspots’ either within the 
active site or as identified by broader sequence scans (i.e. random mutagenesis). 
The term ‘gene shuffling’ refers to the in vitro recombination of template 
progenitor genes and is analogous to homologous recombination and sexual PCR. It 
ostensibly allows for generation of chimeric sequences more diverse than standard 
epPCR without resorting to high polymerase-dependent mutation rates which lead to the 
incorporation of deletory mutations in a high fraction of variants.14 The progenitor genes 
may be comprised of either naturally occurring homologs of a gene family, or selected 
mutants of a single gene generated by other mutagenesis methods. The archetypal DNA 
shuffling method introduced by Stemmer and coworkers shuffles homologous DNA 
sequences by generating oligonucleotide fragments from selected progenitor genes by 
treatment with DNAse, followed by reassembly of the mixed oligonucleotides by PCR.15 
Since then, a number of other protocols have been developed for homologous 
recombination. In StEP (Staggered Extension Protocol), homologous DNA templates are 
mixed together with one or more primers, and subjected to very short annealing and 
extension steps.16 Methods for recombination of non-homologous sequences include 
incremental truncation of hybrid enzymes (ITCHY and SCRATCHY) and sequence 
homology-independent recombination (SHIPREC).17-19 
Frequently, beneficial mutations generated by one of the aforementioned 
methods (random mutagenesis, site-directed mutagenesis, gene shuffling) are 
subsequently combined into a single construct to further optimize enzyme function. By 
generating these combinations, unproductive and/or neutral mutations may also be 
identified and removed. This can be accomplished by gene shuffling, long used for this 
purpose,15 or stepwise site-directed mutagenesis to deconstruct the role of each 
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mutation. It is apparent that most successful directed evolution campaigns utilize 
multiple forms of mutagenesis, both iteratively and sometimes concurrently in a given 
study, with some exceptional studies performing in excess of 20 rounds using a broad 
array of methods.20 
 
Identification of improved variants 
In selection-based methods, a desired enzymatic activity, such as amino acid 
synthesis, is linked to host cell survival through growth under selective conditions, such 
as in minimal medium lacking amino acid. Other typical examples include the synthesis 
of an essential amino acid21-23 or nucleotide18, 19 or degradation of an environmental 
toxin.15, 24-31 Positive selections can be performed on agar plates or rely on enrichment of 
cells harboring enzymes of the desired activity in a liquid culture.32 Negative selection 
methods, in which the desired activity results in death, often entail that cells must be 
sorted and replicated into both library reference and assay microtiter plates to facilitate 
backtracking and resurrection of the desired library cultures, thereby making them lower 
throughput.33, 34 A notable exception is the evolution of tRNA synthetase activity for 
incorporation of unnatural amino acids, in which negative selection was performed to dial 
out undesired activities.35, 36 
An ideal selection scheme involves engineering an organism to be dependent on 
reproduction via the presence of endogenously biosynthesized small molecule in a 
concentration dependent manner. A potential solution to this challenging problem was 
described by Schwimmer and coworkers37 using a yeast two-hybrid system to evolve a 
receptor, capable of transcriptional activation of an essential gene, to bind a new small 
molecule ligand. Specifically, a nuclear receptor retinoid X receptor that naturally binds 
9-cis-retinoic acid was engineered to bind a synthetic retinoid-like compound LG335 with 
an improvement in EC50 from 10 μM to 40 nM. In an alternative approach, ligand binding 
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protein switches have been generated by engineering protein hybrids with resistance 
genes.38 
Challenges to the development of a successful positive selection scheme are not 
limited to the molecular recognition engineering problem. Of critical importance is the 
level of response to the ligand concentration. Once a ligand reaches a concentration 
sufficient for organism survival, selective pressure will diminish; therefore, it is more 
useful that the response occurs in a concentration dependent manner rather than as a 
switch. Moreover, ligands need to be constrained to the intracellular environment to be 
of maximal utility and must not be toxic to the host organism. Despite these challenges, 
in vivo methods allow for assessment of large numbers of variants. In fact, the 
throughput of selection methods is usually only limited by ligation and transformation 
efficiencies. 
In screening-based methods, the rate of substrate turnover is determined via 
biochemical assay, often via colorimetric or fluorometric measurements. In vitro (cell-
free) activity assays generally require the isolation of individual colonies into 96- or 384-
well plates, followed by lysis and multiple reagent transfers. Thus, screening-based 
methods are limited by cost and time to less than 106 mutants (103-104 is more 
common). As an exception, in vivo screening-based methodologies can be applied to 
larger mutant libraries and it is the linking of the desired biochemical activity to a 
phenotype that limits the realistic library size. Examples of in vivo activity assay 
techniques include agar plate colony screening9, 39-48, flow cytometric cell sorting49-54 or 
phage display55, 56, and result in larger libraries on the order of 107-1010 mutant 
constructs. Like selection methods, the throughput of these in vivo methods is solely 
limited by ligation and transformation efficiency. 
Some colorimetric screens can be modified and applied to agar plate colony 
screening. In these methods, colonies displaying a desired color within a certain time 
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window are selected as active. Frequently, the colorimetric agar plate assay is used as a 
primary screen to identify enzyme variants with functional turnover. Subsequently, a 
secondary and sometimes tertiary activity assay is performed in a 96-well microtiter plate 
biochemical assay to confirm and identify the most active clones.57-59 These cases 
benefit from the larger library sizes assayable via the initial agar plate screen before 
encountering the time and cost limitations of single colony isolation techniques.  
Flow cytometry and phage display methods permit the assay of larger mutant 
libraries. Fluorescence activated cell sorting, or FACS, is a type of flow cytometry in 
which a mixture of cells is sorted, one cell at a time, based upon the specific light 
scattering and fluorescent characteristics of each cell. Systems amenable to FACS must 
operate intracellularly, which often requires that substrates of the screen be cell 
permeable and the products impermeable. To address this requirement, FACS methods 
utilizing in vitro compartmentalization (IVC) allow the compartmentalization of DNA, 
transcriptase, ribosomes and fluorescent substrates/products in artificial water-oil 
emulsions thereby linking and rendering sortable product formation, enzyme, and the 
enzyme encoding gene.54  
In phage display screening, the DNA of a gene library is fused to a viral coat 
protein gene, and combined in a phagemid (a vector containing both plasmid and phage 
origins of replication). The phagemid DNA then becomes packaged in the phage capsid 
that displays the protein. The phage are subjected to chromatographic separation 
(affinity binding) to select for desired activity.60 Very rarely is phage display connected 
directly to enzyme activity although an increase in a biosynthetic enzyme activity can be 
identified through tighter binding to a tethered transition state analog.61 Other display 
methods, such as cell surface display, provide the advantage of a large library size in 
addition to facile subsequent screening capability.62 
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As it is challenging to link enzymatic reactions to cell viability it is also difficult to 
contrive reporter systems that induce a change in color or fluorescence in vivo, or in 
compartments. Such systems often require an enzymatic assay for activity in cell lysates 
from colonies isolated in microtiter plates. Although these assays require the growth of 
individual cultures for assay, there is no limit to the varieties of instrumental analysis that 
can be performed, and most assays can be implemented in a 96-well format and auto-
sampling technologies. Examples of these methods include analytical HPLC,63 mass 
spectrometry,25 TLC, 64, 65 radioactivity,66 and UV/Vis spectroscopy (e.g. NADH 
reduction)67-69. 
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Appendix B 
 
TABLE OF STATISTICS FOR SELECTED DIRECTED EVOLUTION STUDIES 
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Table B-1. ■ Experimental details of the selected directed evolution studies included in directed evolution meta-analysis. 
Random mutagenesis – experiments which mutate the whole gene in the absence of guiding criteria. ■ Saturation 
mutagenesis – iterative and/or simultaneous application of saturation mutagenesis. ■ Gene Shuffling – Use of recombinatorial 
methods to generate diversity. ■ Step-wise method application – cases where random mutagenesis, saturation mutagenesis, 
or gene shuffling were used iteratively. ■ Saturation mutagenesis of “hotspots” –probing of positions known to affect function, 
identified through stochastic methods. ■ Combination of improved variants – recombination of variants through site-directed 
mutagenesis or gene shuffling. ▲ Selection or plate-based screens use an agar plate to enable high throughput screening of 
enzyme variants ▲ Assays which require growth of individual variants in liquid cultures ▲ Experiments utilizing fluorescence 
activated cell sorting ▲ Enrichment includes liquid phase selection of improved variants and enrichment by phage display ▲ 
Colorimetric agar plate-based screens which require a secondary or tertiary assay to distinguish the most. ■ Studies which 
enable small-molecule synthesis ■ Evolutionary or other scientific studies ■ Generation of enzymes for detoxification of 
harmful agents 
 
Ref
. EC Enzyme Natural Substrate New Substrate 
Mut. 
Protoco
l 
Screen
. 
Method 
Intent 
of 
Stud
y 
Fold 
Improve
d Rate 
Fold 
Improve
d Km 
Fold 
Improved 
Catalytic 
Efficiency 
1 1.1 Choline oxidase choline 
tris-(2-hydroxyethyl)-
methylammonium 
methylsulfate 
■ ■ ■ ■ ▲ ■ 2.69 3.24 8.72 
2 1.1 Pyranose-2-oxidase glucose galactose ■ ▲ ■ 0.15 21.98 3.33 
3 1.1 Vanillyl-alcohol oxidase vanillyl alcohol creosol ■ ▲ ■ 7 1.54 10.77 
4 1.1 Galactose Oxidase galactose guar ■ ■ ▲ ■ 4.88 3.94 19.2 
5 1.1 β-Isopropylmalate dehydrogenase NAD NADP ■ ▲ ■ 1.36 61.31 83.45 
6 1.11 Cytochrome C peroxidase cytochrome c 
2,2'-azino-bis(3-
ethylbenzothiazoline-6-
sulfonic acid) 
■ ■ ▲ ■ 9.45   
7 1.11 Bromoperoxidase A2 para-nitropheylacetate para-nitrophenyl caprylate ■ ■ ▲ ■ 140.23   
8 1.11 Lignin peroxidase lignin 2,4-dichlorophenol ■ ■ (■) ▲ ■ 8.52 0.48 4.05 
9 1.11 Horseradish peroxidase tyrosinol L-tyrosinol 
■ ■ ■ 
(■) ▲ ■ 32.69   
9 1.11 Horseradish peroxidase tyrosinol D-tyrosinol 
■ ■ ■ 
(■) ▲ ■ 6.16   
10 1.13 
4-Methyl-5-nitrocatechol 
monooxygenase 
4-methyl-5-
nitrocatechol 4-nitrophenol ■ ■ ▲ ■ 3.21 3.5 11.25 
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11 1.13 Extradiol dioxygenase 
1,2-
dihydroxynaphthalene 3,4-dihydroxybiphenyl ■ ■ ■ ▲ ■ 2.38 315.79 750 
12 1.14 Toluene dioxygenase toluene 4-picoline ■ ■ (■) ▲ ■ 5.6   
13 1.14 
Deacetoxycephalosporin 
synthase penicillin N penicillin G ■ ■ ▲ ■ 3.09 13.58 41.91 
14 1.14 Aniline dioxygenase aniline 2,4-dimethylaniline ■ ■ (■) ▲ ■ 3.5   
15 1.14 P450 1A2 
heterocyclic aromatic 
amines 
2-amino-3,5-
dimethylimidazo[4.5.f]quinolin
e 
■ ▲ ■ 4.5 2.6 11.7 
16 1.14 P450 BM-3 fatty acids and alkanes 
12-p-nitrophenyl carboxylic 
acid ■ ▲ ■ novel novel novel 
17 1.14 P450 2A6 indole 4-chloroindole ■ ■ ▲ ■ 0.68 7.52 5.15 
18 1.14 P450 2B1 NADPH H2O2 ■ ▲ ■ 6   
19 1.4 Phenylalanine dehydrogenase phenylalanine DL-propargylglycine ■ ■ (■) ▲ ■ 1.27 5.78 7.4 
20 1.4 D-Amino acid oxidase D-alanine D-aspartate ■ ▲ ■ 1.78 3.38 6 
20 1.4 D-Amino acid oxidase D-alanine D-arginine ■ ▲ ■ 1.38 1.17 1.6 
21 1.4 Glutamate Dehydrogenase 2-ketoglutarate 2-ketoisovalerate ■ ▲ ■ 4.53 1.05 4.75 
22 1.6 Chromate reductase chromium (VI) uranium (VI) ■ ▲ ■ 11.41 0.14 1.6 
23 2.1 (Iso)eugenol 4-O-methyltransferase (Iso)eugenol coniferyl alcohol ■ ▲ ■ 8.83 8.02 70.8 
24 2.2 Transketolase xylulose-5-phosphate / ribose-5-phosphate 
β-Hydroxypyruvate / 
glycolaldehyde ■ ▲ ■ 4.83   
25 2.2 Transketolase Xylulose-5-phosphate / ribose-5-phosphate 
β-Hydroxypyruvate / 
propionaldehyde ■ ▲ ■ 8.92 2.55 22.7 
26 2.3 γ-Glutamyltranspeptidase glutamine glutaryl-7-ACA ■ ■ ▲ ■ 18.28 2.64 48.19 
27 2.3 Simvastatin synthase LovF-ACP-α-S-methyl butyrate 
α-dimethylbutyryl-S-methyl-
mercaptoproprionate ■ ■ ■ ▲ ■ 7.27 0.97 7.1 
28 2.3 N-Acetyltransferase unknown glyphosate ■ ▲ ■ 416 24 9984 
29 2.4 Cyclodextrin glucanotransferase short polysaccharides soluble starch ■ ■ ■ ■ ▲ ■ 10.9   
30 2.4 
Kanamycin/Vancomycin 
glycosyl transferases 
(chimera) 
kanamycin or 
vancomycin / dTDP 
glucose 
2-deoxystreptamine / TDP-
glucose ■ ▲ ■   4 
31 2.4 Glycosynthase XynB2 (E335G mutant) 
α-D-xylopyranosyl-
fluoride α-D-xylopyranosyl-fluoride ■ ▲ ■ 35.15 0.06 2.1 
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32 2.4 
Glutamine 
phosphoribosylpyrophosphat
e amidotransferase 
5-phosphoribosyl-1-
pyrophosphate phosphoribosylanthranilate ■ ▲ ■ 30   
33 2.4 Cellobiose phosphorylase cellobiose lactose ■ ■ ▲ ■ 10.18 0.69 7.04 
34 2.4 Purine nucleoside phosphorylase inosine dideoxyinosine ■ ■ (■) ▲ ■ 4.99 4.38 21.91 
35 2.5 Glutathione transferase 
1-menaphythyl 
sulfate/dichloromethan
e 
7-amino-4-chloromethyl 
coumarin 
■ ■ ■ ■ 
(■) ▲ ■ 844.44 22.71 19176 
36 2.5 Glutathione transferase herbicides flurodifen ■ ▲ ■ 29.25   
37 2.5 Glutathione transferase 
1-menaphythyl 
sulfate/dichloromethan
e 
7-amino-4-chloromethyl 
coumarin ■ ▲ ■ 258.43 2.89 748 
38 2.6 Aspartate aminotransferase aspartate tyrosine ■ ▲ ■   130.91 
39 2.6 Aspartate aminotransferase hydroxyphenylpyruvate hydroxyphenylpyruvate ■ ■ ▲ ■ 1.49 3.1 4.6 
40 2.7 Allokinase allose glucose ■ ▲ ■ 1.3 4.46 5.8 
40 2.7 N-Acetyl-D-mannosamine kinase 
N-acetyl-D-
mannosamine glucose ■ ▲ ■ 3.82 3.13 11.9 
41 2.7 Deoxythymidine kinase deoxythymidine azidothymidine ■ ▲ ■ 1.44 1.15 1.7 
42 2.7 Phosphopantetheinyl transferase Coenzyme A 3′-dephospho-Coenzyme A ■ ▲ ■   329.33 
43 2.7 Deoxynucleoside kinase thymidine fluorescent dideoxythymidine ■ ■ ■ (■) ▲ ■ 0.56 9.93 5.5 
44 3 Phosphotriesterase-homology protein unknown 2-naphthylacetate ■ ■ ■ ▲ ■   44.29 
45 3 E. coli Ebg unknown fluorescein di-β-D-galactopyranoside ■ ■ ▲ ■   3941 
46 3.1 Organophosphorous hydrolase paraoxon chlorpyrifos ■ ▲ ■ 418.13 1.86 777 
44 3.1 Phosphotriesterase Paraoxon 2-naphthylacetate ■ ■ ■ ▲ ■   12.92 
47 3.1 Lipase A 
(R)-1,2-O-
isopropylidene-sn-
glycerol butyrate 
(S)-1,2-O-isopropylidene-sn-
glycerol butyrate ■ ▲ ■ 0.96 1.75 1.7 
48 3.1 Serum paraoxonase L-homocysteine thiolactone γ-thiobutyrolactone ■ ▲ ■   101.42 
49 3.1 Phosphotriesterase organophasphates ethyl paraoxon ■ ▲ ■ 104 5.36 557 
50 3.1 Organophosphorous hydrolase paraoxon methyl parathion ■ (■) ▲ ■ 17.22 1.97 34 
51 3.1 Lipase 2-naphthyl oleate N-(2-naphthyl)oleamide ■ ■ ▲ ■ 2.2   
52 3.1 Lipase 2-naphthyl oleate N-(2-naphthyl)oleamide ■ ■ ▲ ■   27.59 
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53 3.1 Carboxylesterase unknown 6-aminohexanoate-linear-dimer ■ ■ ▲ ■ 5.25 19.55 840.97 
54 3.2 Endo-β-1,4-glucanase β-1,4-glucosidic bonds of amorphous cellulose carboxymethyl-cellulose ■ ■ ▲ ■ 2.55   
55 3.2 Endoglucanase β-1,4-glucosidic bonds of amorphous cellulose carboxymethyl-cellulose 
■ ■ ■ 
(■) ▲ ■ 1.32 0.5 0.66 
56 3.2 β-Galactosidase para-nitrophenyl-β-D-galactopyranoside 
para-nitrophenyl-β-D-
fucopyranoside ■ ▲ ■ 215 0.27 58.89 
57 3.2 β-Glucuronidase para-nitrophenyl-β-D-glucopyranoside 
para-nitrophenyl-β-D-
galactopyranoside ■ ▲ ■   15.65 
58 3.2 β-Glucuronidase glucoronide para-nitrophenyl--D-xylopyranoside ■ ■ ▲ ■ 63 3.27 206.2 
59 3.2 β-Glucosidase cellotetraose cellobiose ■ ▲ ■ 1.44 0.99 1.44 
60 3.4 DD-Transpeptidase D-ala-D-ala cefotaxime ■ ■ ■ (■) ▲ ■ 
17822.9
7   
61 3.5 D-Hydantoinase hydantoin D,L-hydroxyphenylhydantoin ■ ▲ ■ 11.11 0.42 4.6 
62 3.5 β-Lactamase β-lactams cefotaxime ■ ▲ ■ 3083 0.0381 1175 
63 3.5 Glutaryl acylase glutaryl-7-ACA adipyl-7-ADCA ■ ■ ▲ ■ 5.8 6.2 36 
64 3.5 Glutaryl acylase glutaryl-7-ACA adipyl-7-ADCA ■ ■ (■) ▲ ■ 2.02 1.41 2.85 
65 3.5 Glutaryl acylase glutaryl-7-ACA adipyl-7-ADCA ■ ▲ ■ 1.2 6.86 8.2 
66 3.5 Mandelamide hydrolase mandelamide lactamide ■ ■ (■) ▲ ■ 3.84 0.6 2.29 
67 3.5 Metallo-β-lactamase β-lactams Cephalexin ■ ▲ ■ 12.41 0.6 7.42 
68 3.5 Glutaryl acylase glutaryl-7-ACA cephalosporin C ■ ■ ■ ▲ ■ 4.29 0.9 3.86 
69 3.8 Haloalkane dehalogenase haloalkanes 1,2,3-trichloropropane ■ ■ (■) ▲ ■ 3.5 2.2 7.7 
70 4.1 Sialic acid aldolase sialic acid 
ammonium (4R,5R,6R)-6-
(dipropylcarbamoyl)-2,4,5-
trihydroxytetrahydro-2H-
pyran-2-carboxylate 
■ ▲ ■ 1.76 28.21 49.55 
71 4.1 KDPGal Aldolase glyceraldehyde-3-phosphate D-erythrose 4-phosphate ■ ▲ ■ 5.21 11.63 60.64 
72 4.1 Sialic acid aldolase D-sialic acid 3-deoxy-manno-2-octulosonic acid ■ ▲ ■ 9.45 2.68 25.3 
73 4.1 Tagatose-1,6-bisphosphate aldolase 
product: tagatose 
bisphosphate 
product: fructose 
bisphosphate ■ ■ ▲ ■ 8.78 8.13 71.34 
74 4.2 Carbonic Anhydrase II HCO3- 2-naphthylacetate 
■ ■ ■ 
(■) ▲ ■   39 
75 5.3 Phosphoribosyl anthranilate isomerase PROFAR PRA ■ ■ ■ ▲ ■ 800   
76 5.3 Phosphoribosylanthranilate isomerase PROFAR PRA ■ ■ ▲ ■ novel novel novel 
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77 5.5 Muconate lactonizing enzyme cis-cis-muconate 
2-hydroxysuccinyl-2,4-
cyclohexadiene carboxylate ■ ▲ ■   
123456.7
9 
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Figure C-1. 1H NMR of (S)-γ-butyrolactone-γ-carboxylic acid 
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Figure C-2. 13C NMR of (S)-γ-butyrolactone-γ-carboxylic acid 
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Figure C-3. 1H NMR of (S)-γ-hydroxymethyl-γ-butyrolactone 
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Figure C-4. 1H NMR of (S)-γ-hydroxymethyl-γ-butyrolactone 
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Figure C-5. 13C NMR of (S)-γ-hydroxymethyl-γ-butyrolactone 
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Figure C-6. 13C NMR of (S)-γ-hydroxymethyl-γ-butyrolactone 
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Figure C-7. HSQC of (S)-γ-hydroxymethyl-γ-butyrolactone 
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Figure C-8. 1H NMR of 2,3-dideoxyribose 
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Figure C-9. 1H NMR of 2,3-dideoxyribose 
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Figure C-10. 13C NMR of 2,3-dideoxyribose 
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Figure C-11. 13C NMR of 2,3-dideoxyribose 
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Figure C-12. HSQC of NMR of 2,3-dideoxyribose 
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Figure C-13. 1H NMR of (S)-γ-dibenzylphosphomethyl-γ-butyrolactone 
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Figure C-14. 1H NMR of (S)-γ-dibenzylphosphomethyl-γ-butyrolactone 
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Figure C-15. 13C NMR of (S)-γ-dibenzylphosphomethyl-γ-butyrolactone 
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Figure C-16. 13C NMR of (S)-γ-dibenzylphosphomethyl-γ-butyrolactone 
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Figure C-17. 31P NMR of (S)-γ-dibenzylphosphomethyl-γ-butyrolactone 
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Figure C-18. 1H-decoupled 31P NMR of (S)-γ-dibenzylphosphomethyl-γ-butyrolactone 
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Figure C-19. 1H NMR of 2,3-dideoxyribose 5-(di-O-benzyl)phosphate 
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Figure C-20. 1H NMR of 2,3-dideoxyribose 5-(di-O-benzyl)phosphate 
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Figure C-21. 1H-decoupled 31P NMR of 2,3-dideoxyribose 5-(di-O-benzyl)phosphate 
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Figure C-22. 1H NMR of 2,3-dideoxyribose 5-phosphate 
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Figure C-23. 1H NMR of 2,3-dideoxyribose 5-phosphate 
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Figure C-24. 13C NMR of 2,3-dideoxyribose 5-phosphate 
  
 
249 
 
Figure C-25. 13C NMR of 2,3-dideoxyribose 5-phosphate 
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Figure C-26. HSQC of 2,3-dideoxyribose 5-phosphate 
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Figure C-27. 31P NMR of 2,3-dideoxyribose 5-phosphate 
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Figure C-28. 1H-decoupled 31P NMR of 2,3-dideoxyribose 5-phosphat
